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Thesis abstract 
Neuropsychiatric disorders represent an immense global health and economic 
burden, and identifying genetic and environmental factors contributing to these 
diseases is a key challenge in contemporary biomedical research. Efforts to 
identify genetic variation associated with disease risk have had some notable 
success, however the proportion of variance in disease explained by known 
genetic risk variants is limited. There is increasing evidence for epigenetic 
dysregulation in neuropsychiatric disease, with regulatory variation potentially 
induced by psychosocial and environmental risk factors associated with 
pathology. My PhD explores how the analysis of epigenetic variation, using novel 
technologies and unique study designs, can contribute to our understanding of 
how genetic and environmental factors influence disease risk. 
The first part of my thesis focuses on epigenetic correlates of early-life adversity, 
an exposure robustly associated with psychiatric phenotypes. Two 
complementary epidemiological study designs were used to characterise these 
associations: a “natural experiment”, using a sample of Romanian adoptees 
(Chapter 2), and a large longitudinal population-based twin cohort (Chapter 3). 
I identified a differentially methylated region annotated to CYP2E1 associated 
with institutional deprivation and socio-cognitive abilities, but found no robust 
associations between early-life victimisation and DNA methylation in blood. 
Neither study identified epigenetic variation associated with early-life stress in 
previously reported HPA-axis genes. 
The second part of my thesis explores epigenetic variation in the ageing brain 
and neurodegenerative disease. I undertook a systematic characterisation of 
allele-specific DNA methylation across multiple human brain regions and blood, 
finding widespread and tissue-specific patterns of allelic-skewing (Chapter 4). To 
further understand epigenetic variation in neurodegenerative disease, I 
investigated the relationship between the histone modification H3K27ac (which 
marks active gene expression) and Alzheimer’s disease progression (Chapter 
5). I found widespread acetylomic dysregulation associated with neuropathology, 
enriched in disease-specific biological pathways and mapping to regions 
harbouring genetic variants associated with familial and sporadic AD.  
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The work presented in this thesis was funded by an Early Stage Researcher 
Fellowship as part of the Marie Curie Initial Training Network “EpiTrain” (REA 
grant agreement no. 316758). 
 






Sample and data collection was completed by investigators of the English and 
Romanian Adoption Study. Laboratory procedures were undertaken by Dr Joana 
Viana, Dr Emma Dempster and Bethany Crawford. I undertook all analyses, and 
drafted the manuscript in collaboration with Professor Jonathan Mill, Professor 
Robert Kumsta and Professor Edmund Sonuga-Barke. Professor Kumsta and I 
shared joint first-authorship of the paper. 
 
Chapter 3 
Sample and data collection for the E-Risk Longitudinal Twin Study was 
completed by the E-Risk Study team. Laboratory procedures were performed by 
Dr Joe Burrage and data pre-processing by Dr Eilis Hannon. The cumulative 
victimisation measure was derived by Professor Avshalom Caspi. I undertook all 
data analysis and drafted the manuscript text. 
 
Chapter 4 
Post-mortem brain and pre-mortem whole blood samples were provided by the 
MRC London Neurodegenerative Disease Brain Bank. Laboratory work was 
performed by Dr Jose Paya-Cano. Data pre-processing was performed by 
Professor Leonard Schalkwyk. All data analyses were conducted by myself. I 
wrote the manuscript in collaboration with Professor Jonathan Mill, with editorial 
input from Professor Leonard Schalkwyk and Dr Emma Meaburn. 
 
Chapter 5  
Post-mortem brain samples were provided by the MRC London 
Neurodegenerative Disease Brain Bank. Chromatin immunoprecipitation and 
sequencing library preparation was performed by myself in collaboration with Dr 
Teodora Ribarska. The libraries were sequenced at the University of Exeter 
Sequencing Service. All data pre-processing and analyses were conducted by 
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myself. Linkage disequilibrium blocks for the GWAS overlap analysis were 
generated by Dr Eilis Hannon. Pre-processed DNA methylation and 
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This chapter serves to introduce the importance of epigenetics in the context of 
mental health and psychiatric disease. It provides an overview of epigenetic 
mechanisms, experimental methodology, epidemiological considerations and 
presents the main aims of my PhD studies in the broader context of epigenetic 
epidemiology of mental health across the life-course. 
Neuropsychiatric disorders are responsible for an immense burden on affected 
individuals, their families and the health care system. Globally, mental health and 
drug abuse disorders are the leading cause of years lived with disability, as 
shown by a 2013 report (Whiteford et al., 2013). Efforts to identify genetic causes 
of neuropsychiatric disease have thus far had inconclusive success: several large 
consortium efforts have led to the identification of robust disease-associated risk 
variants for diseases including Alzheimer’s disease (Lambert et al., 2013), 
schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014) and depression (Hyde et al., 2016). However, the number of 
associated loci is limited, effect sizes tend to be small and a large part of the 
disease heritability remains unexplained. Beyond heritable effects, most complex 
diseases, including neuropsychiatric disorders, exhibit discordance between 
monozygotic twins and contributions to disease-variation not explained by 
genetic factors (Figure 1-1), indicating that factors beyond genetic variation 
contribute to phenotypic variation. As will be discussed, epigenetics offers a 
potential mechanism by which environmental influences convey molecular 
factors contributing to disease risk (Petronis, 2010). There is increasing evidence 
for epigenetic dysregulation associated with neuropsychiatric disease (Lunnon et 
al., 2014, Hannon et al., 2016a, Sun et al., 2016) and psychosocial environmental 
factors that are risk factors for disease (McGowan et al., 2009, Houtepen et al., 
2016, Kumsta et al., 2016). Identifying a mechanistic role of epigenetic factors in 
psychiatric disease will be invaluable for understanding disease aetiology and 
discovering protective factors or novel psychopharmacological treatments (Boks 
et al., 2012). 
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Figure 1-1. Genetic and environmental contributions to neuropsychiatric diseases. Shown 
are the additive genetic (A), shared environmental (C) and non-shared environmental (E) 





1.1 Epigenetic mechanisms 
With few exceptions, all cells in an organism contain the exact same genetic 
sequence, created at meiosis and remaining stable throughout the life-course. 
Yet, cells differ substantially in their phenotypic properties and the functions they 
fulfil in the living organism. The additional information required to generate the 
adult human body across development, from a single fertilised egg to a fully 
differentiated organism, is encoded not only genetically but also epigenetically 
(Waddington, 2014, Wu and Sun, 2006).  
The term ‘epigenetics’ was first used in 1957 by Conrad Waddington, who used 
it to refer to the establishment of cell-fates throughout development, leading from 
and undifferentiated mass to a complex organism with different organs and 
tissues (Waddington, 2014). To further illustrate this concept, Waddington used 
the metaphor of a ball rolling down a landscape of valleys and peaks, each turn 
determining its cellular-fate one step further (Figure 1-2). A more current and 
functional definition was formulated by the NIH Roadmap Epigenomics 
Consortium, describing epigenetics as both heritable changes in gene regulation, 
or changes in the “transcriptional potential”, which are characterised by long-term 
stability, even though not necessarily heritable. Of note, heritability, in this 
context, can refer to both mitotic heritability (i.e. alterations are passed on at cell 
division) as well as transgenerational heritability (i.e. alterations are passed on to 
the offspring), although empirical evidence of mammalian transgenerational 
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epigenetic inheritance is still sparse (Heard and Martienssen, 2014, Dias and 
Ressler, 2014, Rando, 2016). Biologically, the mechanisms generally 
encompassed by this definition are chemical modifications to the DNA, including 
DNA methylation and hydroxymethylation, alterations to chromatin structure via 
histone modifications as well as non-coding RNAs (Kaikkonen et al., 2011). 
These three types of epigenetic mechanisms are described in the following 
subsections and a comprehensive glossary of key epigenetic terms is provided 






Figure 1-2. Waddington’s Epigenetic Landscape. This image serves as a metaphor for the 
process of cellular differentiation, in which the marble represents a cell following a developmental 
trajectory. It passes through valleys and peaks, symbolising different layers of regulation, 











The protein-DNA complex into which DNA is 
packaged in the nucleus. Its structure can be 
altered via chemical modifications to the DNA 
or the histone proteins associated with it. 
CpG island  
(Gardiner-Garden and Frommer, 1987) 
A region of at least 200bp length with a 
combined GC percentage more than 50% and 
an observed/expected CpG dinucleotide ratio 
greater than 60%. 
DNA hydroxymethylation  
(Kriaucionis and Heintz, 2009, Tahiliani et al., 
2009) 
A chemical modification of cytosine, occurring 
primarily in the context of a CpG dinucleotide, 
in which a hydoxymethyl group is added at the 
5 position of the cytosine pyrimidine ring. 
Hydroxymethylation is the derivative of 
oxidised DNA methylation. 
DNA methylation  
(Jaenisch and Bird, 2003) 
A chemical modification of cytosine, occurring 
primarily in the context of a CpG dinucleotide, 
in which a methyl group is added at the 5 
position of the cytosine pyrimidine ring. DNA 
methylation in certain regions of the genome 
can facilitate repression of gene expression 
by displacing transcription factors and 
attracting methyl-binding proteins.  
Epigenetics  
(Kundaje et al., 2015) 
Heritable changes in gene activity and 
expression (in the progeny of cells or of 
individuals) and also stable, long-term 
alterations in the transcriptional potential of a 
cell that are not necessarily heritable. 
Epigenetic inheritance  
(Richards, 2006) 
Epigenetic modifications can be propagated 
across mitotic division of cells; they are 
mitotically heritable. Evidence for 
transmission through meiosis, a phenomenon 
known as transgenerational epigenetic 
inheritance is so far inconclusive. 
Euchromatin/ active chromatin 
(International Human Genome Sequencing 
Consortium, 2004)  
Active chromatin is characterised by open, 
loose binding of DNA and histones allowing 
the transcriptional machinery to bind and 
facilitating gene expression.  
Genomic imprinting  
(Davies et al., 2005) 
Monoallelic expression of a subset of genes in 
a parent-of-origin specific manner. The 
silencing or “imprinting” of one allele is 
established by allele-specific epigenetic 
marks set in the germline.  
Heterochromatin/ inactive chromatin 
(Huisinga et al., 2006)  
Inactive chromatin is found in a condensed 
state of DNA tightly wrapped around histone 
proteins. It is associated with repressed 
transcription.  
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Histone modifications  
(Berger, 2007) 
Post-translational modifications made to the 
N-terminal histone tails, including acetylation, 
methylation and phosphorylation. Histone 
modifications are key architects of chromatin 
structure.  
Non-coding RNA  
(Birney et al., 2007, Kapranov et al., 2007) 
RNA molecules which are not translated into 
proteins but tend have structural or regulatory 
roles.  
Nucleosome  
(Luger et al., 1997) 
A single DNA-histone complex. The 
nucleosome consists of eight histone proteins 
around which a 147bp section of DNA is 
wrapped.  
X-inactivation  
(Avner and Heard, 2001) 
The epigenetic silencing of one copy of the X-
chromosome in females for dosage 




1.1.1 DNA methylation 
DNA methylation refers to the addition of a methyl-group (-CH3) to the carbon at 
position 5 of the cytosine pyrimidine ring (Figure 1-3), occurring primarily in the 
context of cytosine-guanine dinucleotides (CpG) in the human genome (Lister et 
al., 2009). The resulting modified cytosine base is called 5-methylcytosine. DNA 
methylation plays a key role in a number of biological and developmental 
processes, including genomic imprinting (Davies et al., 2005), X-chromosome 
inactivation (Avner and Heard, 2001), silencing of retroviral transposable 
elements, maintenance of genomic stability, and long-term regulation of gene 
expression (Jones, 2012).  
In contrast to the DNA sequence, DNA methylation, like all epigenetic marks, is 
dynamic and characterised by development- and tissue-specific patterns 
(Horvath, 2013, Davies et al., 2012). Establishment of DNA methylation is 
catalysed by a group of enzymes known as DNA methyltransferases (DNMTs) 
and uses S-adenosylmethionine (SAM) as a methyl donor (Klose and Bird, 2006) 
(Figure 1-3). Two classes of DNMTs have been described: the de novo DNA 
methyltransferases (DNMT3a and DNMT3b) are responsible for establishing 
methylation marks at previously unmethylated sites (Okano et al., 1999), in 
cooperation with DNMT3L (Hata et al., 2002). They are of particular importance 
in creating the developmental trajectories of the human methylome. DNMT1 
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preferentially targets hemimethylated CpG sites and is thus mainly responsible 
for maintenance of methylation patterns at cell-division as the main contributor to 
the mitotic heritability of DNA methylation patterns (Li et al., 1992, Goll and 




Figure 1-3. DNA methylation and demethylation pathways. a) Overview of the different 
modified cytosine bases and the enzymes catalysing these reactions. b) The addition of a methyl-
group at position 5 of the cytosine in a CpG context is catalysed by a group of enzymes called 
DNA methyltransferases (DNMTs). S-adenosylmethionine (SAM) acts as a methyl donor for this 
reaction. Oxidation of DNA methylation is catalysed by a group of enzymes known as ten-eleven 
translocation methylcytosine dioxygenases (TET enzymes). This reaction produces DNA 
hydroxymethylation, and is the first step in the active demethylation cascade, which also includes 
the derivatives 5-formylcytosine and 5-carboxycytosine (Kohli and Zhang, 2013). 
 
 
DNA demethylation takes place via two main pathways: Inactive DNA 
demethylation describes the absence of maintenance methylation at cell-division, 
leading to a fully unmethylated strand after the second division. The biochemical 
processes involved in active DNA methylation are less well characterised. The 
most prominently described mechanism requires a group of enzymes called ten-
eleven translocation methylcytosine dioxygenases (TET enzymes (Wu and 
Zhang, 2010)). TET enzymes sequentially oxidise methylated cytosine (5mC), 
resulting in three main methylcytosine derivatives: 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) (Figure 1-3). 
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Deaminated 5hC, 5fC and 5caC can all be removed by thymine DNA glycosylase 
and are then replaced by unmethylated cytosine as part of the base excision 
repair pathway (Kohli and Zhang, 2013). While these three intermediates in the 
5mC oxidation chain were initially thought to be simply by-products of the 
demethylation process, more recent evidence suggests functional roles, 
particularly for 5hmC, which is found at elevated levels in the mammalian brain 
(Kriaucionis and Heintz, 2009, Globisch et al., 2010, Lunnon et al., 2016). 
Although nearly a quarter of methylated cytosines occur in a non-CG context in 
embryonic stem cells, these disappear almost entirely in differentiated human 
cells and methylation is limited to the 28 million CpG sites located across the 
genome (Lister et al., 2009). This number is lower than expected by chance, due 
to the mutagenic nature of methylated cytosine, which can spontaneously 
deaminate to thymine (Bird, 1980). Exempt from this global CpG depletion are 
regions known as “CpG islands”, which are often found in gene promoters and 
are generally unmethylated (Deaton and Bird, 2011). These regions are 
characterised by an unusually high density of CpG sites (> 50% CG content, > 
60% observed/expected CpG sites) compared to the rest of the genome 
(Gardiner-Garden and Frommer, 1987). They have been the primary focus of 
early work in epigenetic studies of complex traits, although increasingly other 
genomic regions are being highlighted as functionally relevant, including 
enhancers (Kundaje et al., 2015), CpG shores (Irizarry et al., 2009) and intragenic 
islands (Illingworth et al., 2010). 
Traditionally, DNA methylation has been linked to repression of gene expression, 
by disrupting transcription factor binding (Watt and Molloy, 1988). However, more 
recent studies have uncovered a more complex relationship between DNA 
methylation and gene expression, in which the functional role of DNA methylation 
depends largely on the genomic context in which it occurs (Jones, 2012). CpG 
islands occurring at promoters and transcription start sites (TSS) are usually 
hypomethylated. A few exceptions exist, where promoter CpG island 
hypermethylation is associated with long term transcriptional silencing. Most 
notably, this occurs in regions controlling the monoallelic expression of imprinted 
genes and on inactive X-chromosomes in the context of X-chromosome 
inactivation (Jones, 2012) and is observed in combination with the repressive 
H3K9me3 histone modification and  methylated DNA-binding proteins, which in 
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turn recruit histone deacetylases (HDACs), stabilising repression of the region 
(Illingworth and Bird, 2009, Wade and Wolffe, 2001). DNA methylation at non-
CpG island promoters tends to be more variable, and its relationship to gene 
expression is not yet fully understood. Studies linking DNA methylation at these 
promoters to repressed expression have thus far been ambiguous (Weber et al., 
2005, Gal-Yam et al., 2008). In addition to attracting methylated DNA binding 
proteins, which initiate transcriptional repression via chromatin compaction 
(Hendrich and Bird, 1998, Boyes and Bird, 1991), DNA methylation in promoter 
regions can affect transcription factor binding directly, by disrupting the 
recognition motifs (Chen et al., 2011, Watt and Molloy, 1988). Beyond promoter 
methylation, regions up to 2kb upstream of the TSS, known as “CpG island 
shores” exhibit variable DNA methylation associated with gene expression in a 
tissue-specific manner (Irizarry et al., 2009). 
While gene bodies are generally CpG poor and highly methylated, CpG islands 
do occur in these regions. Non-promoter CpG islands have been termed “orphan 
CpG islands” and have been proposed to play a role in development after which 
they become methylated and lose their promoter function (Illingworth et al., 
2010). DNA methylation in gene bodies is positively correlated with gene 
expression, and suggested functions of methylation in intragenic regions include 
the silencing of repetitive DNA elements (Yoder et al., 1997), alternative splicing 
(Shukla et al., 2011) as well as alternative promoter usage (Maunakea et al., 
2010). Other regulatory regions at which DNA methylation may play a functional 
role are enhancers and insulators. Enhancers, short regions of DNA which 
interact with gene promoters to control gene expression, are CpG poor and are 
characterised by variable methylation levels (Jones, 2012). While the function of 
DNA methylation at enhancers is not fully understood, it has been linked to 
reduced enhancer activity (Schmidl et al., 2009). At insulators - DNA elements 
which can block interactions between enhancers and promoters – DNA 
methylation has been linked to instances of differential CTCF-binding. DNA 
methylation has been shown to inhibit CTCF-binding at specific insulators, and 
can thereby alter the enhancer-insulator interaction at some loci (Bell and 
Felsenfeld, 2000); at other loci the resulting absence of CTCF-binding is linked 
to alternative splicing (Shukla et al., 2011).  
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1.1.2 Histone modifications 
Histone proteins play a key role in DNA packaging and compaction inside the cell 
nucleus. The compacted compound of DNA and proteins is called chromatin and 
its basic building blocks are nucleosomes – a complex of approximately 147bp of 
DNA wrapped twice around a core of eight histone proteins. This positively 
charged histone octamer core is comprised of two copies of each of four histone 
proteins: H2A, H2B, H3 and H4 (Spencer and Davie, 1999) (Figure 1-4). The 
“beads on a string” structure resulting from DNA-nucleosome associations is then 
folded into higher-order chromatin structures (Woodcock and Dimitrov, 2001). 
Histone proteins additionally play a role in the regulation of gene expression by 
altering the physical accessibility of DNA sequences (Jiang and Pugh, 2009, 
Venkatesh and Workman, 2015). The most active part of chromatin is labelled as 
euchromatin, representing > 90% of the human genome (International Human 
Genome Sequencing Consortium, 2004). It is often loosely packed and can 
facilitate active gene expression by allowing the transcriptional machinery to bind 
to the DNA. In contrast, heterochromatin is characterised by densely packaged 
chromatin. It is generally silenced either directly by making DNA inaccessible to 
the transcriptional machinery or by post-transcriptional silencing mechanisms 
including RNA interference (Grewal and Jia, 2007, Spencer and Davie, 1999, 
Volpe et al., 2002) (Figure 1-5). The interaction of DNA and histone proteins and 
the resulting chromatin structure is partly controlled via chemical modifications to 
the N-terminal tails of the histone proteins, which extend out of the nucleosome 
complex (Spencer and Davie, 1999). A growing number of histone modifications 
have been identified, including acetylation, methylation, phosphorylation and 
ubiquitylation. The aggregate action of these modifications constitutes a complex 
‘histone code’ (Berger, 2007, Ernst and Kellis, 2010, Kasowski et al., 2013). 
Human tissue-specific variation across a range of histone modifications has 
recently been profiled comprehensively by the NIH Roadmap Epigenomics 




Figure 1-4. Chromatin structure. The nucleosome describes each unit of DNA wrapped around 
a core composed of histone proteins. It is the smallest and most basic level of chromatin structure 
and compaction. At the next level this “beads on a string” structure folds to create a 30 nm 





Lysine acetylation is possibly the best studied histone modification (Strahl and 
Allis, 2000). It is dynamically modified by the enzymes histone acetyltransferase 
(HAT) and histone deacetylase (HDAC), adding and removing acetyl groups, 
respectively (Saha and Pahan, 2006) and is associated with transcriptional 
activity (Berger, 2007, Strahl and Allis, 2000). Other examples of activating and 
repressing modifications include H3K4 methylation, which is associated with 
gene activation, and methylation of H3K9 and 27, which is associated with 
decreased gene expression (Akbarian and Huang, 2009). The most consistently 
and coherently occurring combinations of histone modifications have been 
quantitatively categorised into so-called “chromatin states” (Ernst and Kellis, 
2010, Ernst et al., 2011, Ernst and Kellis, 2012), and more recently recalibrated 
as part of the Epigenomics Roadmap Consortium (Kundaje et al., 2015) (Figure 
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1-6). Each chromatin state shows specific functional annotations and biological 
roles, including “active TSS”, “weak transcription”, “enhancer”, “heterochromatin” 
and “quiescent”. Histone 3, lysine 27 acetylation (H3K27ac), a mark found at 
active promoters and enhancers (Creyghton et al., 2010) could be of particular 
relevance to gene regulation in health and disease, due to its direct link to active 
regulatory states and the elevated levels of inter-individual variation observed in 
H3K27ac at enhancers (Kasowski et al., 2013). Analysis of H3K27ac in post-
mortem entorhinal cortex and its association with Alzheimer’s disease is a key 
focus of my PhD thesis, the results of which are presented in Chapter 5. 
 
1.1.3 Non-coding RNA 
A third type of epigenetic mechanism, in addition to DNA and histone 
modifications, is constituted by non-coding RNA (ncRNA). These RNA molecules 
make up the majority of transcripts (Kapranov et al., 2007) with protein-coding 
genes only making up a small proportion of the human genome (1-2%). While 
previously thought to be silent, projects like ENCODE (Birney et al., 2007, Encode 
Project Consortium, 2012) have highlighted widespread transcription across the 
human genome, including regions overlapping known protein-coding genes, but 
for most of which biological functions have not been identified thus far.  
NcRNAs can be classified into two groups based on their functional role 
(Kaikkonen et al., 2011): Infrastructural ncRNAs, which include ribosomal RNA 
(rRNA), RNAse P RNA, small nuclear RNA (snRNA), small nucleolar RNA 
(snoRNA), telomerase RNA and transfer RNA (tRNA), are ubiquitously 
expressed and required for normal cellular functioning (Prasanth and Spector, 
2007). Regulatory RNAs are comprised of long non-coding RNAs (lncRNAs, > 
200 nucleotides (nt)), microRNAs (miRNAs, 22-23nt), piwi-interacting RNAs 
(piRNAs, 26-31nt) and small interfering RNAs (siRNAs, 20-24nt) (Kapranov et 




Figure 1-5. Epigenetic modifications interact to steer gene regulation. Epigenetic 
modifications, including DNA methylation, histone modifications and non-coding RNAs can alter 
the physical structure of the chromosome. One interaction pathway, for example, is triggered by 
attracting methyl-binding proteins to CpG sites, mediating the access of transcription factors that 
drive gene expression. These methyl-binding proteins can in turn recruit further repressive 
mechanisms including histone deacetylases and chromatin remodelling factors. The two main 
chromatin states of euchromatin (active) and heterochromatin (inactive) are also illustrated in this 
figure (Schones and Zhao, 2008). 
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Figure 1-6. Epigenomic information across tissues and marks profiled by the NIH Roadmap 
Epigenomics Consortium. Various epigenetic modifications were profiled across different 
tissues and cell types in the human body by the NIH Roadmap Epigenomics Consortium. The left 
panel illustrates specific individual epigenomic marks across all epigenomes in which they are 
available; the right panel highlights the three dimensions of the consortium effort: 1) 127 different 
cell- and tissue-types, 2) profiling across the whole genome, 3) characterising at least five core 
histone modifications (H3K4me3, H3K4me1, H3K36me3, H3K27me3 and H3K9me3) and other 
regulatory elements (Kundaje et al., 2015). 
	
Non-coding RNAs have been repeatedly reported to have widespread epigenetic 
effects (Kaikkonen et al., 2011). miRNAs, for example, are involved in post-
transcriptional repression via binding to mRNA of protein coding genes (Bartel, 
2009, Krol et al., 2010), while siRNAs use a similar repression mechanism but 
are additionally linked to the establishment of heterochromatin as further source 
of transcriptional repression (Kaikkonen et al., 2011). LncRNAs, which represent 
the majority of ncRNAs, can modify gene transcription via antisense transcription 
and chromatin remodelling (Mercer et al., 2009, Ponting et al., 2009, Dinger et 
al., 2008). 
 
1.1.4 Interaction of epigenetic mechanisms 
While epigenetic mechanisms are most often studied in isolation, they do not act 
independently of one another, but in a coordinated fashion, interacting in various 
ways to regulate gene expression (Figure 1-5). Previously mentioned examples 
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are methyl-binding proteins, which recruit HDACs, modifying histone acetylation 
(Illingworth and Bird, 2009) or lncRNAs interacting with histone modifications and 
chromatin remodellers (Dinger et al., 2008). Further examples are observed in 
unmethylated H3K4 attracting de novo methyltransferases to initiate DNA 
methylation (Ooi et al., 2007), or DNMTs, which in addition to their role in 
methylating DNA, can recruit HDACs to modify chromatin structure (Jaenisch and 
Bird, 2003). 
The co-occurrence and relationship between epigenetic modifications has been 
studied in detail as part of the NIH Roadmap Epigenomics Consortium project 
(Kundaje et al., 2015), which profiled five key histone modifications (H3K4me3, 
H3K4me1, H3K36me3, H3K27me3 and H3K9me3) in 127 different human cell 
and tissue samples (Figure 1-6). In addition, DNA methylation, DNA accessibility, 
RNA expression and various histone acetylation marks were profiled in a large 
subsample, enabling the establishment of high level epigenomic maps and 
profiling of regulatory elements as well as the quantitative characterisation of 
coordinated regulatory activity across different epigenetic mechanisms (Ernst 
and Kellis, 2012). 
 
1.2 Methods for measuring epigenetic variation 
1.2.1 DNA methylation 
Unlike genotypic information, DNA methylation cannot be quantified by standard 
molecular biology techniques. DNA methylation is erased by polymerase chain 
reaction (PCR) as well as cloning in bacteria. Methylation-dependent pre-
treatments of DNA are thus generally required to quantify DNA methylation. 
There are three main classes of pre-treatments: First, sodium-bisulfite conversion 
is the currently most frequently applied technique for interrogating epigenetic 
correlates of complex disease, allowing quantitative interrogation of DNA 
methylation status at single locus level. DNA is exposed to sodium-bisulfite, 
converting unmethylated cytosine to uracil (and in subsequent PCR to thymine) 
while 5mC remains unaltered. This technique was used to quantify DNA 
methylation in Chapters 2 and 3 of this thesis. Second, genomic DNA can be 
digested by methylation-sensitive restriction enzymes (MSREs), which target 
specific DNA motifs containing CpG sites and cut DNA exclusively when the CpG 
site is unmethylated. Examples of MSREs are HpaII (motif: 5’-CCGG-3’), HhaI 
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(motif: 5’-GCGC-3’) and AciI (motif: 5’-CCGC-3’), which were used to digest DNA 
and identify allelic differences in DNA methylation in Chapter 4 of the thesis. 
Third, affinity enrichment uses 5mC-specific antibodies or methyl-binding 
proteins to identify DNA fragments containing methylated cytosines; most 
commonly this is carried out by methylated DNA immunoprecipitation (MeDIP). 
Following pre-treatment, there exist various experimental approaches to quantify 
the localisation and occurrence of methylated DNA, which vary with regards to 
genomic coverage, number of samples, which can be processed, and associated 
costs. These methods fall into four main categories: locus-specific approaches 
allow the examination of limited target regions, gel-based approaches rely on gel 
electrophoresis, array-based approaches quantify methylation at a larger number 
of sites using pre-defined probe sets on microarrays, and next generation 
sequencing (NGS) based approaches allow for genome-wide quantification of 
DNA methylation profiles, using advanced NGS technology. The different 
combinations of pre-treatment and downstream analysis approaches are 
summarised in Table 1-2 (Laird, 2010).  
When looking for associations between variation in a phenotype or exposure and 
variation in DNA methylation, widespread coverage of variably methylated sites 
in the human genome is of interest. Epigenome-wide association studies (EWAS) 
use high throughput molecular assays to profile DNA methylation, involving array- 
and sequencing based technologies. The Infinium technology by Illumina is at 
present the most commonly used platform for genome-wide methylation profiling, 
owing to the cost efficiency of profiling large numbers of CpG sites (currently > 
850,000) at significantly lower cost than NGS-based approaches. This 
technology relies on a process involving bisulfite-treatment, followed by 
microarray-hybridisation. The currently available EPIC array is the third version 
of this platform and was preceded by the 27K (> 27,000 probes) and 450K (> 
450,000 probes) arrays. The Illumina 450K methylation array was used in 
Chapters 2 and 3 of this thesis.  
While genome-wide technologies offer higher coverage and therefore more 
information, targeted technologies can be a useful compromise when validating 
observed results. One example of a location-specific technology is 
pyrosequencing, in which methylation profiles across CpG sites in a targeted 
genomic region are measured after bisulfite pre-treatment. This technology was 
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used to validate DNA methylation profiles for a differentially methylated region 
(DMR) identified in Chapter 2. 
 
Table 1-2. Experimental techniques used to study DNA methylation by pre-treatment 
approach (adapted from (Laird, 2010)) 
  Pre-treatment 

















































AIMS: amplification of inter-methylated sites 
BC–seq: bisulphite conversion followed by capture and sequencing 
BiMP: bisulphite methylation profiling 
BS: bisulphite sequencing 
BSPP: bisulphite padlock probes 
CHARM: comprehensive high-throughput arrays for relative methylation 
COBRA: combined bisulphite restriction analysis 
DMH: differential methylation hybridization 
HELP: HpaII tiny fragment enrichment by ligation-mediated PCR 
MCA: methylated CpG island amplification 
MCAM: MCA with microarray hybridization 
MeDIP, mDIP and mCIP: methylated DNA immunoprecipitation 
MIRA: methylated CpG island recovery assay 
MMASS: microarray-based methylation assessment of single samples 
MS-AP-PCR: methylation-sensitive arbitrarily primed PCR 
MSCC: methylation-sensitive cut counting 
MSP: methylation-specific PCR 
MS-SNuPE: methylation-sensitive single nucleotide primer extension 
NGS: next-generation sequencing 
RLGS: restriction landmark genome scanning 
RRBS: reduced representation bisulphite sequencing 
–seq: followed by sequencing 
WGSBS: whole-genome shotgun bisulphite sequencing 
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NGS-based approaches, such as whole-genome bisulfite sequencing (WGBS), 
allow comprehensive profiling of DNA methylation across the human genome at 
single-base pair resolution (Lister et al., 2009). However, such methods tend to 
be inappropriate for epidemiological work, given the large numbers of samples 
required and the associated costs. Reduced representation bisulfite sequencing 
(RRBS) (Meissner et al., 2005, Gu et al., 2011) offers a potential compromise: 
DNA is first treated with restriction enzymes and size selected for small 
fragments, ensuring that only CpG dense regions are covered by the subsequent 
bisulfite treatment and sequencing. 
	
1.2.2 DNA hydroxymethylation 
The most commonly used interrogation technique for DNA methylation analysis, 
sodium-bisulfite treatment, cannot distinguish between DNA methylation (5mC) 
and its oxidised derivate DNA hydroxymethylation (5hmC) (Huang et al., 2010, 
Jin et al., 2010). Given the abundance of 5hmC in the mammalian brain 
(Kriaucionis and Heintz, 2009, Globisch et al., 2010), it is desirable for 
epidemiological profiling of DNA modifications in brain to distinguish 5mC and 
5hmC signals, so as not to convolute individual profiles and associations of the 
two modifications. The recent development of oxidative bisulfite treatment, allows 
for unique quantification of 5mC by oxidising 5hmC to 5fC prior to bisulfite 
treatment, and thereby making it susceptible to bisulfite conversion (Booth et al., 
2012, Booth et al., 2013). This method has been consolidated with the Illumina 
450K methylation array and a measure of DNA hydroxymethylation can be 
derived by subtracting the pure 5mC signal from the aggregated measure 
obtained by standard bisulfite treatment (Stewart et al., 2015, Field et al., 2015, 
Lunnon et al., 2016). This technology was used in Chapter 5 to quantify pure 
DNA methylation and hydroxymethylation in post-mortem brain samples as part 
of the secondary analyses. 
 
1.2.3 Histone modifications 
The genomic location of specific histone modifications can also be studied via a 
range of methods, including targeted, global and genome-wide profiling (Huebert 
and Bernstein, 2005). While traditional methods involving immunoblotting 
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(Akbarian and Huang, 2009) or immunohistochemistry (Akbarian et al., 2005) fail 
to quantify levels of histone modifications associated with specific genomic 
locations, this can be achieved by chromatin immunoprecipitation (ChIP) 
techniques. These techniques have certain parallels with the affinity enrichment 
techniques described for DNA methylation profiling; the main difference being 
that an antibody is used to target a specific histone modification rather than DNA 
modification and therefore immunoprecipitation is performed on chromatin, i.e. 
the DNA – histone complex, rather than purified DNA. In brief, a cross-linking 
agent, typically formaldehyde, is used to fix DNA-histone interactions. The cross-
linked lysate is then fragmented and immunoprecipitated with an antibody 
specific to the histone modification of interest. The isolated DNA fragments can 
be quantified by quantitative PCR (ChIP-PCR), microarray-hybridisation (ChIP-
chip) or next generation sequencing (ChIP-seq), in analogy to methylation 
quantification techniques. As with DNA methylation analysis techniques, higher 
genomic coverage comes at an elevated cost. Traditional ChIP protocols require 
relatively large numbers of cells (~107 cells), which can be problematic if working 
on limited samples, such as extracted single cell-types or embryonic tissue. 
Native chromatin immunoprecipitation (N-ChIP) (O'Neill and Turner, 2003, 
Gilfillan et al., 2012, Brind'Amour et al., 2015), in which the cross-linking step is 
circumvented, can be performed on substantially lower numbers of cells making 
it a suitable approach for these scenarios (Buckley, 2007). I optimised and 
applied traditional ChIP-seq techniques to post-mortem brain samples for the 
work presented in Chapter 5, profiling Alzheimer’s disease associated variation 
in H3K27ac in entorhinal cortex samples. 
 
1.3 Drivers of epigenetic variation 
In order to understand the role epigenetic mechanisms play in the aetiology of 
complex diseases, it is important to characterise naturally occurring intra- and 
inter-individual variation across the human genome and understand what factors 
shape epigenetic variation. In this section I will discuss the influence exerted by 
tissue and cell-types, genetic variation, the environment, stochastic events and 
development on epigenetic variation. 
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1.3.1 Tissue-specific epigenetic patterns 
Considering the role epigenetic mechanisms play in cellular differentiation, it 
comes as no surprise that different cell- and tissue-types exhibit strikingly 
different epigenetic profiles (Kundaje et al., 2015, Encode Project Consortium, 
2012). These differences can even be observed between different parts of a 
complex tissue: In the brain, DNA methylation profiles can distinguish between 
functionally discrete regions (Ladd-Acosta et al., 2007, Davies et al., 2012) and 
cell-types (Lister et al., 2013, Kozlenkov et al., 2014, Ziller et al., 2015, Mo et al., 
2015). Chapter 4 highlights the tissue-specificity of allele-specific DNA 
methylation, providing examples of tissue-specific mQTLs and genomic 
imprinting. One major question in epigenetic epidemiology, and particularly in the 
field of psychiatry, is how much we can learn about the affected tissue, in our 
case the brain, using more readily available surrogate tissue, such as whole 
blood or buccal swabs. Chapters 2 and 3 investigate what we can learn about 
epigenetic signatures of early-life adversity in these two surrogate tissues, while 
Chapter 4 contributes to the growing number of maps profiling epigenetic 
phenomena across multiple tissue-types collected from the same samples 
(Davies et al., 2012, Hannon et al., 2015, Marzi et al., 2016) to determine intra- 
and inter-individual variation. 
 
1.3.2 Genetics 
While epigenetic processes are defined as occurring independent of the DNA 
sequence, genetic variation has been shown to have widespread effects on 
epigenetic mechanisms spanning multiple tissues and different epigenetic 
modifications (Kasowski et al., 2013, Kilpinen et al., 2013, McVicker et al., 2013, 
Gutierrez-Arcelus et al., 2013, Hannon et al., 2016b). For DNA methylation, the 
most direct genetic effect is observed in polymorphic CpG sites. If either of the 
two bases mutates, methylation does not occur. Given the increased mutational 
potential of methylated cytosines (Bird, 1980), this substitution can even occur 
somatically during development. Pervasive effects on epigenetic modifications 
can be observed when genetic variation occurs in and disrupts epigenetic 
regulators. These disruptions tend to have genome-wide effects with generally 
severe developmental consequences: mouse knock-down models of 
methyltransferases result in embryonic death (Li et al., 1992), while mutations of 
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the X-linked methyl CpG binding protein 2 gene (MECP2), cause Rett Syndrome, 
a progressive neurological disorder, resulting in severe mental retardation as well 
as physical disability (Amir et al., 1999). 
Finally, epigenetic variation can be influenced by genetic variants in cis or trans. 
Single nucleotide polymorphisms (SNPs) associated with methylomic variation 
are termed methylation quantitative trait loci (mQTLs/ meQTLs) in analogy to 
expression quantitative trait loci (eQTLs). These DNA variants are widespread, 
often overlap with eQTLs and are the main contributors to allelic imbalances in 
DNA methylation (Kerkel et al., 2008, Schalkwyk et al., 2010, Tycko, 2010, 
Shoemaker et al., 2010, Gertz et al., 2011, Bell et al., 2011, Hannon et al., 
2016b). Genetic effects on the epigenome provide a possible link between non-
coding genetic variation and phenotypic effects, in which epigenetic alterations 
act as endophenotypes (Meaburn et al., 2010, Wagner et al., 2014, Gutierrez-
Arcelus et al., 2013). In fact, it has been suggested that rather than disrupting the 
sequence of protein-coding sequences, most common variants associated with 
complex phenotypes have effects on gene regulation (Nicolae et al., 2010, 
Maurano et al., 2012). A systematic investigation of allelic-skewing across human 
brain regions and blood is reported in Chapter 4, highlighting the prevalence and 
tissue-specificity of genetically driven DNA methylation patterns (Marzi et al., 
2016). 
 
1.3.3 Environmental influences on the epigenome 
Despite notable genetic effects on epigenetic variation, various other factors 
contribute to epigenetic variation in humans. Several studies profiling 
monozygotic (MZ) twins have shown widespread epigenetic differences between 
genetically identical twins (Fraga et al., 2005, Kaminsky et al., 2009, Wong et al., 
2010), supporting a role of environmental influences on epigenetic variation. 
There is growing evidence that specific environmental exposures can have 
effects on the human epigenome, and the effects of environmental toxins are now 
being widely studied, including tobacco smoke (Zeilinger et al., 2013, Elliott et al., 
2014, Joehanes et al., 2016, Tsaprouni et al., 2014), bisphenol A (Dolinoy et al., 
2007, Singh and Li, 2012, Mileva et al., 2014) and air pollution (Baccarelli et al., 
2009, Yauk et al., 2008). A recent large-scale meta-analysis of DNA methylation 
signatures in cigarette smoking spanning 16 cohorts and a total of 15,907 DNA 
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samples found 2,623 CpG sites associated with cigarette smoking (Joehanes et 
al., 2016), making it one of the most robust methylation-associated environmental 
stimuli to be identified to date. In the context of epigenetic epidemiology, this has 
the potential to be an important confounder: Patients diagnosed with 
schizophrenia, for example, are more likely to smoke, which can confound the 
disease-associated epigenetic signal, if not adequately accounted for (Hannon et 
al., 2016a). Similarly, other environmental factors can be associated with 
smoking, including socioeconomic status and early-life victimisation exposure. 
Chapter 3 provides evidence that the association between victimisation exposure 
in adolescence and differential DNA methylation is confounded by cigarette 
smoking. 
In addition to biological environments, psychosocial exposures have been 
reported to be associated with epigenetic variation. Early-life adversity has been 
shown to be associated with DNA methylation changes experimentally in rodent 
models (Weaver et al., 2004, Roth et al., 2009, Kember et al., 2012) as well as 
observationally in human studies (McGowan et al., 2009, Labonte et al., 2012, 
Suderman et al., 2012) (see Chapter 3 for a more detailed discussion of the 
literature). Given the mitotic heritability of epigenetic modifications, the 
epigenome is a promising candidate biological mediation mechanism linking 
these early-life exposures with the observed persistent mental and physical 
health sequelae. Chapters 2 and 3 target the question of epigenetic variation 
associated with early-life adversity using two complementary designs: a natural 
experiment and a population-based longitudinal cohort study. 
 
1.3.4 Stochastic events 
Stochastic variation can contribute to intra- and inter-individually observed 
variation in the epigenome (Feinberg and Irizarry, 2010).  X-chromosome 
inactivation, the epigenetically regulated silencing of one of the two female X-
chromosomes to compensate the dosage of X-linked genes, is the most well-
documented form of random epigenetic regulation (Lee and Bartolomei, 2013, 
Cotton et al., 2015). X-inactivation is a further cause of allelic differences in DNA 
methylation profiles in females and X-linked genes were identified as allele-
specifically methylated by the work presented in Chapter 4. Random monoallelic 
gene expression, resembling X-chromosome inactivation, has been also 
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observed in autosomes (Jeffries et al., 2012, Gendrel et al., 2014, Eckersley-
Maslin et al., 2014, Adegbola et al., 2015), invoking the question of whether 
random allelic epigenetic processes are widespread in the genome. 
 
1.3.5 Ageing and development 
Considerable epigenetic variation can be observed in association with 
developmental features, most notably chronological ageing and embryonic 
development. Several studies have identified age-related global hypomethylation 
across several tissues (Drinkwater et al., 1989, Fuke et al., 2004, Heyn et al., 
2012). Site-specific methylomic variation associated with chronological age has 
also been characterised in a number of studies (Gentilini et al., 2013, Heyn et al., 
2012) and shows particularly striking alterations across embryonic development 
(Spiers et al., 2015). The link between DNA methylation and chronological age is 
so robust, that researchers have developed a ‘DNA methylation clock’, a highly 
accurate tissue-wide epigenetic predictor of chronological age in humans, based 
on methylation profiles across ~300 CpG sites (Horvath, 2013). 
 
1.4 Epidemiology 
1.4.1 Epigenetics of complex diseases 
Consistent functioning of mechanisms establishing and maintaining epigenetic 
profiles is essential for the healthy development and functioning of a differentiated 
organism (Robertson, 2005). Hence, when key epigenetic regulators are 
affected, the downstream epigenetic consequences tend to be severe and 
include neurodevelopmental disorders like Rett Syndrome, caused by mutations 
in MeCP2 (Amir et al., 1999), as well as immunodeficiency, centromeric region 
instability and facial anomalies syndrome, driven by mutations in DNMT3b 
(Brown et al., 1995, Xu et al., 1999).  Imprinting disorders are a second category 
of severe neurodevelopmental disorders involving epigenetic mechanisms. The 
best-described case is the Prader-Willi/Angelman syndrome, where a 
chromosomal deletion in an imprinted gene cluster on chromosome 15 leads to 
two distinct disease phenotypes, depending on whether it is paternally or 
maternally inherited (Buiting et al., 1995, Cassidy and Schwartz, 1998). These 
parent-specific genetic effects arise because imprinted genes are expressed in a 
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parent-of-origin specific manner, which is controlled by epigenetic silencing 
mechanisms (Ferguson-Smith, 2011).  
Extensive alterations in DNA methylation are observed in cancer, and it is now 
assumed that both genetic and epigenetic factors contribute to the onset and 
progression of cancer. Typically, cancer-associated epigenetic variation leads to 
the silencing of tumour suppressor genes while at the same time upregulating 
oncogenes, which promote tumour-growth and unconstrained cell proliferation 
(Sharma et al., 2010). 
In recent years, there has been widespread interest in the role epigenetic factors 
play in the aetiology of common and complex diseases (Rakyan et al., 2011, 
Petronis, 2010). There is increasing evidence for epigenetic dysregulation in a 
range of neuropsychiatric phenotypes including schizophrenia (Dempster et al., 
2011, Aberg et al., 2014, Pidsley et al., 2014, Hannon et al., 2016a), autism 
spectrum disorder (Zhu et al., 2014, Sun et al., 2016), depression (Uddin et al., 
2011, Murphy et al., 2017, Davies et al., 2014), bipolar disorder (Dempster et al., 
2011, Xiao et al., 2014) and attention deficit hyperactivity disorder (Xu et al., 
2015, Wilmot et al., 2016). Perhaps the best evidence to date has been found for 
Alzheimer’s disease, with cortex-specific methylomic deregulation patterns 
identified robustly across multiple independent cohorts (Lunnon et al., 2014, De 
Jager et al., 2014). Interestingly, most of these diseases share characteristics 
that are in line with possible epigenetic contributions to the disease aetiology, 
including MZ twin discordance (Figure 1-1), contribution of environmental 
factors, sex differences in disease prevalence, critical periods of disease 
susceptibility as well as parent-of-origin specific effects (Mill and Heijmans, 2013, 
Kaminsky et al., 2006, Kong et al., 2009). Further evidence for a potential 
mechanistic role of epigenetic dysregulation in complex disease comes from 
successful trials of drugs altering epigenetic mechanisms (Heerboth et al., 2014). 
Epigenetic drugs often target broad epigenetic mechanisms and chromatin 
remodelling agents and the most common types of drugs include methylation 
inhibitors, HAT inhibitors, and HDAC inhibitors, impacting upon DNA methylation 
and histone acetylation, respectively. While these drugs are widely used in 
cancer, increasingly applications involving neuropsychiatric phenotypes are 
discovered (Szyf, 2015). HDAC inhibitors in particular, are potent candidate drugs 
for neurodegenerative disease applications and demonstrate widespread effects 
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on synaptic plasticity and memory formation (Guan et al., 2009, Fischer et al., 
2007, Kilgore et al., 2010).  
	
1.4.2 Epigenetic epidemiology in mental health – main challenges 
When investigating associations between epigenetic variation and environmental 
stimuli or phenotypic variation in population-based studies, there are several 
major challenges. Importantly, epigenetic epidemiology is different from genome-
wide association studies (GWAS) in a number of ways, notwithstanding the 
apparent similarities in technologies and statistical methodology (Heijmans and 
Mill, 2012, Mill and Heijmans, 2013, Birney et al., 2016). The human genome is 
stably established in the germline and its sequence will stay constant over a 
lifetime and across every tissue in the body – apart from rare somatic mutation. 
This stability comes with key advantages for genetic epidemiology, including lack 
of confounding by environmental influences, an implicit direction of causality and 
convenience sampling of DNA from any tissue and at any point in time. Epigenetic 
modifications can be more accurately characterised as dynamic human 
phenotypes and therefore study design must consider these potential problems. 
Confounding is a major concern and can happen via any influence associated 
with epigenetic mechanisms. Common confounders are age (Horvath, 2013), sex 
(Kaminsky et al., 2006), cellular heterogeneity (Houseman et al., 2012, Jaffe and 
Irizarry, 2014), and substance use, including tobacco (Joehanes et al., 2016) and 
medication (Menke and Binder, 2014, Boks et al., 2012). If not appropriately 
controlled for, these factors can lead to seemingly significant results, even if the 
phenotype or exposure of interest isn’t actually associated with epigenetic 
variation (see Chapter 1.3 and Chapter 3). Batch effects are a common source 
of spurious associations; they are linked to the experimental procedure (e.g. DNA 
extraction, bisulfite conversion, microarray batch) and should be accounted for 
by randomising samples across batches, as well as accounting for experimental 
batches statistically in the analyses (Leek et al., 2010). 
Causal attribution is extremely difficult in epigenetic epidemiology. In addition to 
potential unobserved confounding factors, there is a potential for reverse 
causation, where variation in the epigenetic profile is a downstream effect of the 
disease progression or even disease-related medication. Unfortunately, 
epigenetic profiles prior to onset of pathogenesis are not always available, but 
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one useful strategy to improve causal inference is Mendelian randomisation 
(Relton and Davey Smith, 2012, Davey Smith and Hemani, 2014). Using genetic 
effects on DNA methylation (mQTLs), genetic variants can be used as 
instrumental variables, testing whether these variants also predict disease status. 
Conversely, identifying epigenetic associations which are independent of genetic 
influence, is a key interest in studies of environmental exposures. 
Given the striking tissue-specificity of epigenetic profiles, tissue- and cell-type 
composition can have substantial effects on epigenetic studies of complex 
disease and needs to be considered as a potential confounder. When working 
with heterogeneous tissues like whole blood or brain, composition differences in 
the cell-types constituting the tissue, will be associated with different epigenetic 
profiles and can confound an EWAS if they also happen to be associated with 
the phenotype of interest. Similarly, age-specific epigenetic changes have the 
potential to confound epigenetic association studies. While chronological age is 
generally available for epidemiological samples, cell-type proportions are not 
typically collected. The advent of reference-based estimators of cell-type 
composition in whole blood (Houseman et al., 2012, Horvath, 2013) and brain 
(Guintivano et al., 2013), based on DNA methylation profiles, has offered an 
indispensable tool for epidemiological studies of DNA methylation profiles. These 
estimators were used in Chapters 3 and 5 to account for cell-type composition 
in whole blood and brain, respectively. 
Tissues are a twofold challenge in epigenetic epidemiology: Further to 
confounding due to cellular heterogeneity (Houseman et al., 2012), the tissue-
specificity of epigenetic mechanisms implies that disease-specific epigenetic 
alterations could also be tissue-specific and therefore the disease-affected tissue 
would be the only informative sample source (Thompson et al., 2010, Lunnon et 
al., 2014). Regrettably, this is often impossible for neuropsychiatric diseases. 
Increasingly, brain banks are providing immensely valuable samples for 
neuropsychiatric research questions (Kretzschmar, 2009); however, they tend to 
be focused on neurodegeneration and diseases of old age and the number of 
samples available is often limited in view of the large numbers ideally required for 
genome-wide epigenomic profiling. For other research questions, including the 
study of epigenetic consequences of early-life environment, this will remain 
impossible.  
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Given all the caveats and challenges to epigenetic epidemiology, it is clear that 
the ‘perfect study’ does not exist. To gain an in-depth understanding of epigenetic 
epidemiology therefore, combinations of different types of studies and 
replications of results across multiple cohorts are necessary. Moreover, maps of 
cross-tissue epigenetic covariation in samples collected from the same 
individuals need to be charted, to calibrate how much we can learn about 
disease-associated variation in surrogate tissue (Mill and Heijmans, 2013). 
	
1.4.3 Epigenetic Epidemiology – study designs 
Experiments are the most controlled form of empirical research. Treatments are 
randomised across participants and external influences are tightly controlled to 
cancel out any external effects (Cochran and Cox, 1950). Unfortunately, most 
research questions from the realm of epigenetic epidemiology cannot be studied 
in experimental form: Any investigation of human disease will have to be 
observational (Rosenbaum, 2002). Even amongst environmental stimuli, 
exposing participants to severely adverse experiences would be highly unethical 
and studying early-childhood adversity experimentally is unthinkable. An 
overview of possible study designs to elucidate the role of epigenetic factors in 
the aetiology of complex diseases across the human life-course is shown in 
Figure 1-7 (Mill and Heijmans, 2013). 
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Figure 1-7. Overview of study designs in epigenetic epidemiology. Several study designs 





Experimental epigenetic work is possible in a limited number of scenarios: Animal 
work has led to some of the most replicated findings in epigenomics of early-life 
stress using maternal separation and care paradigms (Weaver et al., 2004, 
Desarnaud et al., 2008, Kember et al., 2012, Kundakovic et al., 2013). In humans, 
short-term interventions profiling epigenetic marks before and after the 
intervention can shed light on molecular signatures of therapies or medication 
(Boks et al., 2012). The closest alternative to a randomised controlled experiment 
is a natural experiment, in which a naturally occurring environmental 
circumstance is distributed in a quasi-random manner. One of the most 
prominently studied examples is the Dutch Hunger Winter, following individuals 
who were in utero during the Dutch famine of 1944 (Lumey et al., 2007). This 
cohort has provided valuable insights into the sequelae of maternal 
undernutrition, highlighting stable epigenetic effects (Heijmans et al., 2008, Tobi 
et al., 2009). The English and Romanian Adoption Study (ERA) is another 
important natural experiment, following children exposed to severe institutional 
deprivation in the orphanages of Romania before being adopted into UK families 
during the fall of the Ceausescu regime in 1989 (Rutter et al., 2010). Given 
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reported associations between early institutional adversity and intellectual and 
social behavioural deficits (Kumsta et al., 2015), Chapter 2 examines 
associations between deprivation exposure and DNA methylation in adolescence 
in ERA. An overview of different study designs employed across the four 
empirical chapters that constitute this PhD thesis is given in Figure 1-8. 
 
 
Figure 1-8. Overview of different study designs employed in this thesis. Across the different 
studies described in this thesis I have employed a range of different study designs to explore the 
role of epigenetics in mental health from a variety of angles.  
Image credits: Natural experiment: Tom Szalay (http://www.npr.org/sections/health-
shots/2014/02/20/280237833/orphans-lonely-beginnings-reveal-how-parents-shape-a-childs-
brain); Longitudinal cohort: https://moffittcaspi.com/content/aging; Population-based cohort: 
public domain; Twin discordance: Flickr, Donnie Ray Jones, “Happy Twin Girls”; Case-control 
design: (Marquand et al., 2016); Post-mortem tissue: Stacy Jannis, Alzheimer’s Association 
(http://discovermagazine.com/2015/march/16-cracking-the-alzheimers-code); all other parts of 
the Figure were produced by myself. 
 
Longitudinal cohort studies allow the study of epidemiological profiles and 
epigenetic changes over time. Ideally first sampled during gestation or at birth 
they allow long-term prospective follow-up of participants’ health development, 
avoiding any sampling biases incurred by retrospective sampling. The Avon 
Longitudinal Study of Parents and Children (ALSPAC) has investigated 
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epigenetic trajectories and their relation to health and development of ~14,000 
children born in southwest England in the early 1990s (Fraser et al., 2013). Both 
ERA and the Environmental Risk (E-Risk) Longitudinal Twin Study (Moffitt and 
E-Risk Study Team, 2002) profiled in Chapter 3 (Figure 1-9)  are examples of 
prospective longitudinal studies of mental health. While ERA focusses on a 
unique cohort of children exposed to severe early-life adversity in an institutional 
context, E-Risk consists of a population-based cohort, which is representative of 
the UK population with new-born infants in the 1990s. Both studies have followed-
up participants at regular intervals, with detailed profiling of cognitive, mental and 
physical health measures. 
Despite being examples of longitudinal cohorts, with regard to epigenetic profiling 
the two aforementioned cohorts represent cross-sectional studies; i.e. DNA 
methylation was profiled at a single time point and is compared across samples 
rather than longitudinally within the same individuals. This makes causal 
inference elusive and comes as a drawback of phenotypically deeply profiled 
longitudinal cohorts, in which biomaterial is only now being collected in an 
appropriate manner for detailed epigenomic profiling. Following increased 
interest and widespread research in population health epigenetic epidemiology, 
these longitudinal studies, including ERA and E-Risk, are starting to collect tissue 
samples across multiple time points, allowing more precise longitudinal profiling 
of epigenetic trajectories in the future. 
 
 
Figure 1-9. A photo collage of twins enrolled in the ‘Environmental Risk Longitudinal Twin 
Study’. Samples from this cohort were profiled for DNA methylation in the study presented in 
Chapter 3.  
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Studies characterising epigenomic marks across post-mortem tissue are 
inherently cross-sectional as tissue collection is invariably linked to the natural 
occurrence of death. Therefore, while post-mortem brain research provides 
extremely valuable insights into tissue-specific epigenetic variation and 
potentially mechanistic disease-associated epigenetic dysregulation, it will 
always preclude direct causal attribution, as no temporal sequence of epigenetic 
variation and phenotypic outcome can be established. Chapters 4 and 5 
characterise epigenomic profiles in post-mortem brain tissue, both in terms of 
naturally occurring and disease-associated epigenetic variation. A special 
subgroup of cross-sectional designs are case-control studies, in which samples 
from individuals affected by a disease are compared to healthy control individuals 
to identify systematic differences (Breslow and Day, 1980). Chapter 5 represents 
a case-control design, comparing entorhinal cortex samples from patients 
affected by Alzheimer’s disease (AD) with those obtained from neuropathology-
free control individuals for differences in the histone modification H3K27ac. 
Given the substantial genetic and environmental influences on the epigenome, 
twins are a powerful approach for controlling confounding factors in epigenetic 
epidemiology (van Dongen et al., 2012). Monozygotic (MZ) twins share the same 
genetic sequence, sex, birth date and early-life environments. Thus, epigenetic 
profiling of MZ twins discordant for diseases or environmental exposures is an 
effective method to control for variation attributable to these factors. Chapter 3 
uses an embedded twin design, which includes a characterisation of methylomic 
differences between MZ twins discordant for early-life victimisation exposures 
(Figure 1-9). 
 
1.5 Aims of this thesis 
The expanding body of research in epigenetic epidemiology shows promising 
developments in uncovering molecular biological factors contributing to 
phenotypic plasticity across a broad range of phenomena. This PhD thesis aims 
to contribute to this body of research by employing a range of observational 
epidemiological approaches (Figure 1-8) to epigenetic studies of 
neuropsychiatric phenotypes across the human life-course (Figure 1-10). The 
first two empirical chapters focus on questions of how early-life adversity may 
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leave stable epigenetic marks across the human body and explore the question 
whether DNA methylation could act as a biological mediator between the 
experienced adversity and its associated mental health sequelae. At the same 
time these two chapters give insights into the utility of two different surrogate 
tissues (epithelial cells and whole blood). A systematic characterisation of cross-
tissue epigenetic variation is undertaken in Chapter 4, supplying a new atlas of 
skewed DNA methylation in the brain and whole blood. Genetic contributions to 
DNA methylomic variation are investigated in Chapter 3, using a discordant MZ 
twin design, and Chapter 4, showing mQTLs as key contributors to allele-specific 
methylation (ASM). Finally, Chapter 5 focusses on disease-associated 
epigenetic variation, profiling AD-affected post-mortem brain tissue in a novel 
design characterising variation in histone-acetylation. 
 
Aim1:  
The first empirical chapter (Chapter 2) studies the impact of severe institutional 
deprivation experienced in the orphanages of the Romanian communist era in 
the English and Romanian Adoption Study (ERA). Using buccal swab DNA 
samples collected in adolescence DNA methylation was profiled for 49 individuals 
using the Illumina Infinium 450K platform. The resulting profiles were examined 
for differential methylation across probes and regions, associated with 
psychosocial deprivation exposure and its deprivation-related mental health 
deficits. This chapter has been published in Translational Psychiatry (Kumsta, 
Marzi et al., 2016). 
 
Aim2:  
The association between early-life adversity and DNA methylation is followed up 
in a large population-based cohort in the second empirical chapter (Chapter 3). 
Using whole blood samples from 1658 individuals, DNA methylation was profiled 
on the Illumina Infinium 450K platform and associations between multiple 
victimisation exposures across childhood and adolescence and DNA methylation 
were examined. In addition to using fine-grained, longitudinally collected 
phenotypic data, this sample represents one of the largest twin studies of 
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victimisation exposure, enabling me to control for contributions from genetic 




Figure 1-10. Overview of research themes addressed in this thesis. The four empirical 
chapters presented in this thesis are shown in the context of the research themes they explore. 
At the centre of the thesis lies the epigenome and its constitutive modifications, and at the basis, 
all projects involve mental health across the human life-course. While Chapters 2 and 3 focus on 
early-life adverse environments and how these can lead to stable adverse mental health 
outcomes, potentially mediated by epigenetic alterations, Chapters 4 and 5 focus on mental 
health in old age and neurodegenerative disease. Other recurring themes are the influence of 
genetics on the epigenome and the cell- and tissue-type specificity of epigenetic profiles.  
Image credits: Epigenome: Crabtree + Company, ID number 2563 
(https://images.nigms.nih.gov/Pages/DetailPage.aspx?imageID=313); Adverse environments: 
Flickr, publik15, “Australia: Kids Help Line says 44 per cent report physical abuse”; Blood cells: 
Monica Schroeder, “Blood Cell Types”; Brain: Flickr, _DJ_, “human brain on white background”; 
Brain cells: images.emedicinehealth.com; Mental health across the life-course: 
http://www.antibullyingpro.com/blog/2015/11/18/what-do-the-latest-stats-show; All other images: 




The third empirical chapter (Chapter 4) explores inter- and intra-individual 
variation in allele-specific DNA methylation (ASM) across the human brain and 
whole blood. In addition to confirming widespread ASM patterns in blood, this 
study provides evidence for substantial tissue-specific differences in the amount 
and location of ASM. This chapter contributes to the mapping of baseline 
epigenetic variation in the ageing brain as well as the overlap between brain and 
blood epigenetic patterns. This chapter has been published in Epigenetics (Marzi 
et al., 2016) and tissue-specific ASM patterns are available in a browseable 
online database: http://epigenetics.essex.ac.uk/ASMBrainBlood. 
 
Aim4:  
In the fourth empirical chapter (Chapter 5) disease-associated epigenetic 
variation is examined in post-mortem brain samples from Alzheimer’s disease 
(AD) patients and neuropathology-free control samples. Using chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) genome-wide profiles of 
the promoter- and enhancer-associated histone modification H3K27ac were 
characterised across 47 individuals, providing one of the first genome-wide 
epidemiological studies of a histone modification to date. In addition to identifying 
AD-associated variation in a novel epigenetic mark, outcomes were integrated 
using results from genome-wide association studies (GWAS), known disease-
associated proteins, as well as DNA methylation and hydroxymethylation data 
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family one. Furthermore, whereas many in the cohort have
displayed long-term persistent deprivation-related problems, at
least to adolescence, other adoptees are highly resilient, being
indistinguishable in terms of mental health compared with their
non-deprived peers. There is a strong association between length
of institutional deprivation and risk for persisting deﬁcits.
Individuals adopted before 6 months were found to have rates
of impairment no different from non-exposed populations,
whereas about half of the samples adopted between the ages
of 6 and 43 months showed continuing psychological deﬁcits to
adolescence.14 Within the ERA cohort, early adversity is associated
with both intellectual and social behavioral deﬁcits, with a
characteristic pattern of social impairment across two domains.
The ﬁrst has been termed quasi-autism and is a behavioral pattern
characterized by autistic-like features, particularly abnormal
preoccupations and intense circumscribed interests. The differ-
ence to classical autism lies in greater, albeit unusual, social
interest and ﬂexibility, and in the diminishing intensity of these
features over time.15 Deﬁcits in Theory of Mind (ToM) provide
substantial mediation of the quasi-autistic pattern.16,17 The second
shares many features with the new DSM diagnostic category
‘Disinhibited Social Engagement Disorder’18 and is characterized
by a marked disregard for social boundaries, inappropriate levels
of familiarity, social disinhibition and self-disclosure.15,19 Across all
ages there is a substantial overlap between quasi-autism and
disinhibited social engagement.15 These core deﬁcits in social
cognition and behavior are often accompanied by cognitive
deﬁcits (at the age of 15, the mean intelligence quotient (IQ) of the
late adopted group was one s.d. below the UK and early adopted
group) and symptoms of attention-deﬁcit hyperactivity disorder.20
The persistent nature of the negative impact of early severe
deprivation, which for many in the sample was not eradicated by
positive post-adoption experiences, is consistent with an enduring
biological impact of early deprivation. In this study we aimed to
test whether exposure to extreme deprivation is associated with
altered DNA methylation among Romanian adoptees and whether
these effects are also related to variation in intellectual and social
functioning in the ERA group.17
MATERIALS AND METHODS
Sample
The ERA sample was drawn from children adopted from Romania into
families residing in England between February 1990 and September 1992,
who were aged 43 months, or below, at the time of entry to the United
Kingdom (see Rutter et al.13 for detailed description of historical
background and sample characteristics). Brieﬂy, following an age-
stratiﬁed sampling design, the ERA study enrolled roughly equal numbers
of children adopted before 6 months, between 6 and 24 months and over
24–43 months. The Romanian children were compared with a group of 52
children born and adopted within the United Kingdom before the age of
6 months. None of the children in the within-UK adoptee group had been
exposed to early deprivation, neglect or abuse. Most children had been
placed in institutions in the ﬁrst weeks of life (the mean age of entry was
0.34 months, s.d. = 1.26, making it unlikely that the reason for their
admission into institutions was manifest handicap). Out of 217 subjects,
DNA samples were available for 131 individuals, and 49 individuals were
selected for the present study. Our selection strategy was based on the
ﬁnding that at 11 and 15 years of follow-up there was a step-wise
relationship between length of institutional rearing and risk for
psychosocial and developmental outcome, with the difference laying
between institutional deprivation that did not continue beyond the age of
6 months and institutional deprivation that persisted longer than that.13
Accordingly, for the current analyses we focused on the comparison
between individuals experiencing extended (more than 6 months; n= 16)
or limited (less than 6 months; n=17) deprivation. Furthermore, these two
groups were compared with a subgroup of individuals from the within-UK
adoptee group (n= 16). Selection of the participants was carried out at
random for the UK comparison group and the group experiencing
o6-month deprivation. For the 46-month category, participants were
selected at random from the subgroup of individuals showing deprivation-
related impairments. As shown in Supplementary Table 1 and
Supplementary Table 2, there were no signiﬁcant differences between
groups in gender, smoking or the abuse of alcohol, cannabis or other
drugs. With the exception of one individual in the 46-month exposure
group using antidepressants at time of sampling, and the elevated rate of
methylphenidate use in the46-month exposure group, there was no use
of medication among the samples included in this study (antipsychotics,
mood stabilizers and antidepressants). Furthermore, there were no
signiﬁcant differences in birth weight between the early and late adopted
Romanian adoptees. As shown in Supplementary Table 1, and comparable
to the ERA sample as a whole,16 deﬁcits in ToM and lower IQ were
observed in the group with extended deprivation. Furthermore, as
previously observed,13 there were no differences between the short
length of deprivation and the UK comparison group. The study was
approved by the King’s College London ethics committee. Parents gave
informed consent for themselves and their children.
DNA methylation proﬁling
Buccal cell samples were collected at the age of 15 and DNA isolated using
a standard method.21 Genomic DNA was treated with sodium bisulﬁte in
duplicate using the EZ-96 DNA methylation-gold kit (Zymo Research,
Irvine, CA, USA) and DNA methylation proﬁled using the Inﬁnium
HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) processed
on an Illumina HiScan System (Illumina) according to the manufacturers’
standard protocol. All samples were randomized within and between
arrays to avoid potential batch effects.
Data-processing and quality control
Signal intensities for each probe were extracted using the Illumina
GenomeStudio software and were imported into R (ref. 22) using the
methylumi 23 and minﬁ package.24 Multidimensional scaling plots of
variable probes on the sex chromosomes were used to check that the
predicted gender corresponded with the reported gender for each
individual. Stringent quality-control checks, quantile normalization and
separate background adjustment of methylated and unmethylated
intensities of type I and II probes were implemented using the wateRmelon
package in R.25 Samples with ⩽ 5% of sites with a detection P-value40.05
were included in subsequent analyses, and probes with 45% of samples
with a detection P-value40.05 or a bead count o3 in 5% of samples were
removed. We excluded the 65 single-nucleotide polymorphism probes,
probes on sex chromosomes, cross-hybridizing probes26 and probes with
common (minor allele frequency45%) single-nucleotide polymorphisms
in the CG or single-base extension position from subsequent analysis, with
the ﬁnal analysis data set comprising 382 291 probes.
Cognitive and sociocognitive abilities
Cognitive abilities were assessed with the short form of the Wechsler
Intelligence Scale for Children (WISC III, UK) at 15 years of follow-up. This is
the most commonly used standardized measure of young people’s
cognitive abilities, and it has established reliability.27 Four subscales of
the WISC were employed: two from the verbal scales (vocabulary and
similarities) and two from the performance scales (block design and object
assembly). These four subscales were selected to provide a good estimate
of full-scale IQ (reliability coefﬁcient = 0.94).28 The four subscales were pro-
rated to form a full-scale IQ for subsequent analyses. At the age of 11 years,
the ‘strange stories’ task29 was employed as a measure of ToM. The task
required the children to respond to seven ToM-related vignettes. The
responses to the vignettes were scored in terms of the level of ToM
understanding displayed, with ‘0’ indicating a non-ToM-related response,
‘1’ indicating basic-level ToM understanding and ‘2’ indicating evidence of
more sophisticated ToM understanding. Scores were combined across the
seven stories, and the mean scores were used in analyses.
Data analysis
Data was analyzed using a t-test for group mean differences in DNA
methylation between the two Romanian adoption groups of same
ethnicity. No further covariates were included in this test, as all samples
were taken at the same age. The potential confounding effect of sex on the
identiﬁed differences was ruled out through the comparison of results with
a sex-regressed model (Supplementary Figure 1). Associations between
DNA methylation and exposure time (continuous) as well as IQ and ToM
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were analyzed using linear regression. Region-level analysis for deprivation
group, ToM and IQ was performed by spatially combining correlated P-
values using the Python module comb-p.30 We allowed a maximum
distance of 1000 bp between neighboring CpG sites, and only included
probes with a P-valueo0.05 in the initial epigenome wide association scan
as starting points for identifying potential differentially methylated regions
(DMRs). For each DMR, we report the combined P, which is Stouffer–
Liptak–Kechris-corrected for regional correlation structure, and the
multiple-testing-corrected Šidák P-value. The latter corrects the combined
P for na/nr tests, where na is the total number of probes tested in the initial
epigenome wide association scan and nr the number of probes in the
given region. The Bioconductor package bumphunter31 was used to
conﬁrm DMRs identiﬁed by comb-p with an alternative method. We report
the empirical P-value, calculated using 1000 permutations. Genes were
assigned to probes using the Genomic Regions Enrichment of Annotations
Tool (GREAT) package from the Bejerano Lab at Stanford University (http://
bejerano.stanford.edu/great/public/html),32 taking into account the func-
tional signiﬁcance of cis-regulatory regions.
Bisulﬁte-pyrosequencing
To technically validate the 450K array data at the CYP2E1 DMR, a bisulﬁte-
pyrosequencing assay spanning three CpG sites (cg14250048, cg00436603
and cg01465364) was designed using the PyroMark Assay design software
(Qiagen, Hilden, Germany). Bisulﬁte-PCR ampliﬁcation was performed in
duplicate on samples with sufﬁcient remaining DNA using the primers in
Supplementary Table 3 and a PCR annealing temperature of 55 °C. DNA
methylation was quantiﬁed in a subset of 36 samples with sufﬁcient
remaining DNA using the Pyromark Q24 system (Qiagen), following the
manufacturer's standard instructions, and the Pyro Q24 CpG 2.0.6 software.
RESULTS
Sociocognitive consequences of exposure
Phenotypic analyses on the selected subsample of the ERA cohort
used in this study conﬁrmed previously reported negative
associations between exposure to severe early-life institutional
deprivation and performance in sociocognitive tests (Figure 1).
Romanian adoptees exposed to46 months of deprivation scored
signiﬁcantly lower on tests of both IQ (P= 0.004) and ToM
(P= 3.07× 10− 4).
Deprivation-associated DNA methylation differences
We ﬁrst assessed DNA methylation differences at speciﬁc 450K
array probes between Romanian adoptees categorized as having
experienced ‘limited’ (o6 months in institutional deprivation,
n= 17) and ‘extended’ periods of institutional deprivation
(46 months in institutional deprivation, n= 16; see Table 1 and
Supplementary Figure 2 for the top-ranked differentially methy-
lated positions). No probe-wise differences remained signiﬁcant
after correction for multiple correction, although this is not
surprising, given the small number of samples available for this
study. DNA methylation differences for the 100 top-ranked
exposure-associated differentially methylated positions
(Supplementary Table 4) were highly correlated with effect sizes
at the same loci in a quantitative analysis of exposure duration
(r= 0.93, P= 3.03× 10− 44; Supplementary Figure 3), indicating that
the effects of severe deprivation at these loci are likely to be
cumulative.
We next used comb-p30 to identify spatially correlated regions
of differential DNA methylation, identifying a signiﬁcant DMR on
chromosome 10 spanning nine sequential 450K array probes,
which were consistently increased in DNA methylation in the
severe early institutional deprivation group (combined
P= 2.21× 10− 10, corrected Šidák P= 2.98× 10− 5). This region was
also identiﬁed using an alternative DMR analysis method
(bumphunter31) as showing signiﬁcantly elevated DNA methyla-
tion in the severely exposed group (adjusted P= 0.002; Figure 2,
Supplementary Figure 4 and Table 2). By comparing the two
Romanian adoptee groups with the matched group of children
born and adopted within the UK, we were able to show that
increased DNA methylation across this DMR is speciﬁc to the
group that experienced extended deprivation; the control group
of UK adoptees was indistinguishable from the Romanian group
adopted before the age of 6 months at each of the nine CpG sites
comprising the DMR (Figure 2 and Supplementary Figure 4). This
~ 600bp DMR spans the transcription start site and ﬁrst exon of
the cytochrome P450 gene, CYP2E1. There was a signiﬁcant
correlation between DNA methylation levels independently
derived from the 450K array and bisulﬁte-pyrosequencing
experiments (r= 0.52, P= 0.001, Supplementary Figure 5).
Association between DNA methylation and deprivation-related
sociocognitive and intellectual impairments
We next tested whether exposure-associated DNA methylation
differences were associated with established deprivation-related












































Figure 1. Exposure to severe early-life deprivation is negatively associated with performance in sociocognitive tasks in the English and
Romanian Adoptees study (ERA) subsample included in methylomic proﬁling. Prolonged exposure (⩾6 months) was signiﬁcantly associated
with lower scores for (a) intelligence quotient (IQ) at the age of 15 (P= 0.004) (b) and the Theory of Mind at the age of 11 (P= 3.07× 10− 4).
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which 450K array data were available. For the 100 top-ranked
exposure-group differentially methylated positions, there was a
highly signiﬁcant negative correlation between exposure-group
DNA methylation differences and effect sizes at the same probes
for both IQ (r=− 0.82, P= 4.48× 10− 25, Supplementary Figure 6)
and ToM (r=− 0.89, P= 2.23× 10− 35, Figure 3a). Furthermore,
using comb-p to identify DMRs for sociocognitive and intellectual
impairments, we found that DNA methylation across the nine CpG
sites in the deprivation-associated CYP2E1 DMR on chromosome
10 was signiﬁcantly associated with ToM (combined
P= 4.87× 10− 9; Table 3 and Figure 3b) and cognitive impairment
(combined P= 2.912× 10− 5).
DISCUSSION
Using samples from a unique ‘natural experiment’ following
children exposed to prolonged severe institutional deprivation, we
provide evidence for signiﬁcant alterations in DNA methylation in
response to severe early-life social adversity in humans. We
identiﬁed a DMR that was associated with extended institutional
deprivation across nine adjacent CpG sites spanning the
transcription start site and ﬁrst exon of the cytochrome P450
gene CYP2E1. Elevated DNA methylation across this DMR was
speciﬁc to the group exposed to more than 6 months in Romanian
institutions; early-adopted Romanian adoptees were indistinguish-
able from the control group of UK adoptees—an effect that
mirrors prior ﬁndings relating deprivation and psychiatric dis-
orders and cognition.13 DNA methylation across the nine CpG sites
in the CYP2E1 DMR was also associated with ToM performance
and cognitive impairment.
The CYP2E1 protein is a member of the cytochrome P450 (CYPs)
super family of enzymes, with a role in the metabolism of various
exogenous compounds including drugs of abuse and
neurotoxins.33 It is also involved in gluconeogenesis and the
synthesis of cholesterol, steroids and other lipids.34 CYP2E1 is most
abundantly expressed in the liver, although like other CYPs it is
present and is active in the human brain, including the frontal
cortex, hippocampus, amygdala, hypothalamus and cerebellum
(GTEx Analysis Release V4: dbGaP Accession phs000424.v4.p1
(ref. 33)). There is evidence to suggest that CYPs in the brain
may have a role in modulating behavior35 and cognitive processes
(for example, shown by imaging genetic studies36) as well as
susceptibility to central nervous system diseases and drug
dependence.37
It is currently unknown which molecular pathways in the brain
might be affected by changes in CYP2E1 function, and how
deprivation-related sociocognitive deﬁcits might be mechanisti-
cally connected to epigenetic variation regulating CYP2E1. Of note,
increased methylation of a CpG site in close proximity (o1 kb) to
our DMR in neonates has been recently associated with prenatal
exposure to selective serotonin reuptake inhibitors38
(Supplementary Figure 4). Although this speciﬁc CpG site was
not within the DMR identiﬁed in our study, it was nominally
signiﬁcantly associated with exposure to adversity (P= 0.034).
Prenatal selective serotonin reuptake inhibitor exposure, similar to
severe early-life adversity, has been implicated as a risk factor for
long-term cognitive deﬁcits and psychopathology.39 In a mouse
model, it was shown that chronic psychoemotional stress reduced
CYP2E1 protein levels by one half, suggesting that stress exposure
Table 1. The top-ranked differentially methylated positions associated with exposure to severe institutional deprivation
Probe GREAT gene annotation P-value DNA methylation difference 46-Month exposure (mean) o6-Month exposure (mean)
cg11634248 CHKA, SUV420H1 2.35× 10−5 0.03 0.88 0.85
cg14272935 FGF5 6.89× 10− 5 0.05 0.37 0.32
cg16668903 SNX24, PPIC 9.75× 10− 5 0.07 0.79 0.72
cg06969206 HHIPL1 1.08× 10− 4 0.05 0.24 0.19
cg22982014 LGALS4, HNRNPL 1.26× 10− 4 0.03 0.24 0.21
cg24843511 S100A2, S100A16 1.38× 10− 4 0.03 0.82 0.79
cg18015809 GPR110, TNFRSF21 1.60× 10− 4 0.03 0.90 0.88
cg08157194 SLC25A17, MCHR1 1.63× 10− 4 0.02 0.89 0.87
cg04213775 SLC12A7, NKD2 1.68× 10− 4 0.03 0.85 0.82
cg07085824 SGK196 1.72× 10− 4 0.02 0.13 0.10



























Figure 2. A differentially methylated region (DMR) spanning the
transcription start site of CYP2E1 shows signiﬁcantly increased DNA
methylation levels in adoptees exposed to severe early-life adversity.
A DMR on chromosome 10 spanning nine sequential 450K array
probes (chr10:135340445-135341026) was identiﬁed by comb-p.
DNA methylation across this region is signiﬁcantly elevated
(combined P= 2.21× 10− 10; corrected Šidák P= 2.98× 10− 5) in
individuals exposed to severe long-term (⩾6 months) institutional
deprivation compared with the low-exposure (o6 months) group
and UK control group. Data for an extended region around this DMR
are shown in Supplementary Figure 4.
Epigenetic markers of extreme early childhood psychosocial deprivation
R Kumsta et al
4




might have a role in CYP2E1 regulation.40 Our observation that
DNA methylation differences in the regulatory region of CYP2E1
associated with extended deprivation also correlated with
reduced IQ, and ToM is consistent with the view that shared
processes may be involved in mediating the observed deﬁcits in
both social and intellectual functioning.17,41
There is now a large body of evidence and a strong, scientiﬁc
consensus that childhood stress and early adversity, especially in
such extreme forms as the institutional deprivation experienced
by the ERA sample, are associated with disturbances of childhood
mental health and life-long risks of chronic disorders of mental
and physical health.42 The exact mechanisms by which signals
from the social environment impinge on the developing brain to
shape the neural circuitry and what role epigenetic processes may
have in stabilizing developmental trajectories across the lifespan
are only just beginning to be elucidated. Brain structure and
function are especially responsive to experience early in life, and
development is characterized by the key developmental stages of
heightened plasticity.43 Recent research shows that during these
critical periods the genome may be particularly vulnerable to
Table 2. Association statistics for the nine individual probes in the chromosome 10 DMR













cg07381788 135 340 445 0.003 0.419 0.12 0.67 0.55 0.58
cg09208540 135 340 467 7.71× 10− 4 0.408 0.16 0.67 0.51 0.55
cg10986462 135 340 539 3.00× 10− 4 0.545 0.17 0.65 0.48 0.51
cg01465364 135 340 721 0.001 0.554 0.08 0.70 0.63 0.64
cg00436603 135 340 740 0.007 0.316 0.07 0.71 0.64 0.67
cg14250048 135 340 785 0.010 0.790 0.09 0.73 0.64 0.63
cg19571004 135 340 850 0.003 0.586 0.08 0.73 0.65 0.66
cg19837601 135 340 871 0.053 0.666 0.04 0.64 0.60 0.58
cg21024264 135 341 025 0.004 0.660 0.08 0.68 0.61 0.62
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1.0 1.5 0.5 1.0 1.5 0.5 1.0 1.5
0.5
Theory of Mind at age 11 Theory of Mind at age 11 Theory of Mind at age 11
1.0 1.5 0.5 1.0 1.5 0.5 1.0 1.5
0.5
Theory of Mind at age 11 Theory of Mind at age 11 Theory of Mind at age 11
1.0 1.5 0.5 1.0 1.5 0.5 1.0 1.5
Figure 3. Exposure-associated DNA methylation variation is associated with Theory of Mind test performance. (a) For the 100 top-ranked
exposure-associated differentially methylated positions (DMPs; see Supplementary Table 4), effect sizes for association with exposure group
correlated signiﬁcantly with effect sizes for association with Theory of Mind at the age of 11 (r=− 0.89, P= 2.23× 10− 35). The top 10 exposure-
associated DMPs (see Table 1) are highlighted in red. (b) The CYP2E1 DMR associated with exposure group is also signiﬁcantly associated with
the Theory of Mind (combined P= 4.87× 10− 9, corrected Šidák P= 8.79× 10− 5). Associations between DNA methylation and Theory of Mind
are shown for the nine probes constituting the DMR, with the previously used coloring scheme (UK adoptees: red, short deprivation exposure
group: blue, extended exposure group: green).
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epigenetic disruption.44 With regard to the ERA sample, it can be
speculated that the lack of emotional, sensory and cognitive
stimulation associated with deprivation of personalized care
during sensitive periods in infant life might have led to epigenetic
changes resulting in insufﬁcient ﬁne-tuning of the brain circuitry
mediating socioemotional behaviors and underlying higher
cognitive function.
One previous study has investigated epigenetic alterations in 8-
year-old institutionalized children. Differential methylation pat-
terns (at an extremely non-stringent uncorrected Po0.01) were
found at 914 CpG sites, with ~ 90% of these nominally
differentially methylated sites showing elevated methylation in
the institutionalized group.45 In addition to the analytical
differences between the studies, samples in this prior study were
not exposed to signiﬁcant deprivation, which may explain the
difference in number and magnitude of exposure-associated
changes.
Our study has a number of important limitations. First, the
number of samples proﬁled in this study is small, and replication
in cohorts with similar types of deprivation experience is
warranted. However, the ERA represents a unique natural
experiment cohort, and access to equivalent samples exposed
to a similar level of adversity for replication is by necessity difﬁcult.
Second, the small number of samples means that it is under-
powered to formally assess whether deprivation effects on
sociocognitive processes are mediated by epigenetic effects.
Furthermore, our analyses were cross-sectional, and it is not
possible to causally link exposure to the variation we observe. It
cannot be ruled out that the observed differences in DNA
methylation were caused by deprivation-related impairments
observed in the high-risk group, or by other confounding factors
such as adverse prenatal conditions (although no differences in
birth weight were observed between the long- and short-exposed
Romanian adoptees) or medication use. Finally, the observed
differences in DNA methylation were observed in buccal cells, and
the extent to which peripheral markers index epigenetic variation
in central nervous tissue is still debated.12,46 Of note, buccal cells
derive from the same embryonic cells as brain tissue (ectoderm)
and have less cellular heterogeneity compared with whole
blood.47 Although there are well-documented tissue-speciﬁc
differences in DNA methylation, exposure-associated changes in
DNA methylation can be identiﬁed in many cell types, and
peripheral tissues may have some utilities as potential biomarkers
of exposure or disease.12,46,48 Despite these limitations, our data
are consistent with the notion that environmental insults of
sufﬁcient biological impact during early development might be
associated with epigenetic variation detectable in peripheral cells,
and provide further support for a role of epigenetic processes
in linking the effects of early-life adversity to cognitive and
neurobiological phenotypes.
To conclude, children exposed to extreme early institutional
deprivation were characterized by signiﬁcantly increased DNA
methylation across a region of the CYP2E1 gene with putative
functional signiﬁcance for brain function. These ﬁndings support
the notion that severe social adversity may induce epigenetic
variation in human subjects. Future studies should replicate and
extend this ﬁnding with larger samples and investigate long-
itudinal changes in DNA methylation over time as a function of
post-adversity environments and genomic variations, and relate
these to changes in phenotype. It will be important to further
investigate the neurobiological signiﬁcance of these changes by
linking DMRs to brain structure and function.
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Supplementary Table 1 
	
Table 2-4 Demographic information on samples. Associations between exposure and 
cognitive and social cognitive outcome measures are reported. 








P >6 months 
vs <6 months 
derivation* 
Sex (m/f) 7/9 9/8 10/6 0.732 
Mean deprivation time 
(months) 
20.69 3.47 - 1.41 × 10-5 
Mean IQ at age 15 87.00 105.06 105.75 0.004 
Mean Theory of Mind at age 
11 
0.80 1.32 1.38 3.07 × 10-4 
* P values were calculated using a Fisher’s exact test for sex and a two-sample t-test for deprivation time, IQ and 







Supplementary Table 2 
 
Table 2-5. Sample characteristics for potential confounders – including birth weight and 
substance use. 








P >6 months 
vs <6 months 
derivation* 
Birth weight (kg) 2.86 2.96 3.28 0.557 
Smoking, alcohol, drug abuse (yes/no) 
Self-report     
    Smoking (>5 cigarettes/day) 1/15 2/16 5/16 0.525 
    Any sign of alcohol abuse 3/16 3/16 4/15 0.641 
    Occasional cannabis use 1/15 2/15 3/15 0.500 
    Hard Drug Use 0/15 0/16 2/15 - 
Parent report     
    Smoking (>5 cigarettes/day) 0/15 0/17 0/16 - 
    Any sign of alcohol abuse 1/16 3/17 2/16 0.324 
    Occasional cannabis use 1/16 0/16 0/16 0.500 
    Drug use 0/15 0/17 0/16 - 
* P values were calculated using a Fisher’s exact test for smoking, alcohol, cannabis and other drug use and a 
two-sample t-test for birth weight.  
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Supplementary Table 3 
	
Table 2-6. Primers used for pyrosequencing validation. 
Sequencing 
Primer 










Supplementary Table 4 
 
Table 2-7. Top 100 differentially methylated probes associated with exposure (>6 months vs <6 months exposure). Association between methylation at the 
top 100 DMPs and deprivation time (quantitative), IQ and Theory of Mind are also reported. 
   GREAT_gene 
annotation 
Exposure group Deprivation time IQ Theory of Mind 
Rank Probe Position P value Effect P value Effect P value Effect P value Effect 
1 cg11634248 11:67926133 CHKA, SUV420H1 2.35 × 10 -5 0.03 0.004 0.04 0.052 -0.06 0.113 -0.03 
2 cg14272935 4:81185765 FGF5 6.89 × 10 -5 0.05 0.067 0.04 0.250 -0.06 0.021 -0.06 
3 cg16668903 5:122206322 SNX24, PPIC 9.75× 10 -5 0.07 0.109 0.05 0.049 -0.13 0.007 -0.09 
4 cg06969206 14:100111183 HHIPL1 1.08 × 10 -4 0.05 0.005 0.06 0.037 -0.09 0.002 -0.07 
5 cg22982014 19:39322497 LGALS4, HNRNPL 1.26 × 10 -4 0.03 0.031 0.03 0.020 -0.07 0.002 -0.05 
6 cg24843511 1:153579799 S100A2, S100A16 1.38 × 10 -4 0.03 0.009 0.03 0.255 -0.03 0.022 -0.03 
7 cg18015809 6:47202254 GPR110, TNFRSF21 1.60 × 10 -4 0.03 0.070 0.02 0.021 -0.06 0.068 -0.03 
8 cg08157194 22:41185264 SLC25A17, MCHR1 1.63 × 10 -4 0.02 5.53 × 10 -4 0.03 0.006 -0.06 0.023 -0.03 
9 cg04213775 5:1063087 SLC12A7, NKD2 1.68 × 10 -4 0.03 0.025 0.03 0.028 -0.07 0.019 -0.04 
10 cg07085824 8:42948105 SGK196 1.72 × 10 -4 0.02 0.062 0.02 0.136 -0.04 0.102 -0.02 
11 cg02132051 14:73020007 DPF3, RGS6 1.84 × 10 -4 0.04 0.078 0.03 0.174 -0.06 0.013 -0.06 
12 cg24780167 2:179744587 TTN, CCDC141 1.98 × 10 -4 0.06 0.041 0.05 0.270 -0.06 0.009 -0.08 
13 cg11708358 6:150183516 LRP11, PCMT1 2.22 × 10 -4 0.09 0.023 0.09 0.003 -0.25 0.011 -0.12 
14 cg14441262 6:33140769 COL11A2, HLA-DPB1 2.22 × 10 -4 0.05 0.034 0.04 0.300 -0.05 0.291 -0.03 
15 cg08241115 16:722688 RHBDL1 2.26 × 10 -4 0.03 0.002 0.04 0.146 -0.05 0.059 -0.03 
16 cg21483883 7:37487352 AOAH, ELMO1 2.27 × 10 -4 -0.05 0.152 -0.03 0.279 0.05 0.165 0.04 
17 cg16699861 16:30429204 ZNF771, DCTPP1 2.45 × 10 -4 0.01 0.003 0.01 0.344 -0.01 0.321 -0.01 
18 cg21145140 5:110409467 WDR36, TSLP 2.69 × 10 -4 0.07 0.004 0.08 0.020 -0.14 0.004 -0.09 
19 cg25021532 8:107782513 ABRA 2.86 × 10 -4 0.04 0.423 0.02 0.834 -0.01 0.428 -0.02 
20 cg14566624 1:6321582 GPR153 2.91 × 10 -4 0.07 0.005 0.09 0.078 -0.11 0.032 -0.07 
21 cg10986462 10:135340539 CYP2E1 3.00 × 10 -4 0.17 0.014 0.19 7.57 × 10 -4 -0.53 1.10 × 10 -4 -0.32 
	 68	
22 cg13628514 12:110271439 TRPV4 3.00 × 10 -4 0.06 0.037 0.06 0.810 -0.01 0.105 -0.05 
23 cg18167179 14:74058881 ACOT4 3.01 × 10 -4 -0.01 0.236 -0.01 0.426 0.01 0.697 0.00 
24 cg13443165 9:33130375 SMU1, B4GALT1 3.13 × 10 -4 0.21 0.002 0.28 0.062 -0.39 0.022 -0.26 
25 cg26385743 2:131101463 CCDC115, IMP4 3.18 × 10 -4 0.05 0.088 0.04 0.153 -0.08 0.027 -0.07 
26 cg08397920 16:2258580 C16orf79, MLST8 3.56 × 10 -4 0.03 0.038 0.03 0.092 -0.05 0.351 -0.02 
27 cg07805911 7:818287 SUN1, PRKAR1B 3.66 × 10 -4 0.05 0.008 0.07 0.670 -0.02 0.019 -0.06 
28 cg22443762 1:197890608 NEK7, LHX9 3.82 × 10 -4 0.07 0.053 0.06 0.219 -0.08 0.035 -0.07 
29 cg03131097 10:43802881 FXYD4, RASGEF1A 4.00 × 10 -4 0.03 0.012 0.03 0.001 -0.09 0.020 -0.04 
30 cg20011352 8:37655269 GPR124 4.23 × 10 -4 0.02 0.015 0.03 0.148 -0.03 0.001 -0.04 
31 cg12748499 1:244374172 ZNF238, ADSS 4.32 × 10 -4 0.04 0.013 0.04 0.271 -0.04 0.049 -0.04 
32 cg09206774 10:3581233 PITRM1, KLF6 4.38 × 10 -4 0.05 0.021 0.05 0.423 -0.04 0.358 -0.02 
33 cg16268769 1:156890782 PEAR1, ARHGEF11 4.61 × 10 -4 0.04 0.017 0.05 0.041 -0.10 0.002 -0.08 
34 cg06705986 10:86004888 LRIT1, RGR 4.88 × 10 -4 0.08 0.213 0.05 0.011 -0.18 0.006 -0.10 
35 cg18170229 12:322587 SLC6A12 5.08 × 10 -4 0.06 0.012 0.07 0.039 -0.11 0.004 -0.09 
36 cg13898430 1:25292274 RUNX3, SYF2 5.10 × 10 -4 0.04 0.008 0.05 0.016 -0.10 0.050 -0.04 
37 cg12973753 6:26208128 
HIST1H4E, 
HIST1H2BG 5.17 × 10 -4 0.03 0.019 0.03 0.084 -0.05 0.257 -0.02 
38 cg08064292 15:98196234 ARRDC4 5.52 × 10 -4 0.10 0.122 0.07 0.130 -0.15 0.067 -0.10 
39 cg09000469 10:134229757 INPP5A, STK32C 5.53 × 10 -4 0.04 0.035 0.04 0.139 -0.06 0.326 -0.02 
40 cg18243598 7:2172011 MAD1L1, ELFN1 5.67 × 10 -4 0.02 0.092 0.02 0.049 -0.05 0.180 -0.02 
41 cg12637397 5:1229127 SLC6A18, TERT 5.72 × 10 -4 0.03 0.158 0.02 0.049 -0.06 0.236 -0.02 
42 cg19099736 22:29702810 GAS2L1 5.86 × 10 -4 0.03 0.005 0.04 0.398 -0.03 0.338 -0.02 
43 cg20203971 2:240171099 HDAC4, TWIST2 5.97 × 10 -4 0.02 0.004 0.03 0.005 -0.06 0.009 -0.03 
44 cg07335357 17:77758850 CBX2, CBX8 6.14 × 10 -4 0.02 0.030 0.02 0.661 0.01 0.341 -0.01 
45 cg05914582 12:6588003 VAMP1, MRPL51 6.18 × 10 -4 0.03 0.012 0.03 0.003 -0.08 0.002 -0.05 
46 cg04522915 20:646942 SRXN1, SCRT2 6.59 × 10 -4 0.04 0.036 0.04 0.020 -0.11 0.020 -0.06 
47 cg01164118 3:74571289 CNTN3 6.87 × 10 -4 -0.05 0.076 -0.04 0.368 0.04 0.730 0.01 
48 cg15889768 17:42619247 GPATCH8, FZD2 6.92 × 10 -4 0.04 0.076 0.03 0.260 -0.04 0.020 -0.05 
	 69	
49 cg13392468 9:139701199 C9orf86 6.95 × 10 -4 0.06 0.162 0.04 0.908 -0.01 0.140 -0.05 
50 cg01573067 6:168067266 TCP10, MLLT4 7.55 × 10 -4 0.06 0.004 0.08 0.010 -0.14 7.34 × 10 -4 -0.09 
51 cg09208540 10:135340467 CYP2E1 7.71 × 10 -4 0.16 0.061 0.15 0.004 -0.44 0.001 -0.27 
52 cg21648202 19:14171331 PALM3 7.89 × 10 -4 0.07 0.115 0.05 0.173 -0.10 0.060 -0.08 
53 cg08144503 16:67450471 ZDHHC1 7.91 × 10 -4 0.03 0.010 0.04 0.048 -0.07 0.197 -0.03 
54 cg23709618 4:119273073 PRSS12 8.19 × 10 -4 0.04 0.021 0.05 0.003 -0.12 0.005 -0.06 
55 cg07509161 14:54552632 CDKN3, BMP4 8.52 × 10 -4 -0.04 0.023 -0.05 0.228 0.05 4.08 × 10 -4 0.08 
56 cg00368296 19:8052183 TIMM44, ELAVL1 8.66 × 10 -4 0.04 0.132 0.03 0.651 -0.02 0.279 -0.02 
57 cg05387404 3:47888039 DHX30, MAP4 8.73 × 10 -4 0.03 0.040 0.03 0.395 -0.02 0.038 -0.03 
58 cg16005818 1:7700504 VAMP3, CAMTA1 8.78 × 10 -4 -0.01 6.12 × 10 -4 -0.01 2.77 × 10 -4 0.03 0.001 0.01 
59 cg26380116 12:125927452 TMEM132B 8.86 × 10 -4 0.04 0.011 0.05 0.452 -0.04 0.163 -0.04 
60 cg17313945 6:32977983 HLA-DOA 9.10 × 10 -4 0.05 0.397 0.02 0.274 -0.06 0.037 -0.06 
61 cg00476944 7:157411142 DNAJB6, PTPRN2 9.35 × 10 -4 0.04 0.038 0.04 0.001 -0.15 0.009 -0.06 
62 cg00958409 1:155023062 ADAM15 9.39 × 10 -4 0.03 0.010 0.03 0.138 -0.07 0.018 -0.06 
63 cg16008138 17:60885892 MARCH10 9.88 × 10 -4 0.04 0.083 0.04 0.131 -0.07 0.002 -0.07 
64 cg23053407 1:104068312 RNPC3 9.89 × 10 -4 0.04 0.042 0.04 0.638 -0.03 0.128 -0.05 
65 cg00171161 4:88343636 NUDT9 0.001 0.01 0.010 0.01 0.076 -0.02 0.072 -0.01 
66 cg04636557 1:231472424 C1orf124, EXOC8 0.001 0.07 0.049 0.07 0.404 -0.07 0.009 -0.12 
67 cg00053916 8:37457329 ZNF703, KCNU1 0.001 0.06 0.016 0.07 0.051 -0.13 0.014 -0.08 
68 cg19506311 7:994742 ADAP1 0.001 0.07 0.032 0.08 0.022 -0.19 0.032 -0.10 
69 cg02334521 10:324041 ZMYND11, DIP2C 0.001 0.02 0.015 0.02 0.003 -0.06 0.031 -0.02 
70 cg04770705 16:28509428 APOBR, IL27 0.001 0.05 0.270 0.03 0.080 -0.10 0.201 -0.04 
71 cg03272089 19:2191261 SF3A2, DOT1L  0.001 0.02 0.003 0.03 0.001 -0.09 0.194 -0.02 
72 cg19786808 17:71431877 CDC42EP4, SDK2 0.001 0.04 0.002 0.06 0.033 -0.09 8.51 × 10 -4 -0.07 
73 cg18101118 3:45017337 EXOSC7, ZDHHC3 0.001 0.07 0.168 0.05 0.069 -0.13 0.161 -0.05 
74 cg14375923 13:91827042 GPC5 0.001 0.05 0.011 0.06 0.173 -0.08 0.005 -0.09 
75 cg06801943 1:2101479 SKI, PRKCZ 0.001 0.05 0.047 0.05 0.086 -0.09 0.016 -0.07 
76 cg01465364 10:135340721 CYP2E1 0.001 0.08 0.007 0.10 0.003 -0.24 2.78 × 10 -4 -0.15 
	 70	
77 cg20610031 4:1950081 WHSC2, WHSC1 0.001 0.03 0.002 0.04 0.024 -0.07 0.108 -0.03 
78 cg16498741 8:41144520 ZMAT4, SFRP1 0.001 0.10 0.039 0.10 0.150 -0.16 0.012 -0.15 
79 cg10013969 7:128003601 PRRT4 0.001 -0.08 0.026 -0.09 0.021 0.22 0.075 0.09 
80 cg03440989 17:40155391 DNAJC7, CNP 0.001 0.03 0.066 0.03 0.199 -0.03 0.012 -0.03 
81 cg02420027 13:41632640 WBP4 0.001 0.04 0.001 0.07 0.438 -0.04 0.472 -0.02 
82 cg15426878 3:50368947 TUSC2 0.001 0.02 0.017 0.02 0.020 -0.05 0.393 -0.01 
83 cg05357287 11:67408159 TBX10 0.001 0.07 0.020 0.08 0.843 -0.02 0.246 -0.05 
84 cg14868466 10:134018073 DPYSL4, STK32C 0.001 -0.02 0.005 -0.03 0.035 0.05 0.026 0.03 
85 cg23205676 1:17046897 NBPF1, MST1P9 0.001 0.06 0.212 0.04 0.263 -0.08 0.005 -0.10 
86 cg11099375 17:62141556 ICAM2, ERN1 0.001 0.06 0.006 0.08 0.017 -0.15 7.27 × 10 -6 -0.13 
87 cg07617759 2:33050475 LTBP1, TTC27 0.001 0.10 0.564 0.03 0.527 0.07 0.431 -0.04 
88 cg18524934 2:97164073 NEURL3, NCAPH 0.001 0.07 0.078 0.06 0.106 -0.11 0.002 -0.11 
89 cg21672450 12:132663793 NOC4L, GALNT9 0.001 0.06 0.022 0.07 0.245 -0.07 0.003 -0.10 
90 cg26343667 3:156391915 TIPARP 0.001 0.03 0.076 0.03 0.278 -0.04 0.333 -0.02 
91 cg11516031 4:15776675 CD38 0.001 0.02 0.072 0.02 0.015 -0.05 0.004 -0.03 
92 cg07813851 1:7466976 VAMP3, CAMTA1 0.001 0.05 0.060 0.05 0.680 0.02 0.352 -0.03 
93 cg27207776 16:71393801 CALB2, ZNF23 0.001 0.06 0.082 0.05 0.069 -0.11 0.233 -0.04 
94 cg27028750 5:1349422 CLPTM1L 0.001 0.06 0.119 0.04 0.147 -0.09 9.49 × 10 -4 -0.11 
95 cg13173415 11:12065669 MICAL2, DKK3 0.001 0.05 0.065 0.05 0.111 -0.09 0.018 -0.07 
96 cg14186846 6:15256907 JARID2, DTNBP1 0.001 0.07 0.091 0.06 0.050 -0.15 0.027 -0.09 
97 cg26053073 8:131455383 ASAP1 0.001 0.07 0.022 0.08 0.212 -0.12 0.195 -0.07 
98 cg24134918 6:149886976 C6orf72 0.001 0.05 0.009 0.06 0.017 -0.11 0.296 -0.03 
99 cg03511957 1:167765211 MPZL1, ADCY10 0.001 0.08 0.013 0.10 0.020 -0.18 0.038 -0.09 
100 cg23330788 4:21699988 KCNIP4 0.001 0.07 0.225 0.05 0.999 0.00 0.644 -0.02 
	 71	
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Figure 2-4. Associations of DNA methylation with exposure and outcome measures were 
highly correlated comparing sex-regressed and covariate free models. Effect sizes of the 
100 top-ranked DMPs associated with (a) exposure group (> 6 months vs < 6 months) (b) 
quantitative measures of exposure time (c) IQ at age 15 and (d) Theory of Mind at age 11 in 
covariate-free tests are correlated almost perfectly effect sizes in sex-regressed models at the 
same 100 probes (r = 1.00, P ≤ 1.00 × 10-50 for each test). The top ten associated sites for the 
covariate-free model are highlighted in red in each of the panels
























































































Figure 2-5. The four top-ranked DMPs associated with severe early-life adversity. 
Associations were identified comparing the >6 months and <6 months exposure groups. (a) 
cg11634248, P = 2.35 × 10-5, (b) cg14272935, P = 6.89 × 10-5, (c) cg16668903, P = 9.75 × 10-5, 
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Figure 2-6. Correlations between the top 100 exposure-associated DMPs and continuous 
exposure duration. For the 100 top ranked exposure-associated DMPs (see Supplementary 
Table 4) effect sizes for association with exposure group correlated significantly with effect sizes 
for association with continuous exposure duration (r = 0.93, P = 3.03 × 10-44). The top ten DMPs 





Supplementary Figure 4 
 
	
Figure 2-7. A DMR on chromosome 10 spanning nine sequential 450K array probes 
(chr10:135340445-135341026) was identified by comb-P. DNA methylation across this region 
is significantly elevated (P = 2.21 × 10-10; corrected Šidák P = 2.98 × 10-5) in individuals exposed 
to severe institutional deprivation. The >6 months institutionalized group (green) is characterized 
by consistent hypermethylation across the whole DMR compared to the <6 months 
institutionalized group (blue) and UK control group (red). An extended ~3kb region spanning the 
first two exons of CYP2E1 is shown with the DMR region highlighted in light blue. The probe 
found to be associated with prenatal maternal antidepressant exposure in neonates by Gurnot et 
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Figure 2-8. DNA methylation values for CpG sites within the CYP2E1 DMR quantified using 
the Illumina 450K array were validated using bisulfite-pyrosequencing. The assay spanned 
three CpG sites (cg14250048, cg00436603, and cg01465364) within the DMR, for which there 
was a highly-significant correlation between DNA methylation levels independently derived from 
the 450K array and bisulfite-pyrosequencing experiments (r = 0.52, P = 0.001). Shown is the 
average DNA methylation (%) across the three CpG sites as measured by bisulfite-
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Figure 2-9.	Correlations between the top 100 exposure-associated DMPs and IQ at age 15. 
For the 100 top ranked exposure-associated DMPs (see Table 2-7) effect sizes for association 
with exposure group correlated significantly with effect sizes for association with IQ at age 15 (r 
= -0.82, P = 4.48 × 10-25). The top ten DMPs associated with exposure group (see Table 2-1) are 
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The question of “how stress gets under the skin” has intrigued and puzzled 
researchers for decades (Rutter, 1981, Lupien et al., 2009, McEwen, 2012). 
Early-life stress and victimisation have been linked to numerous and often 
persistent adverse health outcomes, both physical and psychological (Fisher et 
al., 2015, Gilbert et al., 2009, Widom et al., 2012, Anda et al., 2006), including 
but not limited to obesity (Baldwin et al., 2016), inflammation (Danese et al., 2009) 
and depression (Danese et al., 2009). Furthermore, these adverse exposures 
have been associated with neurobiological sequelae including altered brain 
development, plasticity and structure (McEwen, 2012, Lupien et al., 2009, 
Teicher and Samson, 2016). Direct effects of stress on the neuroendocrine 
response system involving HPA axis activation and glucocorticoid release have 
been identified both in animal (Liu et al., 1997) and human work (Taylor, 2010, 
Gunnar and Quevedo, 2007). Epigenetic modifications and specifically DNA 
methylation have been proposed as the missing link in the cascade between 
stress exposure and outcomes, providing a heritable but dynamically adaptive 
mechanism by which the organism responds to the environment and resulting in 
stable gene expression changes (Petronis, 2010, Szyf and Bick, 2013, Gluckman 
et al., 2008, Provencal and Binder, 2015, Lutz and Turecki, 2014).  
An increasing body of research has experimentally linked adverse early-life 
environments to alterations in DNA methylation in brain tissue of rodents (Weaver 
et al., 2004, Desarnaud et al., 2008, Kember et al., 2012, Kundakovic et al., 2013, 
Doherty et al., 2016, Saunderson et al., 2016, Murgatroyd et al., 2009, Roth et 
al., 2009) and primates (Provencal et al., 2012). There appears to be a clear 
focus on genes involved in HPA axis response with a majority of the work 
concentrating on the glucocorticoid receptor gene NR3C1, and some studies 
considering AVP (Kember et al., 2012, Murgatroyd et al., 2009) and BDNF 
(Kosten and Nielsen, 2014, Doherty et al., 2016, Roth et al., 2009). Most studies 
in human samples have been observational and often conducted in surrogate 
tissue, including blood, epithelial tissue or saliva. A substantial body of research 
has accumulated linking early-life stress to differences in DNA methylation in the 
glucocorticoid receptor (Palma-Gudiel et al., 2015). A few studies have been able 
to conduct research on post-mortem human brain tissue, confirming the 
differences in DNA methylation at NR3C1 observed in rodent brains for human 
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samples (Labonte et al., 2012, Suderman et al., 2012, McGowan et al., 2009). 
Studies in peripheral tissues have furthermore linked methylation in a variety of 
other genes to adverse early-life environments, including FKBP5 (Tyrka et al., 
2012), SLC6A4 (Ouellet-Morin et al., 2013, Booij et al., 2015, Devlin et al., 2010), 
and KITLG (Houtepen et al., 2016). The only quasi-experimental settings, in 
which exposure to adverse early-life environments is randomised, involve studies 
of institutionalisation (Naumova et al., 2012, Non et al., 2016, Kumsta et al., 
2016). Findings identifying differential DNA methylation associated with the 
institutionalisation exposure from these studies are sparse and non-overlapping, 
but include differential methylation at the genes FKBP5, SLC6A4 and CYP2E1. 
Despite the large number of studies, few have taken an unbiased, genome-wide 
approach and there appears to be a mostly heterogeneous picture when 
considering results from this subset of studies (Houtepen et al., 2016, Kumsta et 
al., 2016, Weder et al., 2014). In addition to the results the exposure variables 
are varied and include institutionalisation (Naumova et al., 2012), maternal 
psychiatric disease (Devlin et al., 2010), sexual abuse (Beach et al., 2010), 
neglect (Weder et al., 2014), and trauma (Tyrka et al., 2012); many of which were 
collected retrospectively and are potentially liable to confounding (Danese et al., 
2016). Other types of confounding including from familial environments, toxic 
substance exposure or cell-type composition in studies using whole blood are 
rarely addressed. Most studies in animal and human samples are characterised 
by very small sample sizes, even though most research on human samples was 
conducted in peripheral tissues. 
In this study, we undertook the largest and most systematic investigation of early-
life victimisation and its association with DNA methylation in whole blood to date 
(n = 1,658). Using the Environmental Risk (E-Risk) Longitudinal Twin Study we 
tested whether victimisation exposure in adolescence or childhood was 
associated with altered DNA methylation in whole blood at age 18, profiled on the 
Illumina 450K HumanMethylation Array. To interrogate the effects of specific 
forms of victimisation, we ascertained multiple different victimisation types across 
the first two decades of life, allowing us to study the combined, shared and unique 
effects of these exposures. We were able to examine two major developmental 
periods, adolescence and childhood, teasing apart their individual and cumulative 
epigenomic correlates. Our full sample of 1,658 individuals profiled for DNA 
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methylation allowed us to undertake the most powerful epigenomic association 
study of early-life victimisation to date, at the same time we exploited the twin 
design of the E-Risk study to investigate twin pair epigenomic differences linked 
to divergent victimisation exposures, enabling us to control for familial 
environments as well as genetic effects. Our main aim was to provide a 
comprehensive and systematic analysis of DNA methylation signatures of early-
life victimisation in blood and their potential role in the biological embedding of 
developmental adversities.  
 
3.2 Methods 
3.2.1 Study sample 
Participants were members of the Environmental Risk (E-Risk) Longitudinal Twin 
Study, which tracks the development of a birth cohort of 2,232 British children. 
The sample was drawn from a larger birth register of twins born in England and 
Wales in 1994-95 (Trouton et al., 2002). Full details about the sample were 
reported previously (Moffitt and E-Risk Study Team, 2002). Briefly, the E-Risk 
sample was established in 1999-2000, when 1,116 families (93% of those 
eligible) with same-sex 5-year-old twins participated in home-visit assessments. 
This sample consisted of 55% monozygotic (MZ) and 45% dizygotic (DZ) twin 
pairs; sex was evenly distributed within zygosity (49% male) and 7% of the 
sample self-reported as Black, Asian, or mixed-race. Families were recruited to 
be representative of the UK population with newborns in the 1990s, to ensure 
adequate numbers of children in disadvantaged homes and to avoid an excess 
of twins born to well-educated women using assisted reproduction. The study 
sample represents the full range of socioeconomic conditions in Great Britain, as 
reflected in the families’ distribution on a neighbourhood-level socioeconomic 
index (Odgers et al., 2012). 
Follow-up home visits were conducted when children were aged 7 (98% 
participation), 10 (96% participation), 12 (96% participation), and most recently, 
18 years (93% participation).  At age 18, 2,066 participants were assessed. The 
average age at the time of assessment was 18.4 years (SD = 0.36); all interviews 
were conducted after the 18th birthday.  
Our epigenetic study used DNA from a single tissue: blood. At age 18, whole 
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blood was collected from 82% (n = 1,700) of the participants in 10mL K2EDTA 
tubes. DNA was extracted from the buffy coat using a Flexigene DNA extraction 
kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. There 
were no differences between those who did and did not provide blood in terms of 
SES (P = 0.34, chi-squared test), age-5 IQ scores (P = 0.14, t-test), age-5 
internalising or externalising behaviour problems (P = 0.23 and P = 0.64, t-tests), 
childhood polyvictimisation (P = 0.42, Z-test), or adolescent polyvictimisation (P 
= 0.21, Z-test). Study members who did not provide blood provided buccal swabs, 
but these were not included in our methylation analysis to avoid tissue-source 
confounds. 
The Joint South London and Maudsley and the Institute of Psychiatry Research 
Ethics Committee approved each phase of the study. Parents gave informed 
consent and twins gave assent between 5-12 years and then informed consent 
at age 18. The analysis plan for this study was posted in advance 
(http://www.moffittcaspi.com).  
 
3.2.2 Measures  
Adolescent victimisation. The adolescent victimisation measures have been 
described previously (Fisher et al., 2015). Briefly, at age 18, participants were 
interviewed about exposure to a range of adverse experiences between 12-18 
years using the Juvenile Victimization Questionnaire (JVQ) (Finkelhor et al., 
2011, Hamby et al., 2004), adapted as a clinical interview. Our adapted JVQ 
comprised 45 questions covering seven different forms of victimisation: Crime 
victimisation, peer/sibling victimisation, internet/mobile phone victimisation, 
sexual victimisation, family violence, maltreatment, and neglect. Exposure to 
each type of adolescent victimisation was coded on a 5-point scale, in which “0” 
indicated “no exposure” and “5” indicated “definite” or “very severe” exposure.  
The adolescent polyvictimisation variable was derived by summing all 
victimisation experiences that received a code of at least “4”: (i.e., severe 
exposure). We winsorized the polyvictimisation distribution into a four-category 
variable (representing 0, 1, 2, 3+ experiences), as we did childhood 
polyvictimisation (Table 3-1). An overview of all victimisation exposures analysed 
in adolescence is given in Table 3-2. 
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Table 3-1. Overview of adolescent victimisation, smoking exposure and SES. Shown are 
the distributions of gender, smoking exposure and socioeconomic status (SES) across adolescent 













m/f 538/526 171/154 74/76 48/70 1/0 
Smoking yes/no 155/908 98/226 51/99 73/45 0/1 
Pack-years (mean) 0.28 0.77 0.87 1.75 - 
SES (mean) 2.10 1.89  1.83 1.69 - 












m/f 594/598 169/186 41/29 28/13  
Smoking yes/no 207/983 111/244 38/32 21/20  
Pack-years (mean) 0.37 0.75 1.45 1.85  
SES (mean) 2.13 1.77  1.59 1.24  












m/f 425/409 138/116 190/222 79/79  
Smoking yes/no 102/731 65/189 125/286 85/73  
Pack-years (mean) 0.22 0.59 0.69 1.68  
SES (mean) 2.19 1.67  2.03 1.51  
 
 
Childhood victimisation. The childhood victimisation measures have been 
described previously (Danese et al., 2016). Briefly, exposure to several types of 
victimisation was assessed repeatedly when the children were 5, 7, 10, and 12 
years of age. These were exposure to domestic violence between the mother and 
her partner; frequent bullying by peers; physical maltreatment by an adult; sexual 
abuse; emotional abuse; and physical neglect. Exposure to each type of 
victimisation was coded on a 3-point scale, in which “0” indicated “no exposure,” 
“1” indicated “probable” or “less severe” exposure, and “2” indicated “definite” or 
“severe” exposure.  
We operationalised polyvictimisation as the count of forms of victimisation 
experienced by a child. This variable was derived by summing all childhood 
victimisation experiences coded as 2. Next, we winsorized the polyvictimisation 
distribution into a four-category variable (representing 0, 1, 2, 3+ experiences; 
Table 3-1). An overview of all victimisation exposures analysed in childhood is 
given in Table 3-2. 
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Cumulative victimisation. Latent Class Analysis (LCA) is a person-centered 
analytical approach that classifies individuals into groups or classes based on a 
profile of variables, in this case the degree of exposure (i.e., none, moderate, or 
severe) to the six types of victimisation experienced during childhood (ages 5-12 
years) and seven types of victimisation experienced during adolescence (ages 
12-18 years). Since we were interested in the profiles of individuals who were 
victimised, we only classified n = 1,043 subject members who experienced at 
least one severe form of victimisation across childhood or adolescence. LCA was 
conducted in MPlus v7.4 and accounted for clustering of twins within families. 
The results of the Latent Class Analysis are described in the Results section and 
Table 3-1. For sensitivity analyses we additionally operationalised cumulative 
victimization as the sum of the childhood and adolescent victimization (Table 
3-2). 
 
Smoking. We assessed smoking among E-risk participants by calculating pack-
years, where pack-years = (number of cigarettes smoked per day × number of 
years smoked) / 20; one pack-year = 7,305 cigarettes. 
 
Socioeconomic status. This measure has been described previously 
(Trzesniewski et al., 2006): socioeconomic status (SES) was operationalised as 
a standardised composite of income, education, and occupation. 
 
 
3.2.3 Genome-wide quantification of DNA methylation  
Experimental procedure. We assayed 1,669 samples (out of 1,700 available 
whole blood samples); 31 samples were not useable (e.g., due to low DNA 
concentration). ~500ng of DNA from each sample was treated with sodium 
bisulfite, using the EZ-96 DNA Methylation kit (Zymo Research, CA, USA). DNA 
methylation was quantified using the Illumina Infinium HumanMethylation450 
BeadChip (Illumina Inc, CA, USA) (“Illumina 450K array”) run on an Illumina iScan 
System (Illumina, CA, USA) using the manufacturers’ standard protocol. 
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Members of complete twin pairs (n = 743 pairs; n = 1,486 individuals) were 
randomly assigned to bisulfite-conversion plates and Illumina 450K arrays, with 
siblings processed in adjacent positions to minimise batch effects. Singletons (n 
= 183) – i.e., members of incomplete twin-pairs - were randomised and processed 
on two separate bisulfite-conversion plates. Fully methylated control samples 
(CpG Methylated HeLa Genomic DNA; New England BioLabs, MA, USA) were 
included in a random position on each plate; the distinct DNA methylation profile 
of this sample enabled us to confirm the experiment was successful and to ensure 
there were no plate mix-ups or rotations.  
 
Data pre-processing. Data from 1,669 unique individuals entered our Quality 
Control (QC) pipeline, which was performed in the R statistical programing 
environment (R Core Team, 2013). Data were imported using the 
methylumIDAT() function from the methylumi package (Davis et al., 2015). The 
first QC step assessed the signal intensities, excluding samples with both median 
methylated (‘M’) and unmethylated (‘U’) intensities < 2500. Second, the fully 
methylated controls were identified - their intensity profiles were characteristic of 
the sample being fully methylated and confirmed that no plate rotations or plate 
mislabelling had occurred – and subsequently removed from the dataset. Third, 
using ten control probes included on the 450K array, we examined the efficiency 
of the sodium bisulfite conversion reaction; samples were excluded if their 
“conversion score” was < 80. Fourth, multidimensional scaling was performed for 
DNA methylation probes on each of the sex chromosomes and compared to the 
reported gender. Fifth, to confirm genetic identity of the DNA samples, we 
assessed genotype concordance between SNP probes on the 450K array and 
data generated using Illumina OmniExpress24v1.2 genotyping BeadChips.  
1,658 samples passed our stringent QC pipeline, which will be referred to as the 
‘Sample of Individuals’. The data were then processed with the pfilter() function 
from the wateRmelon package (Pidsley et al., 2013) excluding 0 samples with > 
1% of sites with a detection P value > 0.05, 567 sites with  bead count < 3 in 5% 
of samples and 1,448 probes with > 1% of samples with detection P value > 0.05. 
The data were normalised with the dasen() function from the wateRmelon 
package (Pidsley et al., 2013). From this dataset, we extracted all complete twin 
pairs (i.e. both members passed QC and were run on the same chip) (n = 732 




Figure 3-1. Distribution of DNA methylation age acceleration in the E-Risk EWAS sample. 
 
 
As a further check, DNA methylation values for all samples were uploaded to the 
online Epigenetic Clock software (Horvath, 2013) for DNA methylation age 
(DNAmAge) and tissue prediction. The majority of samples (72%) were predicted 
within 5 years as illustrated by the distribution of DNA methylation age 
acceleration (DNA methylation age acceleration = chronological age – DNA 
methylation age estimate; Figure 3-1) and all were predicted as of blood origin. 
Prior to any analyses, probes with common (> 5% MAF) SNPs within 10bp of the 
single base extension and probes with sequences previously identified as 
potentially hybridising to multiple genomic loci were excluded (Price et al., 2013, 















3.2.4 Statistical methods 
All statistical analyses were conducted in R version 3.3.0 unless otherwise 
specified.  
 
Testing the association between victimisation and DNA methylation: An 
individual-level analysis  
Our first analysis used the Sample of Individuals, which includes all E-risk 
participants included in DNA methylation profiling who passed QC and filtering. 
We used a linear model to test the association between DNA methylation 
variation (dependent variable) and victimisation. The model included the following 
covariates: Sex, batch, and cell-type proportion estimates. Because the sample 
included members of twin pairs, we accounted for the non-independence of 
observations by calculating robust standard errors using the R packages plm 
(Croissant and Millo, 2008), lme4 (Bates et al., 2015) and sandwich (Zeileis, 
2004). To control for smoking, we re-estimated the model by adding smoking 
pack-years (see Measures) as an additional covariate. 
The same basic linear model was used to test methylomic variation associated 
with (1) adolescent polyvictimisation and its seven subtypes of victimisation: 
maltreatment, neglect, sexual victimisation, family violence, peer/sibling 
victimisation, internet/mobile phone victimisation and crime victimisation; (2) 
childhood polyvictimisation and its six subtypes: physical abuse, physical neglect, 
emotional neglect, sexual victimisation, domestic violence and bullying; and (3) 
cumulative polyvictimisation. The victimisation variables are summarised in 
Table 3-2. 
 
Testing the association between victimisation and DNA methylation: A twin- 
difference analysis 
Because the majority (88%) of individuals in E-Risk who were profiled for DNA 
methylation are members of a twin-pair, we were able to use a discordant-twin 
design to control for the confounding effects of family background and genetic 
factors when testing the association between victimisation and DNA methylation. 
We ran a dizygotic (DZ) twin-difference model to control for family background 
and a monozygotic (MZ) twin-difference model to correct for both family 
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background and genetic influences for each of the three main exposure 
measures: (1) adolescent polyvictimisation, (2) childhood polyvictimisation, and 
(3) cumulative polyvictimisation. A linear fixed effects model was used to test the 
association between DNA methylation differences within twin pairs (dependent 
variable) and differences in their victimisation exposure, controlling for 
differences in blood cell-type proportion estimates. Because members of each 
twin pair were run in the same batch and are of the same sex, controlling for batch 
and sex was not necessary.    
  
Table 3-2. Victimisation variables used in this study 
Time period Victimisation 
type 
Variable measurement Levels Type 
Adolescence Polyvictimisation 
- continuous 
Sum of individual victimisation 
types, winsorized at 3. 
0-3+ Continuous 
 Maltreatment Severity code  0-5 Continuous 
 Neglect  Severity code 0-5 Continuous 
 Sexual 
victimisation 
Severity code   0-5 Continuous 
 Family violence Severity code  0-5 Continuous 
 Peer/sibling 
victimisation 




Severity code  0-5 Continuous 
 Crime 
victimisation 
Severity code  0-5 Continuous 
Childhood Polyvictimisation 
- continuous 
Sum of individual victimisation 
types, winsorized at 3. 
0-3+ Continuous 
 Physical abuse Severity code  0-2 Continuous 
 Physical neglect Severity code  0-2 Continuous 
 Emotional 
neglect 
Severity code  0-2 Continuous 
 Sexual 
victimisation 
Severity code  0-2 Continuous 
 Domestic 
violence  
Severity code. 0-2 Continuous 
 Bullying Severity code  0-2 Continuous 
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Cumulative Latent Class 
Analysis (LCA) -
factor 
A latent class analysis of 
individual childhood and 
adolescent victimisation types 
resulted in four subgroups of 
participants: 0. never 
victimised, 1. domestic 
violence during childhood, 2. 
victimised by peers and ‘street’ 
crime, 3. revictimised by 
multiple severe types of 
victimisation  
0-3 Factor 
 Additive model Cumulative victimisation = 







Multiple testing threshold 
To establish an array-wide multiple testing significance threshold, 5,000 
permutations were performed repeating a linear regression model for randomly 
selected groups of cases and controls. For each permutation, P values from the 
EWAS were saved and the minimum identified. Across all permutations the 
5th percentile was calculated to generate the 5% alpha significance threshold (P 
< 1.61 ´ 10-7). Identifying a study-wide multiple-testing threshold would be 
extremely challenging, given the correlated nature of the analyses performed on 
each phenotype (robust standard error EWAS, twin difference models, smoking 
correction) as well as the correlation of the different victimisation exposure 
measures. Therefore, we report raw P values for all analyses, highlighting the 
array-wide significance level in plots and text. 
 
Cell counts 
Cell-type heterogeneity is known to affect studies of DNA methylation and should 
therefore be adjusted for where possible (Houseman et al., 2012). Cell-type 
proportion estimates were obtained using the online tool at 
https://dnamage.genetics.ucla.edu (Horvath, 2013), which bases its estimates on 
the Houseman et al reference-based estimator (Houseman et al., 2012) for CD4+ 
T cells, natural killer cells, monocytes and granulocytes and on an algorithm 
developed by Horvath (Horvath, 2013) for naïve CD8 T cells, CD8+ T cells and 









Candidate gene analyses 
We interrogated candidate genes which are known to be involved in stress 
reactivity and which have been previously reported to be associated with 
response to trauma and with indices of psychosocial stress. The candidates 
comprise HPA-axis genes N3RC1, FKBP5, CRHR1, BDNF and AVP. 
Additionally, we included SLC6A4 because of its link to stress reactivity (Caspi et 
al., 2003) as well as CYP2E1, which has been shown to be differentially 
methylated in the context of severe early-life institutional deprivation (Kumsta et 
al., 2016). Probes were annotated to genes using the Genomic Region 
Enrichment and Annotation Tools (GREAT) (McLean et al., 2010). For each 
candidate gene, we examined the association between all annotated probes and 
adolescent and childhood victimisation, respectively.  We provide a regional 
Manhattan plot showing the array-wide P value threshold as well as a gene-wide 
significance threshold based on a Bonferroni-correction for the number of probes 
annotated to the gene. In addition, we calculated combined gene-wide P values 
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Regional Manhattan plots were generated using the Bioconductor package ggbio 
(Yin et al., 2012). 
 
Testing the association between victimisation and epigenetic age acceleration  
For each participant, we calculated DNA methylation age acceleration by 
subtracting their chronological age at the time blood was collected from their DNA 
methylation age estimate based on the epigenetic clock (Horvath, 2013). DNA 
methylation age acceleration was regressed onto adolescent, childhood and 






3.3.1 Victimisation in the peak period of adolescence 
Adolescents are victimised by a more diverse set of actors across a wider range 
of environments than any other age group.  Exposure to multiple types of 
victimisation - including relational aggression, sexual victimisation, and serious 
violent crime - peaks during adolescence (Brown et al., 2005, Sickmund and 
Puzzanchera, 2014, Peskin et al., 2006). Therefore, we tested whether 
victimisation during this peak period of victimisation exposure was associated 
with methylomic variation quantified in whole blood at age 18. We regressed DNA 
methylation onto adolescent polyvictimisation (see Methods, Table 3-1) 
accounting for family structure across all 1,658 samples passing our stringent QC 
pipeline (see Methods), and including batch, sex and derived blood cell-type 
proportion estimates as covariates. DNA methylation at four differentially 
methylated positions (DMPs) (cg05575921, cg26703534 and cg21161138 
annotated to AHRR and C5orf55, and cg14179389 annotated to GLMN and 
GFI1) was associated with adolescent polyvictimisation at an array-wide 
significance level (P < 1.61 ´ 10-7; Figure 3-3, top panel; Table 3-3). Across all 
probes on the array, the effect sizes were small (Figure 3-4) and each of the four 
significant DMPs were characterised by methylation differences of less than 1.5% 




Table 3-3. We identified four array-wide significant DMPs associated with adolescent 
polyvictimisation. Shown for each DMP are chromosomal location (hg19), annotated genes as 
identified by GREAT (McLean et al., 2010), P value from our linear model with robust standard 
errors (Methods) and effect size (difference in DNA methylation (%) for each additional form of 
victimisation experienced). 
Probe Position Annotated genes P value Effect size 
cg05575921 5:373378 AHRR; C5orf55 2.20 ´ 10-10 -1.36 
cg26703534 5:377358 C5orf55; AHRR 2.57 ´ 10-10 -0.67 
cg21161138 5:399360 C5orf55; AHRR 1.52 ´ 10-08 -0.67 




Figure 3-3. The association between DNA methylation and adolescent polyvictimisation is 
confounded by smoking. The four panels show –log10 P values for the association between 
DNA methylation and adolescent polyvictimisation. Top panel: Four probes pass the array-wide 
multiple testing threshold (P < 1.61 ´ 10-7) in a regression model controlling for batch, sex and 
cell-type proportion estimates (see Table 3-3). Second panel: We identify no significant DMPs 
when adding smoking pack-years as a further covariate. The bottom panels show P value 
distributions from two twin difference models, which examine the association between twin-pair 
differences in DNA methylation and differences in polyvictimisation, while controlling for 
differences in cell-type proportion estimates. No significant associations were observed for either 






Figure 3-4. Volcano plot showing effect sizes and P values for the association between 
DNA methylation and adolescent polyvictimisation. The distribution of –log10 P values and 
effect sizes (DNA methylation change for each increase in polyvictimisation score) are shown. 





Figure 3-5. DNA methylation patterns across the four array-wide significant probes 







































































One important challenge to interpreting the association between victimisation and 
DNA methylation is that victimisation is often correlated with exposure to 
environmental toxins; specifically, victimised adolescents are more likely to 
smoke (Nichols and Harlow, 2004, Norman et al., 2012). Additionally, exposure 
to tobacco smoke has been reported to be associated with striking effects on 
DNA methylation at specific CpG sites across the genome (Elliott et al., 2014, 
Zeilinger et al., 2013, Tsaprouni et al., 2014) and is an important confounder in 
epigenetic epidemiology (Hannon et al., 2016a). In particular, DNA methylation 
differences in the gene AHRR, to which three of our four array-wide significant 
probes are annotated, have been found to be robustly associated with smoking 
(Joehanes et al., 2016).  We assessed smoking among E-Risk participants by 
calculating the number of pack-years that they smoked (see Methods), observing 
that victimised adolescents were significantly more likely to smoke (P = 2.51 ´ 




Figure 3-6. Smoking is associated with adolescent polyvictimisation and DNA methylation. 
(A) Smoking pack-years were significantly associated with adolescent polyvictimisation (P = 4.92 
´ 10-14) in E-Risk, with victimised adolescents more likely to smoke and to smoke more pack-
years. (B) DNA methylation at 64 probes was significantly associated (P < 1.61 ´ 10-7) with 
smoking pack-years in a model regressing DNA methylation onto pack-years, controlling for 
batch, sex and cell-type composition. 	
 
	
We subsequently performed an EWAS of smoking among E-Risk participants, 
regressing DNA methylation onto smoking pack-years, while controlling for 
family-relatedness structure as well as covarying batch, sex and derived blood 
cell-type proportion. As expected, we identified widespread DNA methylation 




















significant at P < 1.61 ´ 10-7 (Table 3-4). All 64 probes were identified as 
associated with smoking in large recent EWAS of smoking (Joehanes et al., 
2016). Interestingly, there is substantial overlap between the probes identified to 
be associated with adolescent polyvictimisation and those associated with 
smoking pack-years in E-Risk, with three of the four array-wide significant probes 
from the polyvictimisation EWAS – those annotated to AHRR (Table 3-3) – also 




Table 3-4. 64 probes associated are significantly associated with smoking pack-years at 
an array-wide significance level (P < 1.61 ´ 10-7). All 64 probes had previously been reported 
as significantly associated with smoking by Joehanes et al., 2016. 
Probe Location Genes P value Beta (%) 
cg21161138 5:399360 C5orf55; AHRR 2.75 ´ 10-22 -1.27 
cg05575921 5:373378 AHRR; C5orf55 7.11 ´ 10-22 -3.00 
cg01940273 2:233284934 ALPI; ALPPL2 1.35 ´ 10-20 -1.24 
cg05951221 2:233284402 ALPI; ALPPL2 1.17 ´ 10-19 -1.19 
cg14753356 6:30720108 DDR1; IER3 1.79 ´ 10-18 -0.82 
cg22132788 7:45002486 PURB; MYO1G 2.09 ´ 10-18 1.38 
cg03636183 19:17000585 F2RL3 3.91 ´ 10-16 -1.15 
cg07826859 7:45020086 MYO1G 1.81 ´ 10-15 -0.40 
cg26703534 5:377358 C5orf55; AHRR 2.74 ´ 10-15 -1.15 
cg19572487 17:38476024 RARA; GJD3 3.65´ 10-15 -0.55 
cg14817490 5:392920 C5orf55; AHRR 4.15 ´ 10-15 -0.83 
cg25648203 5:395444 C5orf55; AHRR 5.09 ´ 10-15 -0.91 
cg03991871 5:368447 AHRR; C5orf55 4.81 ´ 10-14 -1.01 
cg12803068 7:45002919 PURB; MYO1G 1.05 ´ 10-13 1.92 
cg11071448 1:202584465 SYT2; PPP1R12B 1.52 ´ 10-13 -0.59 
cg01899089 5:369969 AHRR; C5orf55 3.01 ´ 10-13 -0.53 
cg06126421 6:30720080 DDR1; IER3 4.49 ´ 10-13 -1.05 
cg19089201 7:45002287 PURB; MYO1G 7.34 ´ 10-13 0.86 
cg21322436 7:145812842 CNTNAP2 9.23 ´ 10-13 -0.41 
cg02451831 7:26578098 SNX10; SKAP2 1.18 ´ 10-12 -0.60 
cg23916896 5:368804 AHRR; C5orf55 1.54 ´ 10-12 -0.77 
cg08709672 1:206224334 AVPR1B 1.98 ´ 10-12 -0.59 
cg25189904 1:68299493 GNG12 3.51 ´ 10-12 -1.18 
cg07986378 12:11898284 BCL2L14; ETV6 1.39 ´ 10-11 -0.71 
cg09935388 1:92947588 GLMN; GFI1 1.69 ´ 10-11 -1.24 
cg15542713 1:42385581 HIVEP3 2.43 ´ 10-11 0.98 
cg07339236 20:50312490 NFATC2; ATP9A 4.76 ´ 10-11 -0.53 
cg24049493 1:42385941 HIVEP3 1.38 ´ 10-10 0.81 
cg24688690 5:345850 AHRR; C5orf55 2.81 ´ 10-10 -0.28 
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cg04640972 10:8373522 GATA3 8.42 ´ 10-10 0.45 
cg16145216 1:42385662 HIVEP3 9.00 ´ 10-10 0.70 
cg15159987 19:17003890 F2RL3; CPAMD8 9.14 ´ 10-10 -0.45 
cg04885881 1:11123118 SRM 1.18 ´ 10-9 -0.58 
cg03450842 10:80834947 PPIF; ZMIZ1 1.23 ´ 10-9 -0.49 
cg02013841 13:49159767 CYSLTR2; RCBTB2 1.23 ´ 10-9 -0.63 
cg25949550 7:145814306 CNTNAP2 1.34 ´ 10-9 -0.26 
cg15342087 6:30720209 DDR1; IER3 1.69 ´ 10-9 -0.26 
cg05460226 17:8804279 PIK3R6; PIK3R5 2.40 ´ 10-9 -0.61 
cg26529655 5:424371 C5orf55; AHRR 2.65 ´ 10-9 -0.28 
cg20295214 1:206226794 AVPR1B; C1orf186 2.75 ´ 10-9 -0.42 
cg21733098 12:127931219 TMEM132C 4.26 ´ 10-9 -1.16 
cg04224247 X:9984515 CLCN4; SHROOM2 4.40 ´ 10-9 -0.68 
cg26764244 1:68299511 GNG12 4.45 ´ 10-9 -0.52 
cg00950497 10:116393423 AFAP1L2; ABLIM1 5.86 ´ 10-9 0.55 
cg02228160 5:143192067 NR3C1; YIPF5 7.65 ´ 10-9 0.46 
cg08442823 11:45951803 GYLTL1B; PHF21A 9.70 ´ 10-9 0.60 
cg02532700 12:37257404 NCF4 1.16 ´ 10-8 -0.47 
cg21446172 1:223745234 SUSD4; CAPN8 1.18 ´ 10-8 -0.43 
cg08266095 5:123149716 CSNK1G3; ZNF608 1.25 ´ 10-8 -0.58 
cg20505728 3:43800538 C3orf23; ABHD5 1.52 ´ 10-8 0.31 
cg10420527 11:68138505 PPP6R3; LRP5 1.83 ´ 10-8 -0.32 
cg09560590 5:143191663 NR3C1; YIPF5 1.98 ´ 10-8 0.40 
cg23973524 19:18873222 COMP; CRTC1 2.06 ´ 10-8 0.54 
cg19406367 1:66999929 SGIP1 2.13 ´ 10-8 0.41 
cg06395298 17:46651225 HOXB3 2.17 ´ 10-8 -0.62 
cg11824827 16:31075547 ZNF668 2.19 ´ 10-8 0.50 
cg14712058 19:16988083 F2RL3; SIN3B 2.28 ´ 10-8 -0.39 
cg04551776 5:393366 C5orf55; AHRR 2.50 ´ 10-8 -0.45 
cg16624521 5:172064552 NEURL1B 3.30 ´ 10-8 0.35 
cg03604731 2:96824799 DUSP2; STARD7 3.63 ´ 10-8 -0.22 
cg17287155 5:393347 C5orf55; AHRR 5.08 ´ 10-8 -0.25 
cg09651136 15:72525012 PKM2 6.45 ´ 10-8 0.33 
cg23126342 13:67801125 PCDH9 1.12 ´ 10-7 0.70 
cg00310412 15:74724918 CYP11A1; SEMA7A 1.26 ´ 10-8 -0.30 
 
 
We next regressed DNA methylation onto adolescent polyvictimisation including 
smoking pack-years as an additional covariate and found no DMPs passing our 
stringent array-wide significance threshold (Figure 3-3, second panel).  
 
Another prominent challenge to interpreting the association between victimisation 
and DNA methylation is that the association may be confounded not only by 
shared family-wide environmental factors, such as poverty, but also by genetic 
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factors.  For example, twin studies reveal that exposure to victimisation is under 
genetic influence (implying the presence of a gene-environment correlation) 
(Fisher et al., 2015), and that DNA methylation at a large number of sites across 
the genome is also heritable (Bell et al., 2011, Zhang et al., 2010, Hannon et al., 
2016b, Marzi et al., 2016). Studying exposure-discordant twins is a powerful 
approach to causal inference in epigenetic epidemiology because it allows 
researchers to compare same-age siblings who differ in their victimisation 
exposure but who otherwise grow up in the same family and share family-wide 
environmental risks (e.g., poverty) as well as twins who are genetically-identical 
(in the case of MZ twins) (Mill and Heijmans, 2013, Rakyan et al., 2011, Birney 
et al., 2016). We used a twin-difference design in which we regressed differences 
in DNA methylation between twins onto differences in victimisation exposure 
(Figure 3-7), controlling for differences in cell-type proportions. We found no 
array-wide significant associations between adolescent polyvictimisation and 















































Of course, not all forms of victimisation are alike. Some types involve physical 
injury whereas others involve psychological insult; some may be immediate, 
whereas others remote (e.g., cyberbullying); some are perpetrated by strangers 
whereas others by people known to the victim. Moreover, some forms of 
victimisation may have more severe consequences.  Measuring polyvictimisation 
may be diluting the effects of specific forms of victimisation. Thus, we next 
disaggregated our measure of polyvictimisation into its constituent parts and 
tested the association between exposure to each victimisation type (i.e. 
maltreatment, neglect, sexual victimisation, family violence, peer/sibling 
victimisation, internet/mobile phone victimisation, and crime victimisation; Table 
3-5) and DNA methylation. The results revealed few novel associations and 
sparsely distributed significant findings: we detected seven array-wide significant 
associations across the seven types of victimisation (Figure 3-8, Table 3-6). Four 
of these were previously identified in our analysis of adolescent polyvictimisation 
and only one probe emerged as significant across multiple types of victimisation 
(cg05575921 annotated to AHRR and C5orf55). Additional controls for smoking, 





Table 3-5. Distribution of individual victimisation types in adolescence. Shown are the 
sample distributions across adolescent victimisation types. 
Severity 0 1 2 3 4 5 NA 
Maltreatment 1435 42 66 60 45 10 0 
Neglect  1553 16 15 36 27 10 1 
Sexual victimisation 1447 41 58 67 12 31 2 
Family violence 1326 15 12 95 129 80 1 
Peer/sibling victimisation 686 40 223 447 219 42 1 
Internet/mobile phone 
victimisation 
1323 15 100 116 68 35 1 







Table 3-6. Six probes are associated with individual types of victimisation in adolescence, 
specifically with neglect, peer/sibling victimisation and crime victimisation. None of the 
associations remain significant when controlling for smoking. 




Probe Location Genes P Beta (%) P Beta (%) 
Neglect        

























   
cg05575921 5:373378 AHRR; 
C5orf55 
4.26E-12  -0.78 
 
8.81E-03 -0.24 
cg07826859 7:44986611 MYO1G 1.02E-09  -0.23 
 
7.61E-06 -0.17 
cg26703534 5:430358 C5orf55; 
AHRR 
4.78E-09  -0.34 
 
1.23E-02 -0.13 
cg21161138 5:452360 C5orf55; 
AHRR 
2.41E-08  -0.35 
 
2.87E-02 -0.12 














Figure 3-8. Few novel associations and sparsely distributed significant findings were 
observed for the association between DNA methylation and seven individual types of 
victimisation. For the seven individual victimisation types constituting the adolescent 
polyvictimisation measure (i.e., maltreatment, neglect, sexual victimisation, family violence, 
peer/sibling victimisation, internet/mobile phone victimisation, and crime victimisation) a total of 
seven array-wide significant associations were observed across three victimisation types 
(neglect, peer/sibling victimisation and crime victimisation). Four of these associations had been 
identified in the EWAS of adolescent polyvictimisation (Figure 3-3) and DNA methylation at one 
probe (cg05575921annotated to AHRR and C5orf55) was significantly associated with multiple 
types of victimisation. 
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Figure 3-9. Manhattan plots of –log10 P values for maltreatment, neglect and crime 
victimisation in adolescence, controlling for smoking pack-years. No probes pass the array-





3.3.2 Testing the sensitive period of childhood victimisation  
Although victimisation experiences peak in adolescence, it is hypothesised that 
the most biologically consequential victimisation is experienced earlier in life 
(Andersen et al., 2008). To test for such a sensitive period to victimisation, we 
next tested whether children victimised in the first decade of life exhibited 
differences in DNA methylation that were detectable in blood at age 18, 
regressing DNA methylation onto childhood polyvictimisation accounting for 
family structure and including batch, sex and cell-type proportion estimates as 
covariates. 
DNA methylation at one CpG probe (cg10318825 annotated to TMEM120A and 
POR) was associated with childhood polyvictimisation at an array-wide 
significance level (P = 1.02 ´ 10-7, Figure 3-10, top panel). The association 
between polyvictimisation and cg10318825 was attenuated when controlling for 
smoking, although another probe (cg10911283 annotated to FTMT) reached 
array-wide significance (P = 1.38 ´ 10-7, Figure 3-10, second panel). Of note, 
effect sizes for the top 100 ranked DMPs identified in the model not controlling 
for smoking are highly correlated with the effect sizes controlling for smoking (r = 
0.966, P < 2.2 ´ 10-16, Figure 3-11). No probes passed the array-wide 
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significance threshold in the DZ or MZ twin difference models (Figure 3-12; 
Figure 3-10, bottom panels).  
 
	
Figure 3-10. No consistent associations between DNA methylation and childhood 
polyvictimisation are observed across multiple models. The four panels show –log10 P values 
for the associations between DNA methylation and childhood polyvictimisation. Top panel: Only 
one probe is array-wide significant (cg10318825 annotated to TMEM120A and POR, P = 1.02 ´ 
10-7) in a regression model controlling for batch, sex and cell-type proportion estimates. Second 
panel: A different probe passes the array-wide significance threshold when adding smoking pack-
years as a further covariate (cg10911283 annotated to FTMT, P = 1.38 ´  10-7). The bottom panels 
show P value distributions from two twin difference models, which examine the association 
between twin-pair differences in DNA methylation and differences in polyvictimisation, while 
controlling for differences in cell-type proportion estimates. No significant associations were 
observed for either the DZ (third panel) or MZ twin difference model (fourth panel).	
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Figure 3-11. Effect sizes of the top 100 probes identified in the regression of DNA 
methylation on childhood polyvictimisation not controlling for smoking. Shown are the 
effect sizes in the model not controlling for smoking (x-axis) compared to those found in the model 
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Table 3-7. Distribution of individual victimisation types in childhood. Shown are the sample 
distributions across childhood victimisation types. 
Severity 0 1 2 NA 
Physical abuse 1319 253 86 0 
Physical neglect  1506 123 29 0 
Emotional neglect 1465 140 53 0 
Sexual victimisation 1629 15 14 0 
Domestic violence 871 493 294 0 






As with adolescent polyvictimisation, we disaggregated our measure of childhood 
polyvictimisation into its constituent parts and tested the association between 
exposure to each victimisation type (i.e. physical abuse, physical neglect, 
emotional neglect, sexual victimisation, domestic violence and peer/sibling 
victimisation; Table 3-7) and DNA methylation. A total of nine probes passed the 
array-wide threshold for childhood sexual victimisation (Table 3-8), while none of 
the other childhood victimisation types were significantly associated with DNA 
methylation (Figure 3-13). Seven of the nine associations between DNA 
methylation and childhood sexual victimisation remained significant when 
controlling for smoking (cg00713005 annotated to TSSK3, cg06927775 
annotated to ATP6V0A1, cg04577451 annotated to KCTD5 and PRSS27, 
cg20974621 annotated to HHATL and HIGD1A, cg06454157 annotated to CCR6 
and FGFR1OP, cg08755156 annotated to RHEB and PRKAG2, and cg17898054 
annotated to SLC2A1 and EBNA1BP2) and an additional three probes became 
significant in the model controlling for smoking (cg11087774 annotated to NKX6-
2 and TTC40, cg19897017 annotated to MAD1L1 and ELFN1, and cg01954930 
annotated to DHFRL1; Figure 3-14, Table 3-8). These findings may indicate that 
sexual victimisation is associated with stable DNA methylation differences in 
whole blood in young adulthood, beyond what is detectable with the aggregated 
polyvictimisation measure. However, these findings should be interpreted with 
caution because only a small group of children were sexually victimised (n = 29).   
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Table 3-8. Nine probes are significantly associated with childhood sexual victimisation. 
Seven of these associations remain significant when controlling for smoking and three additional 
associations become significant in the smoking-controlled model. 




Probe Location Genes P Beta (%) P Beta (%) 














cg04577497 12:10766264 MAGOHB 1.08E-08 
 
0.32 3.35E-09 0.34 



































































Figure 3-13. Sexual victimisation is the only victimisation type in childhood which was 
found to be significantly associated with DNA methylation. For the six individual victimisation 
types constituting the childhood polyvictimisation measure (i.e. physical abuse, physical neglect, 
emotional neglect, sexual victimisation, domestic violence and peer/sibling victimisation) only 
sexual victimisation showed any array-wide significant associations with DNA methylation. A total 






Figure 3-14. Manhattan plots of –log10 P values for sexual victimisation in childhood, 
controlling for smoking pack-years. 
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3.3.3 Testing the cumulative stress load hypothesis 
Perhaps the most consequential stressors are those that are experienced 
chronically or that reoccur. A striking finding in epidemiology is the phenomenon 
of revictimisation (Widom et al., 2008). For example, in E-Risk, every type of 
victimisation in childhood was associated with a significantly greater risk of 
victimisation in adolescence, and polyvictimised children were 60% more likely to 
be polyvictimised in adolescence (RR = 1.60, (95% CI: 1.42, 1.82)). This raises 
the possibility that the biological embedding of victimisation is especially like to 
occur in response to a greater cumulative stress load. 
Using our longitudinal data about victimisation over the first two decades of life -
across childhood and through adolescence - a latent class analysis (see 
Methods) identified four types of individuals:   
1) The first group consisted of individuals who were not exposed to childhood or 
adolescent victimisation (group 0, n = 834 in the EWAS sample). 2) Childhood 
domestic violence defined the victimisation profile of n = 308 individuals (group 
1, n = 254 in the EWAS sample). In this group, 89% of individuals experienced 
moderate to severe domestic violence as a child; 3) Peer victimisation defined 
the violence profile of n = 529 individuals (group 2, n = 412 in the EWAS sample). 
88% of individuals classified into this group experienced moderate or severe peer 
victimisation during adolescence; 4) Exposure to multiple moderate or severe 
types of violence defined the victimisation profile of n = 206 individuals (group 3, 
n = 158 in the EWAS sample). 36% of individuals in this group suffered two or 
more types of severe victimisation during childhood and 68% experienced two or 
more types of severe victimisation during adolescence (Table 3-1). We tested 
the cumulative stress load hypothesis by treating these four victimisation 
categories as a factor, and testing the for differences in DNA methylation between 
each victimisation group (groups 1-3) compared to the non-victimised individuals 
(group 0). No probes showed differential methylation between groups 1 or 2 and 
the non-victimised individuals, while six probes passed the array-wide 
significance threshold when comparing the most severely victimised individuals 
(group 3) with non-victimised individuals (P < 1.61 ´ 10-7, Figure 3-15, third 
panel). These included the four probes previously found to be associated with 
adolescent polyvictimisation (Table 3-1, Table 3-9). None of these six probes 
remained array-wide significant when controlling for smoking, but another probe 
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(cg13854030 annotated to SPIN1 and CDK20) reached array-wide significance 
in this analysis. Sensitivity analyses performed with a different scaling of 
cumulative victimisation revealed similar results (Table 3-9).  
 
	
Figure 3-15. The association between DNA methylation and cumulative polyvictimisation 
is confounded by smoking. The four panels show –log10 P values for the associations between 
DNA methylation and cumulative polyvictimisation. No probes pass the array-wide multiple testing 
threshold (P < 1.61 ´  10-7) in a regression model controlling for batch, sex and cell-type proportion 
estimates when comparing groups 1 (top panel) or 2 (second panel) with the non-victimised 
group. Third panel: Six probes are array-wide significant when comparing the most severely 
victimised individuals (group 3) with non-victimised individuals. These include the four probes 
previously identified to be significantly associated with adolescent polyvictimisation (Figure 3-3). 
Bottom panel:  None of the six probes identified as significantly differentially methylated between 
group 3 and the non-victimised subgroup remain significant when additionally controlling for 
smoking. One additional probe passes the array-wide multiple testing threshold in this analysis. 
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Table 3-9. Eight probes are significantly associated with two different cumulative 
victimisation measures. Of these, three probes (cg05575921, cg26703534 and cg21161138) 
are significant across both models. 
Probe Location Genes P Beta (%) 
LCA score –group 3 vs non-victimised individuals 
  cg05575921 5:373378 AHRR; C5orf55 8.84E-11 -5.35 
 cg26703534 5:430358 C5orf55; AHRR 2.22E-09 -2.37 
cg03636183 19:17000585 F2RL3  2.67E-08 -2.67 
cg21161138 5:452360 C5orf55; AHRR 3.06E-08 -2.44 
cg06126421 6:30828059 DDR1; IER3 1.08E-07 -2.22 
cg00944304 15:40738072 CHST14, BAHD1 1.51E-07 -1.16 




cg05575921 5:373378 AHRR; C5orf55 7.71E-12 -1.14 
 cg21161138 5:452360 C5orf55; AHRR 1.95E-09  -0.54
 cg26703534 5:430358 C5orf55; AHRR 2.90E-09 -0.50 
 cg10318825 7:75611554 TMEM120A; POR 2.92E-09 0.11 





3.3.4 Epigenetic interrogation of stress-related genes  
A hypothesis-free approach to the study of stress overlooks cumulative evidence 
about biological plausibility of candidate genes. In particular, genes involved in 
HPA-axis reactivity may be differentially methylated in response to victimisation. 
Genes widely hypothesised to play a role in mediating stress-reactivity include 
NR3C1 (the glucocorticoid receptor, which is primarily involved in response to 
inflammation (McGowan et al., 2009)); FKBP5 (an important regulator of the 
glucocorticoid receptor network (Klengel et al., 2013)); BDNF (the brain derived 
neurotrophic factor, a member of the nerve growth factor family (Roth et al., 2009, 
Unternaehrer et al., 2012)); AVP (the gene encoding the neuropeptide 
vasopressin (Murgatroyd et al., 2009), which is secreted in as part of the HPA 
response to stress (Meyer-Lindenberg et al., 2011)), and CRHR1 (the 
corticotrophin releasing hormone receptor, another major player in the HPA 
pathway (Todkar et al., 2015, Polanczyk et al., 2009, Bradley et al., 2008)). In 
addition, genetic variants in SLC6A4 (the serotonin transporter gene), have been 
implicated in stress reactivity and some evidence suggests that these effects may 
be mediated by altered DNA methylation (Alexander et al., 2014, Duman and 
Canli, 2015, Provenzi et al., 2016). Evidence from severely deprived children has 
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also flagged CYP2E1 (Kumsta et al., 2016), a member of the cytochrome P450 
super family of enzymes, with a role in the metabolism of various exogenous 
compounds including drugs of abuse and neurotoxins (Strobel et al., 2001).  
We identified all probes on the Illumina 450K array annotated to each of these 
seven genes (see Methods).  The number of probes per gene ranged from 25 to 
140. Within each gene, we tested the association between levels of DNA 
methylation and victimisation in childhood and adolescence, controlling for sex, 
batch and cell-type proportion estimates. While none of the probes annotated to 
any of these seven genes reached array-wide significance in any of the genome-
wide analyses reported here, we recognise the importance of also reporting 
individual gene-level results for these candidate genes. 
To illustrate, Figure 3-16 shows a plot of log-10 P values and effect directions 
(negative [hypo-] vs. positive [hyper-] methylation) for all probes annotated to 
NR3C1, with two thresholds: the array-wide significance level and a gene-wide 
Bonferroni-corrected significance level (0.05/number probes annotated to the 
gene and included in this analysis). For NR3C1, we observed no gene-wide 
significant probes associated with either adolescent polyvictimisation or 
childhood polyvictimisation. The regional Manhattan plots of the other genes are 
shown in Figure 3-17-Figure 3-22 and individual association statistics for all 
probes annotated to these seven genes are reported in Appendix A. Overall, 
only one probe reached gene-wide significance across all further six genes and 
two victimisation periods: cg00140191, a probe upstream of FKBP5, passed 
gene-wide significance for the association with childhood polyvictimisation (P = 
7.63 ´ 10-4). Together, these data are not supportive of robust changes in DNA 
methylation in the vicinity of previously nominated candidate genes in victimised 




Figure 3-16. Polyvictimisation in childhood or adolescence is not associated with 
differential methylation across probes annotated to NR3C1. Regional Manhattan plot of -log10 
P values for all 140 probes annotated to NR3C1, showing summary statistics from the 
associations between DNA methylation and adolescent polyvictimisation (top panel) and 
childhood polyvictimisation (bottom panel). Effect directions are indicated by blue 
(hypermethylated) and red (hypomethylated) colour. Of the 140 probes annotated to NR3C1 none 






























































































































































Chromosomal position; hg19 build
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Figure 3-17. Polyvictimisation in childhood or adolescence is not associated with 
differential methylation across probes annotated to AVP. Regional Manhattan plot of -log10	
P values for all probes annotated to AVP, showing summary statistics from the associations 
between DNA methylation and adolescent polyvictimisation (top panel) and childhood 
polyvictimisation (bottom panel). Effect directions are indicated by blue (hypermethylated) and 
red (hypomethylated) colour. Of the 28 probes annotated to AVP none pass the array- or gene-




















































































Chromosomal position; hg19 build
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Figure 3-18. Polyvictimisation in childhood or adolescence is not associated with 
differential methylation across probes annotated to BDNF. Regional Manhattan plot of -log10 
P values for all probes annotated to BDNF, showing summary statistics from the associations 
between DNA methylation and adolescent polyvictimisation (top panel), childhood 
polyvictimisation (bottom panel). Effect directions are indicated by blue (hypermethylated) and 
red (hypomethylated) colour. Of the 95 probes annotated to BDNF none pass the array- or gene-

















































































































Chromosomal position; hg19 build
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Figure 3-19. Polyvictimisation in childhood or adolescence is not associated with 
differential methylation across probes annotated to CRHR1. Regional Manhattan plot 
of -log10 P values for all probes annotated to CRHR1, showing summary statistics from the 
associations between DNA methylation and adolescent polyvictimisation (top panel) and 
childhood polyvictimisation (bottom panel). Effect directions are indicated by blue 
(hypermethylated) and red (hypomethylated) colour. Of the 38 probes annotated to CRHR1 none 























































































Chromosomal position; hg19 build
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Figure 3-20. Polyvictimisation in childhood or adolescence is not associated with 
differential methylation across probes annotated to CYP2E1. Regional Manhattan plot 
of -log10 P values for the all probes annotated to CYP2E1, showing summary statistics from the 
associations between DNA methylation and adolescent polyvictimisation (top panel) and 
childhood polyvictimisation (bottom panel). Effect directions are indicated by blue 
(hypermethylated) and red (hypomethylated) colour. Of the 57 probes annotated to CYP2E1 none 

































































































Chromosomal position; hg19 build
	 116	
	
Figure 3-21. Polyvictimisation in adolescence is not associated with differential 
methylation across probes annotated to FKBP5. Regional Manhattan plot of -log10 P values 
for all 42 probes annotated to FKBP5, showing summary statistics from the associations between 
DNA methylation and adolescent polyvictimisation (top panel) and childhood polyvictimisation 
(bottom panel). Effect directions are indicated by blue (hypermethylated) and red 
(hypomethylated) colour. Of the 42 probes annotated to FKBP5 none pass the array-wide 
threshold for adolescent polyvictimisation. One probe, cg00140191, passes the gene-wide 
threshold for childhood polyvictimisation, exhibiting hypomethylation with victimisation exposure. 
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Chromosomal position; hg19 build
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Figure 3-22. Polyvictimisation in adolescence or childhood is not associated with 
differential methylation across probes annotated to SLC6A4. Regional Manhattan plot 
of -log10 P values for the all probes annotated to SLC6A4, showing summary statistics from the 
associations between DNA methylation and adolescent polyvictimisation (top panel) and 
childhood polyvictimisation (bottom panel). Effect directions are indicated by blue 
(hypermethylated) and red (hypomethylated) colour. Of the 28 probes annotated to SLC6A4 none 
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3.3.5 Does victimisation accelerate epigenetic ageing?  
Stress is hypothesised to accelerate epigenetic ageing. A promising biomarker of 
aging is the “epigenetic clock”, a highly accurate multi-tissue predictor of 
chronological age based on DNA methylation patterns at 353 CpG sites (Horvath, 
2013).  Individuals whose DNA methylation age exceeds their chronological age 
are thought to be ageing faster, and faster epigenetic ageing has been shown to 
predict all-cause mortality (Marioni et al., 2015). More recently, stressful life 
events and stress-related phenotypes have also been linked to accelerated 
epigenetic ageing (Zannas et al., 2015, Boks et al., 2015, Wolf et al., 2016). 
We tested whether polyvictimisation is associated with accelerated epigenetic 
ageing by regressing DNA methylation age acceleration (the difference between 
DNA methylation age and chronological age) onto polyvictimisation. DNA 
methylation age acceleration was not significantly associated with 
polyvictimisation in adolescence (P = 0.42), childhood (P = 0.24) or cumulatively 





Figure 3-23. Distributions of DNA methylation age acceleration by polyvictimisation in 
three different exposure time periods. DNA methylation age acceleration is not significantly 
associated with polyvictimisation in adolescence (P = 0.42), childhood (P = 0.24) or cumulatively 




































































This study represents, to our knowledge, the most comprehensive analysis yet 
undertaken in humans of epigenetic variation associated with victimisation 
experiences across the first two decades of life. Using a large longitudinal 
population-based cohort of twins, we investigated associations between 
victimisation across childhood and adolescence and DNA methylation isolated 
from whole blood at age 18. Overall, we find little evidence to support widespread 
differences in DNA methylation associated with early-life exposure to stress. The 
results of our study have important implications for analyses of epigenetic 
variation associated with psycho-social exposures in population-based cohorts. 
In particular, our study highlights the importance of controlling for potential 
confounders, especially exposure to tobacco smoke, in such analyses. 
First, while we find statistically significant associations (P < 1.61 ´ 10-7) between 
DNA methylation at four Illumina 450K probes (cg05575921, cg26703534, 
cg21161138 and cg14179389) and adolescent as well as cumulative 
victimisation, we show that these associations are confounded by smoking 
exposure. There are no statistically significant DNA methylation differences 
between DZ or MZ twin pairs discordant for victimisation in adolescence or 
childhood. Second, across different exposure periods only one probe, 
cg10911283, shows a significant association between childhood 
polyvictimisation and DNA methylation when controlling for smoking, but DNA 
methylation at this probe is not significantly associated with childhood 
polyvictimisation in the model not controlling for smoking or in the DZ or MZ twin 
difference models. Third, with the exception of childhood sexual victimisation, no 
significant associations between individual types of victimisation in adolescence 
or childhood and DNA methylation are found, which survive smoking-correction. 
Childhood sexual victimisation is significantly associated with DNA methylomic 
variation at nine probes, seven of which remain significant when correcting for 
smoking. However, this association is to be interpreted with caution because of 
the small sample size (only n = 29 exposed individuals). A follow-up project based 
on a sample with greater numbers of exposed individuals could shed more light 
onto this association.  
Many current studies of epigenetic variation associated with early-life stress in 
human populations have focussed on specific a priori candidate genes – for 
	 120	
example NR3C1 (McGowan et al., 2009, Tyrka et al., 2012, Martin-Blanco et al., 
2014, Guillemin et al., 2014), FKBP5 (Non et al., 2016, Yehuda et al., 2016, Tyrka 
et al., 2015) and SLC6A4 (Beach et al., 2010, Ouellet-Morin et al., 2013, Booij et 
al., 2015). We therefore undertook a detailed investigation of candidate stress 
genes, finding no robust evidence for altered DNA methylation associated with 
victimisation exposure in probes annotated to any of these candidate loci. Only 
one probe out of a total 428 tested pass our relatively lenient gene-wide 
thresholds: cg00140191 annotated to FKBP5 for childhood polyvictimisation (P = 
7.63 10-4) and it would not have been significant at a Bonferroni threshold 
correcting for all 428 probes (P < 1.17 ´ 10-4). Notably, a number of probes would 
be classed as “significant” at the nominal P value threshold often employed for 
such candidate gene analyses, highlighting that many of these previous studies 
are likely to be reporting false positive associations. Furthermore, while some 
recent publications have linked stressful life events and trauma, to an increase in 
DNA methylation age (Zannas et al., 2015, Wolf et al., 2016, Boks et al., 2015), 
we were not able to replicate these findings for victimisation exposure and 
accelerated epigenetic ageing.  
Taken together, we find very little evidence for robust associations between early 
life victimisation exposure and DNA methylation in whole blood at age 18, beyond 
those associations confounded by smoking. Even the sparse individual array-
wide significant probes need to be viewed with caution, as our analyses involved 
many (possibly correlated) analyses and there is an increased possibility of false 
positives. 
Our study has several specific strengths and advantages that improve its validity 
and strengthen the evidence supporting our conclusions: The E-Risk Longitudinal 
Twin Study is one of the most detailed and thorough studies of child and 
adolescent development and the consequences of early life adverse exposures 
(Fisher et al., 2015). By oversampling high-risk families E-Risk achieves a 
population-representative sample of early-life development, underlining its 
external validity. To our knowledge this study represents the largest study of the 
epigenetic consequences early-life stress yet undertaken and we are well 
powered to detect variation in DNA methylation associated with external 
exposures. This is exemplified by the fact that we detect 64 array-wide significant 
probes associated with smoking pack-years. Furthermore, we employed an 
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embedded twin difference model on large subsamples of our full sample (307 DZ 
twin pairs and 425 MZ twin pairs), allowing us to control for confounding caused 
by the family environment as well as genetic influences. Previous studies of 
epigenetic variation in humans associated with early-life stress, in contrast, have 
been relatively small (Guillemin et al., 2014, Romens et al., 2015, McGowan et 
al., 2009, Labonte et al., 2012, Yehuda et al., 2016, Booij et al., 2015, Suderman 
et al., 2012); given their predominant focus on candidate genes in a limited 
number of samples, it is likely that many of the previously reported associations 
in the literature represent false-positive findings. 
One of the most important questions concerning our results therefore is how to 
interpret them in the greater context of the existing literature. This question is 
particularly salient given existing reports that document DNA methylation 
differences in peripheral tissues following stress. First, with studies of mental 
health and psychiatric phenotypes the organ of main interest is usually the brain. 
In our longitudinal study, we are limited to whole blood as a surrogate tissue. 
While it is a heterogeneous tissue, there are several validated reference-based 
estimators (Houseman et al., 2012, Horvath, 2013) controlling for cell-type 
composition. In addition, the stress response of the HPA-axis has a direct impact 
on the immune response and T cell composition in blood (Palacios and 
Sugawara, 1982, Elenkov, 2004) and it would therefore be plausible to see 
differences in DNA methylation associated with severe stress exposure, such as 
the one caused by victimisation experiences. However, we did not find any robust 
associations between victimisation and DNA methylation in whole blood and it is 
possible that blood does not represent a useful surrogate tissue for this research 
question. 
Second, there may be issues relating to our stress exposure measures leading 
us to observe different findings to previous studies. The measures of victimisation 
exposure reported for E-Risk are thorough and detailed, spanning different 
exposure periods across the first two decades of life. We disaggregate the 
polyvictimisation measures in childhood and adolescence into its constituent 
parts at a comprehensive severity coding level, making it possible to uncover 
effects of individual victimisation types that might have been diluted by the 
composite measure. Additionally, we consider multiple scalings of the cumulative 
victimisation variable (LCA model, additive model; Table 3-2) thereby minimising 
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the effect any particular operationalisation of this exposure could have on the 
outcome. The victimisation measures in E-Risk are robustly associated with 
adverse physical and mental health outcomes (Arseneault et al., 2006, Fisher et 
al., 2012, Jaffee et al., 2004, Baldwin et al., 2016, Fisher et al., 2015), 
substantiating the validity of our variables. DNA methylation data was collected 
and processed through a streamlined and stringent pipeline. These data are of 
high quality as evidenced by a filtering rate of < 1% of samples in our QC pipeline, 
and our confirmation of known smoking-associated probes (Joehanes et al., 
2016). 
Third, by using a population representative sample we allow maximum external 
validity of our study. In addition, we use a longitudinal study design with minimal 
attrition, so exposures are unlikely to be associated with study-related 
confounding factors. This comes at the cost of lower numbers of exposed 
individuals in some of the victimisation categories. Sexual victimisation in 
childhood is characterised by particularly low numbers of exposed individuals and 
the significant associations between DNA methylation and sexual victimisation 
should be interpreted with caution in consequence. However, for our main 
polyvictimisation variables, we have substantial numbers of exposed individuals, 
with 593 individuals having experienced at least one type of victimisation in 
adolescence and 118 of those exposed to three or more different types of 
victimisation. We also looked at victimisation across different time periods, 
disaggregated our polyvictimisation measures into individual victimisation 
exposures and used a literature-informed candidate gene approach with gene-
wide P value thresholds. However, despite the variety of angles from which we 
studied the association between early-life victimisation and DNA methylation, we 
find no robust evidence for an association. 
Fourth, while E-Risk is a longitudinal study and our exposure and mental health 
measures are collected over time, whole blood was collected at a single time 
point (age 18) and the DNA methylation data is therefore cross-sectional. 
Unfortunately, blood samples from earlier periods of life are not available for this 
study, but the longitudinal collection of DNA methylation profiles, to evaluate 
changes in DNA methylation in relation to exposures is a promising future avenue 
of research. We have little understanding of the temporal effects of stress and 
methylation, and it is possible that the lag in our research, looking at effects of 
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victimisation which took place between age 5 and 18, is simply not the correct 
temporal scale. 
Fifth, by nature of the technology we are limited in our study of DNA methylation 
to the probes featured on the Illumina 450K HumanMethylation Array. This is a 
subset of all CpG sites in the genome and the relevant sites may not be featured 
on this microarray. More generally, while epigenetic modifications may play a 
mediating role in translating and establishing the long-term mental health 
outcomes associated with early-life stress and victimisation, DNA methylation 
may not be a modification directly involved in this process. 
Sixth, there may be problems with the previously reported epigenetic 
associations with early-life stress. Much of the previous work was based on 
animal models and investigated DNA methylation changes in the brain (Weaver 
et al., 2004, Kundakovic et al., 2013, Desarnaud et al., 2008, Kember et al., 
2012). These may not directly translate to human epidemiology, because of 
differences in biology or experimental design, but could also include false 
positives as sample sizes in these animal studies tend to be extremely small, 
often with five or fewer animals per exposure group (Weaver et al., 2004, 
Desarnaud et al., 2008, Daniels et al., 2009, Henningsen et al., 2012, Doherty et 
al., 2016). Similarly, with few exceptions in recent years (Mehta et al., 2013, van 
der Knaap et al., 2014, Martin-Blanco et al., 2014, Beach et al., 2010), work in 
human epigenetic epidemiology has often used small sample sizes (Guillemin et 
al., 2014, Naumova et al., 2012, Yehuda et al., 2016, Kumsta et al., 2016, Borghol 
et al., 2012). This is particularly true for studies performed on brain tissue 
(McGowan et al., 2009, Labonte et al., 2012, Suderman et al., 2012). To 
complicate matters further, some studies were performed on clinical populations 
with limited generalisability (Steiger et al., 2013, Melas et al., 2013, Martin-Blanco 
et al., 2014). The majority of studies, including nearly all animal work, used 
suboptimal targeted technologies including targeted bisulfite sequencing or 
bisulfite pyrosequencing which only allow the investigation of very small regions 
of methylation and increase the likelihood of false positives in the context of 
publication bias (Weaver et al., 2004, Desarnaud et al., 2008, Daniels et al., 2009, 
Kember et al., 2012, Liberman et al., 2012, Kundakovic et al., 2013, Kosten et 
al., 2014, Steiger et al., 2013, Tyrka et al., 2012, Melas et al., 2013, van der 
Knaap et al., 2014, Martin-Blanco et al., 2014, Romens et al., 2015, Guillemin et 
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al., 2014, McGowan et al., 2009, Labonte et al., 2012, Non et al., 2016, Ouellet-
Morin et al., 2013, Doherty et al., 2016, Saunderson et al., 2016, Beach et al., 
2010, Beach et al., 2011, Murgatroyd et al., 2009, Roth et al., 2009, Kinnally et 
al., 2010, Booij et al., 2015, Yehuda et al., 2016). Even studies using array 
technologies sometimes employed forms of targeted or variance based filtering 
to overcome sub-threshold results (Esposito et al., 2016, Mehta et al., 2013). In 
addition, interpretation of significance levels in a greater genomic context is often 
prevented by only reporting P value thresholds (e.g. P < 0.05) rather than the raw 
P values themselves, often observed in combination with an omission of multiple-
testing correction (Weaver et al., 2004, Desarnaud et al., 2008, Kember et al., 
2012, Kundakovic et al., 2013, Tyrka et al., 2012, Martin-Blanco et al., 2014, 
McGowan et al., 2009, Labonte et al., 2012, Non et al., 2016, Naumova et al., 
2012, Doherty et al., 2016, Saunderson et al., 2016, Murgatroyd et al., 2009, 
Borghol et al., 2012, Suderman et al., 2012, Yehuda et al., 2016). Some studies 
used very lenient thresholds for FDR correction (Esposito et al., 2016, Suderman 
et al., 2012) or applied more lenient candidate gene thresholds post hoc (Weder 
et al., 2014). Interestingly, three previous studies using array-wide profiling did 
not report differential methylation in any of the HPA-axis candidate stress genes 
investigated here (AVP, BDNF, CRHR1, FKBP5, NR3C1) at array-wide multiple 
testing thresholds (Houtepen et al., 2016, Weder et al., 2014, Kumsta et al., 
2016). 
In summary, even in the context of the existing literature, we find that there is 
insufficient evidence to conclude that there is a robust association between early-
life victimisation and DNA methylation detectable in whole blood. With regard to 
genomic and epigenomic studies, our results demonstrate the importance to 
adequately address for confounders, including smoking, cell-type heterogeneity, 
familial environments and genetics. Our findings also highlight the fact that 
genome- or array-wide methods in the affected tissue are warranted to 
understand the neurobiology of stress and its long-term mental health impact. 
Finally, perhaps we need to come to terms with the possibility that experimental 
work and animal models are not necessarily well matched to human epigenetic 
epidemiology in uncovering the molecular pathways linking stress exposures to 
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ABSTRACT
While DNA methylation is usually thought to be symmetrical across both alleles, there are some notable
exceptions. Genomic imprinting and X chromosome inactivation are two well-studied sources of
allele-speciﬁc methylation (ASM), but recent research has indicated a more complex pattern in which
genotypic variation can be associated with allelically-skewed DNA methylation in cis. Given the known
heterogeneity of DNA methylation across tissues and cell types we explored inter- and intra-individual
variation in ASM across several regions of the human brain and whole blood from multiple individuals.
Consistent with previous studies, we ﬁnd widespread ASM with > 4% of the »220,000 loci interrogated
showing evidence of allelically-skewed DNA methylation. We identify ASM ﬂanking known imprinted
regions, and show that ASM sites are enriched in DNase I hypersensitivity sites and often located in an
extended genomic context of intermediate DNA methylation. We also detect examples of genotype-
driven ASM, some of which are tissue-speciﬁc. These ﬁndings contribute to our understanding of the
nature of differential DNA methylation across tissues and have important implications for genetic studies
of complex disease. As a resource to the community, ASM patterns across each of the tissues studied are








DNA methylation is the most widely studied and stable epige-
netic mark across the mammalian genome, playing a key role
in the developmental regulation of gene expression. DNA
methylation is generally symmetrical across both alleles,
although exceptions characterized by allelic asymmetry include
differentially methylated regions (DMRs) regulating the mono-
allelic expression of genes associated with X chromosome inac-
tivation in females and genomic imprinting.1-5 Recently, it has
been shown that the allelic-skewing of DNA methylation can
also be driven by DNA sequence variation, with methylation
quantitative trait loci (meQTLs) predominantly acting in
cis.6-11 ASM can be regarded as a special case of intermediate
DNA methylation (IM), which has been found to occur in
regions spanning a large portion of the human genome. It has
been estimated that ASM contributes up to 18% of IM in the
human genome.12
DNA methylation patterns are highly dynamic during nor-
mal development and cellular differentiation13-16 and tissue-spe-
ciﬁc patterns of DNA methylation have been widely studied in
humans.17-20 In complex tissues such as the brain, for example,
DNA methylation differentiates between functionally distinct
regions21,22 and cell types.16,23-26 Patterns of IM can also be tis-
sue-speciﬁc,12 with growing evidence for the widespread preva-
lence of tissue-speciﬁc ASM.27,28 In mouse, for example, it has
been reported that 28% of imprinted genes are monoallelically
expressed in a single tissue type, often the brain or extra-embry-
onic tissue.29 Examples of tissue-speciﬁcally imprinted genes
include KCNQ1, which becomes biallelically expressed in
embryonic heart development,30 GNAS, which is maternally
expressed in a wide-range of tissues including the anterior pitui-
tary, thyroid and ovaries but biallelically expressed in others,
such as bone and visceral adipose tissue,31,32 and GRB10, which
is maternally expressed in most peripheral tissues but paternally
expressed in the brain.29,33Genetic inﬂuences on DNAmethyla-
tion can also be tissue-speciﬁc, with meQTLs determining allelic
patterns of methylation in cis in certain tissues or cell types.11,34
Increasing evidence supports a role for inter-individual vari-
ation in DNA methylation in the etiology and pathogenesis
associated with a diverse range of complex disease pheno-
types.35 Allelic differences in DNA methylation may be particu-
larly important in this regard, acting as endophenotypes of
genetic variation or additional epi-allelic layers mediating the
functional consequences of genotypic variation.36,37 Teasing
apart genetic and non-genetic effects in a tissue- and cell type-
speciﬁc manner will be a crucial step in understanding the asso-
ciation between non-coding genetic variation, DNA methyla-
tion, and complex disease.
To investigate the role of tissue-speciﬁc variation of ASM in
the human brain and its relation to allelic biases in whole blood,
we examined ASM across multiple brain regions and matched
blood samples collected from multiple donors. Our data shows
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that although a large proportion of ASM is conserved across
tissues, there are speciﬁc differences in the extent and distribu-
tion of ASM sites between regions of the brain and whole
blood. Genome browser tracks displaying ASM signals as well
as an online tool plotting ASM for sites of interest are available
for download from a searchable database (http://epigenetics.
essex.ac.uk/ASMBrainBlood).
Results
DNA methylation is allelically-skewed at speciﬁc locations
across the genome
The majority of the genome is not characterized by notable
allelic biases in DNA methylation in any of the tissues assessed
in this study. The array-wide average of ASM score (in absolute
values) is consistently low (mean D 0.025, range D 0.023 to
0.030) (Fig. S1A, Fig. S1B and Table S1). As expected, there is,
however, evidence for allelically-biased DNA methylation at a
notable number of speciﬁc genomic regions; in total 9,311
(4.22%) of the 220,449 informative SNPs in our assay show evi-
dence for allelic-skewing of DNA methylation, deﬁned by an
absolute ASM score ! 0.10 in at least one tissue and individual.
The percentage of amplicons characterized by an ASM score
! 0.10 in each of the 21 proﬁled samples is given in Table S2.
The top-ranked loci showing evidence for allelically-skewed
DNA methylation in whole blood, cerebellum, and cortex
(BA9), and cerebellum are listed in Tables 1–3. Genome
Browser tracks and an online ASM database are available from
our laboratory website (http://epigenetics.essex.ac.uk/ASM
BrainBlood).
Patterns of ASM in whole blood overlap with those
identiﬁed in a previous study
In a previous study we characterized allelically-skewed DNA
methylation in whole blood derived from 5 monozygotic twin
pairs.7 There is a highly signiﬁcant correlation between absolute
ASM scores across all probes informative in both data sets
(n D 129,559, r D 0.21, P < 1.0 £ 10¡50, Fig. S2), even though
the majority of the probes do not exhibit ASM. Of the 2,704
ASM loci identiﬁed in Schalkwyk et al., 1,717 (63.50%) are
informative in the current study, with a highly signiﬁcant
cross-study correlation of ASM scores at these probes (r D
0.52, P < 1.0 £ 10¡50). Likewise, there is a highly signiﬁcant
correlation between ASM scores across the two studies at sites
showing allelically-skewed DNA methylation in blood in the
current study which were also informative in our previous
study (r D 0.38, P D 3.0 £ 10-28). Of the 15 top-ranked blood
ASM sites identiﬁed in our current study (Table 1), 7 of the 9
sites (78%) also informative in our previous study of ASM in
blood7 were characterized by an absolute ASM score ! 0.10 in
both analyses. These data conﬁrm the validity of the MSNP
approach for identifying allelically-skewed DNA methylation,
reinforcing our previous conclusions about the extent of ASM
in whole blood.7
The extent and distribution of ASM differs across tissues
The average proportion of informative sites characterized by
allelically-skewed DNA methylation (absolute ASM score
! 0.10) in each of the 8 tissues proﬁled was examined (Fig. 1A).
Table 4 lists the top-ranked consistently allelically-skewed
probes across cerebellum, whole blood, and cortex (BA9), with
speciﬁc examples shown in Fig. 2A and Fig. 2B. Allelically-
skewed DNA methylation appears to be consistently less preva-
lent in cortical regions (informative probes with ASM score
! 0.10D 0.54%) compared to the cerebellum (1.14%) and whole
blood (0.84%). The elevated level of allelically-skewed DNA
methylation in the cerebellum and whole blood relative to cortex
is more pronounced at more extreme ASM score thresholds
(i.e., ASM score ! 0.20, cortexD 0.003%, cerebellum D 0.019%,
whole bloodD 0.013%) (Fig. S1C, Fig. S1D and Fig. S3). Of note,
there is little variation in the prevalence and distribution of ASM
scores between different regions of the cortex (average correla-
tion between 2 cortical areas D 0.52, Fig. 1B and Fig. S4). We
therefore selected one representative cortical region (BA9) for
inclusion in subsequent analyses. In contrast, we ﬁndmore strik-
ing differences between cortex, cerebellum and whole blood
samples with inter-tissue correlations ranging from r D 0.42 to
0.48 (Figs. 1C-E). Table 5 lists the probes showing the highest
level of variation in ASM scores across tissues with speciﬁc
Table 1. Top 15 ASM sites in whole blood, ASM score averaged across individuals.
Rank SNP ID Location Associated gene(s) Schalkwyk et al. (2010) Blood ASM score Cerebellum ASM score BA9 ASM score
1 SNP_A-2180729 (rs10276966) 7p15.2 HIBADH, EVX1b 0.29 0.25 0.01 0.03
2 SNP_A-8438077 (rs585451) 15q21.2 ATP8B4, DTWD1 NA 0.25 0.01 0.03
3 SNP_A-1841543 (rs10234308) 7p15.3 MGC87042 0.34 0.23 0.25 0.23
4 SNP_A-1946136 (rs927000) 20q13.12 STK4 NA 0.23 0.04 0.01
5 SNP_A-8450837 (rs4404067) 16q12.2 SLC6A2, LPCAT2 0.28 0.22 0.05 0.04
6 SNP_A-4279002 (rs335554) 1q41 CENPF, KCNK2 NA 0.22 0.08 0.09
7 SNP_A-8450539 (rs10916799) 1p36.12 CAMK2N1, LOC339505 0.18 0.22 0.11 0.15
8 SNP_A-8633222 (rs13165930) 5q33.3 CCNJL NA 0.22 0.02 0.12
9 SNP_A-8472169 (rs11193683) 10q23.1 NRG3 0.01 0.22 0.09 0.07
10 SNP_A-2071005 (rs4687210) 3q28 UTS2D NA 0.22 0.16 0.17
11 SNP_A-2185394 (rs852454) 7p22.1 RNF216 0.06 0.22 0.11 0.11
12 SNP_A-8702215 (rs12978286) 19p13.11 FCHO1, MAP1S 0.19 0.22 0.00 0.07
13 SNP_A-1807006 (rs10481354) 8p23.3 CLN8, DLGAP2a 0.22 0.22 0.00 0.05
14 SNP_A-8326632 (rs1542180) 2q31.1 HOXD3, HOXD4 NA 0.21 0.24 0.19
15 SNP_A-2008150 (rs869108) 11p15.1 OTOG, MYOD1, USH1C 0.22 0.21 0.16 0.07
a Known imprinted gene




examples shown in Fig. 3A and Fig. 3B. We used clonal bisulﬁte
sequencing to validate tissue-speciﬁc ASM identiﬁed by the
MSNPmethod in these 2 regions (Fig. 3C and Fig. 3D), conﬁrm-
ing the patterns observed in our array data for both loci.
Informative MSNP probes within DNase I hypersensitive
regions are characterized by elevated ASM scores
Enrichment analyses were performed using a Kruskal-Wallis
rank-sum test for ASM rank differences between the annotated
genic regions (see Materials and Methods). We observed a dif-
ferential distribution of ASM scores across annotated genic
regions (i.e., coding, 50UTR, intergenic, intron, promoter,
30UTR) in cortex (BA9) (P D 1.29 £10¡15), cerebellum
(P D 3.98 £10¡14), whole blood (P D 2.06 £10¡12), and the
cross-tissue analysis (P D 2.12 £10¡26). Post-hoc tests identi-
ﬁed these differences to be primarily driven by an enrichment
of high ASM scores in promoter regions (Fig. S5). We used
data from ENCODE38 to assess whether ASM is enriched in
regions associated with DNase I hypersensitive (DHS) sites
identiﬁed in multiple tissues including frontal cortex and cere-
bellum, as well as CD14C monocytes and na€ıve B cells (as a
proxy for blood). We compared the ASM score ranks for infor-
mative probes between regions deﬁned by the presence or
absence of DHS sites using a Wilcoxon rank-sum test (see
Materials and Methods). DHS peaks across all tissues are
enriched for higher ASM scores identiﬁed in cortex (BA9), cer-
ebellum, and whole blood (Table S3 and Fig. S6). Of note, the
most striking enrichment is found for cerebellum ASM scores
in regions characterized by cerebellum DHS peaks in ENCODE
(P D 3.51 £ 10¡220).
Inter-individual variation in ASM
We next examined inter-individual differences in ASM score at
speciﬁc loci, deﬁning probes with a large range of ASM scores
across the 3 individuals as being characterized by “variable
ASM.” Differentially methylated regions (DMRs) associated
with genomic imprinting, for example, are characterized by
parental-origin-speciﬁc ASM and are expected to show consis-
tently large ASM scores that exhibit allelic-ﬂipping, resulting
from genotype-independent ASM. Genotype-driven ASM, in
contrast, is likely to be exempliﬁed by consistent allelic biases
in DNA methylation across individuals, and is generally not
variable between individuals of the same genotype. Fig. S7
shows the correlation in ASM scores across the 3 individuals
proﬁled by MSNP, with tissue-speciﬁc correlations given in
Table S4. As expected, the individuals were more highly corre-
lated for loci characterized by high ASM scores. For probes
informative in at least 2 individuals we examined the range of
Table 2. Top 15 ASM sites in cerebellum, ASM score averaged across individuals.
Rank SNP ID Location Associated gene(s) Cerebellum ASM score Blood ASM score BA9 ASM score
1 SNP_A-4255628 (rs959246) 18q12.3 SLC14A2, SETBP1 0.30 0.03 0.05
2 SNP_A-8696273 (rs1003533) 5q31.1 C5orf56 0.29 0.16 0.07
3 SNP_A-1820553 (rs7959070) 12q22 CLLU1OS, BTG1 0.26 0.03 0.05
4 SNP_A-1841543 (rs10234308) 7p15.3 MGC87042 0.25 0.23 0.23
5 SNP_A-2002282 (rs12246813) 10q22.1 COL13A1, C10orf35 0.24 0.10 0.10
6 SNP_A-8625237 (rs12493005) 3q26.32 TBL1XR1 0.24 0.20 0.24
7 SNP_A-8326632 (rs1542180) 2q31.1 HOXD3, HOXD4 0.24 0.21 0.19
8 SNP_A-2160121 (rs7205794) 16q23.3 CDH13, MPHOSPH6 0.24 0.01 0.01
9 SNP_A-2052542 (rs3098382) 5q13.2 MAP1B 0.24 0.04 0.19
10 SNP_A-2040586 (rs17097827) 14q32.2 BCL11B, C14orf177 0.23 0.10 0.18
11 SNP_A-8420373 (rs10186346) 2p22.1 TMEM178 0.23 0.01 0.07
12 SNP_A-1788157 (rs7158663) 14q32.2 MEG3a 0.23 0.01 0.03
13 SNP_A-4235630 (rs9641549) 7q31.2 TFEC, MDFIC 0.23 0.05 0.13
14 SNP_A-4264458 (rs1358229) 4q27 TRPC3, KIAA1109 0.23 0.01 0.00
15 SNP_A-1931666 (rs6707698) 2q34 IKZF2, ERBB4 0.22 0.03 0.02
a Known imprinted gene
Table 3. Top 15 ASM sites in cortex (BA9), ASM score averaged across individuals.
Rank SNP ID Location Associated gene(s) BA9 ASM score Cerebellum ASM score Blood ASM score
1 SNP_A-8625237 (rs12493005) 3q26.32 TBL1XR1 0.24 0.24 0.20
2 SNP_A-8463467 (rs17164474) 7q35 OR2F2, OR2F1 0.23 0.17 0.17
3 SNP_A-1841543 (rs10234308) 7p15.3 MGC87042 0.23 0.25 0.23
4 SNP_A-8652129 (rs2479084) 1p36.21 FHAD1 0.22 0.13 0.18
5 SNP_A-8301602 (rs398225) 3p25.3 SRGAP3, RAD18 0.21 0.18 0.21
6 SNP_A-2107106 (rs987377) 6q21 AIM1a, ATG5 0.20 0.16 0.15
7 SNP_A-2052542 (rs3098382) 5q13.2 MAP1B 0.19 0.24 0.04
8 SNP_A-2307481 (rs716591) 15q26.2 LOC400456, MCTP2 0.19 0.21 0.17
9 SNP_A-8643280 (rs3121125) 1q21.1 HFE2, NBPF10 0.19 0.17 0.15
10 SNP_A-8326632 (rs1542180) 2q31.1 HOXD3, HOXD4 0.19 0.24 0.21
11 SNP_A-1998023 (rs9722212) 9q34.11 TOR1B, PTGES 0.19 0.15 0.19
12 SNP_A-8640607 (rs12632177) 3q27.1 MCF2L2 0.18 0.11 0.07
13 SNP_A-4291638 (rs12670584) 7p13 YKT6 0.18 0.19 0.01
14 SNP_A-1892234 (rs17303015) 5p12 MGC42105 0.18 0.11 0.03
15 SNP_A-8653671 (rs4871852) 8p21.3 TNFRSF10D 0.18 0.09 0.11
a Known imprinted gene




ASM scores across individuals and identiﬁed the top ranked
variable ASM probes in each tissue (Table S5-S7) as well as
cross-tissue variable sites, which show consistent inter-individ-
ual variation across all tissues (Table 6). Some sites show evi-
dence of allelic-ﬂipping in ASM score between individuals,
indicative of genomic imprinting. These included several
probes in the vicinity of the imprinted gene cluster on chromo-
some 15q11.2 (Figs. 4A-C). High ASM scores were also
observed in the vicinity of other known imprinted loci, for
example, SNRPN (Fig. S8A), DLGAP2 (Fig. S8B), AIM1
(Fig. S8C), MEG3 (Fig. S8D), BLCAP (Fig. S8E), and GRB10
(Fig. S8F), in addition to loci suspected to be imprinted, e.g.,
TRAPPC9 (Fig. S8G), EVX1 (Fig. S8H), and TGFBI/VTRNA2
(Fig. S8I); however, we were unable to examine variable ASM
in many of these regions because they were only informative
(i.e., heterozygous) in a single individual. Notably, we also iden-
tiﬁed allelic-ﬂipping in the vicinity of loci not previously char-
acterized as being imprinted, for example WRB (Fig. 4D) and
ITPKI (Fig. S9). Other variable ASM sites are marked by both
high and low ASM scores in different individuals, rather than
allelic-ﬂipping between them, for example,MGST3/LOC400794
(Table S5). Interestingly, we identiﬁed a number of sites charac-
terized by tissue-speciﬁc variable ASM. A notable example is
the imprinted gene GRB10, which has been previously shown
to be differentially maternally- and paternally-expressed in a
tissue-speciﬁc manner29,33 (Fig. S8F).
Variable ASM sites are ﬂanked by extended regions of
intermediate DNA methylation
We next quantiﬁed genome-wide patterns of DNA methyla-
tion in a larger sample (nD39) of matched whole blood,
cortex (BA9), and cerebellum samples using the Illumina
Inﬁnium HumanMethylation450 BeadChip (450K array).
For the 100 top-ranked ASM sites in each of the 3 tissues,
plus the 100 top-ranked cross-tissue, tissue-speciﬁc, and
variable ASM sites we identiﬁed probes on the array located
within 1 kb of the ASM marker SNPs (Table S8; detailed in
Table S9–S17) to investigate patterns of DNA methylation
across an extended region. As expected, regions around
known imprinted loci identiﬁed by our ASM analysis are
ﬂanked by extended regions of intermediate DNA methyla-
tion (i.e., average levels of DNA methylation between 0.4
and 0.6) (Fig. 5A and Fig. 5B). We observe a highly signiﬁ-
cant enrichment (P range D 6.82 £ 10¡11 – 0.005) of inter-
mediate DNA methylation relative to overall levels
identiﬁed on the 450K array in regions ﬂanking variable
ASM sites in all 3 tissues (Table 7 and Fig. 6). For example,
intermediate DNA methylation was observed around the
variable ASM site overlapping WRB (Fig. 5C), that showed
evidence of allelic-ﬂipping (Fig. 4D). Another probe exhibit-
ing variable ASM annotated to TGFBI/VTRNA2-1 on chro-
mosome 5 also shows a similar pattern of intermediate
DNA methylation (Fig. 5D). Interestingly, 4 individuals are
distinguished by consistent hypomethylation in whole blood
and cortex across 16 of the 19 sites, consistent with previ-
ous reports describing polymorphic imprinting of this
locus.39,40
Identiﬁcation of tissue-speciﬁc genotype-driven ASM
In contrast to the intermediate DNA methylation patterns
enriched in the vicinity of variable ASM sites, non-variable
ASM (i.e., characterized by consistent ASM scores across indi-
viduals) is not signiﬁcantly enriched for intermediate DNA
methylation and in some cases is exempliﬁed by trimodal pat-
terns of DNA methylation, which are highly suggestive of geno-
type-driven ASM acting in cis. Of note, we also observe
examples of tissue-speciﬁc genotype-driven ASM. For example,
a tissue-speciﬁc ASM site identiﬁed as showing allelically-
skewed DNA methylation in cerebellum (ASM score D 0.16)
but not whole blood (ASM score D 0.03) or cortex (ASM score
D 0.04) (Fig. 7A) located in an intron of the gene SYNJ2 is
Figure 1. Allelic-skewing is less prevalent and less variable across cortical regions
compared to cerebellum and whole blood. (A) The average proportion of informa-
tive amplicons showing an ASM score ! 0.10 for the 6 cortical regions proﬁled as
well as averaged across the cortical areas (Ctx) is consistently lower (ASM score
rangeD 0.34–0.61%) than in cerebellum (Cer) (ASM prevalenceD 1.14%) or blood
(ASM prevalence D 0.84%). Standard errors are shown for tissues for which sam-
ples were available from all 3 individuals. (B) – (E) Correlations of ASM scores are
shown with each point representing one probe in one individual. Probes classiﬁed
as allelically-skewed at an ASM score ! 0.10 in only one of the 2 compared tissues
are highlighted in red. A higher degree of between-tissue variability is observed
between cerebellum, cortex, and whole blood than between different cortical
regions (shown as an example is BA8 vs. BA10). This difference becomes even
more pronounced when restricting the set of probes to those that show allelic-






ﬂanked by trimodal levels of DNA methylation in cerebellum
but not blood or cortex (Fig. 7B).
Discussion
This study conﬁrms the relatively widespread distribution of
allelically-skewed DNA methylation in the human genome,
corroborating our previous data generated in whole blood.7 We
also present evidence for tissue-speciﬁc differences in the quan-
tity and distribution of ASM between different regions of the
human brain, and between brain and whole blood. Our ﬁnd-
ings are in line with previous reports, conﬁrming the impor-
tance of tissue-speciﬁc DNA methylation proﬁles across the
brain.22,41
Although our data conﬁrm previous studies, identifying
more between-tissue variation than inter-individual variation,28
we ﬁnd clear examples where ASM is variable between individ-
uals. While the number of samples proﬁled in this study is too
small to accurately determine how much of the observed inter-
individual variation in ASM results from genetic and non-
genetic effects, previous studies suggest that the majority of
such variation is likely to be genetically driven.7,8,11 Interest-
ingly, we identify instances of tissue-speciﬁc allelically-skewed
DNA methylation resulting from both genomic imprinting and
genotypic effects. For example, we observe tissue-speciﬁc vari-
able ASM around the imprinted growth factor receptor-bound
protein 10 gene (GRB10), which encodes a protein that inter-
acts with insulin-like growth factors42,43 and we observe geno-
type-driven ASM exclusively in cerebellum for several probes
within the synaptojanin 2 gene (SYNJ2), which encodes a pro-
tein involved in the uncoating of vesicles.44,45 Such tissue-spe-
ciﬁc ASM has important implications for epigenetic
epidemiology, and provides a mechanism by which genotype
may exert an effect on gene function and regulation in a tissue-
speciﬁc manner.
This study has a number of important limitations. First,
although we used a unique set of samples comprising of
matched tissues obtained from the same donors, the number of
individuals proﬁled in our analysis was small, meaning we can-
not deﬁnitively distinguish between genetic and non-genetic
effects, or make broad statements about general patterns of
inter-individual variation of ASM. Our Illumina 450K array
validation studies were undertaken in a larger set of individuals,
but could only conﬁrm intermediate levels of DNA methylation
and not detect allele-speciﬁc patterns. Second, given the limited
availability of RNA from the same samples, we were unable to
relate our ASM ﬁndings to allelic patterns of gene expression in
the same individuals. Previous studies, however, have shown
that ASM is linked to allele-speciﬁc expression of nearby
genes.28 Third, our analyses were undertaken on whole tissue,
and represent aggregate values across a number of individual
cell types. Fourth, the MSNP approach utilizes SNP
Figure 2. Multiple loci are characterized by consistent allelic-skewing of DNA methylation across all tissues. Heatmaps display allele signal intensities for genomic DNA
(G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A and B denote the 2 alleles of the SNP and brightness represents the quantile
normalized signal intensity, with the scale displayed below the heatmap. Shown are the 2 top-ranked probes characterized by consistent ASM across tissues. These two
probes were informative in (A) individual 2 for rs10234308 and (B) individual 3 for rs12493005.
Table 4. Top 15 loci characterized by consistent ASM across cerebellum, whole blood, and cortex (BA9).








ASM score Tissue average
1 SNP_A-1841543 (rs10234308) 7p15.3 MGC87042 0.25 0.23 0.23 0.24
2 SNP_A-8625237 (rs12493005) 3q26.32 TBL1XR1 0.24 0.20 0.24 0.22
3 SNP_A-8326632 (rs1542180) 2q31.1 HOXD3, HOXD4 0.24 0.21 0.19 0.21
4 SNP_A-8301602 (rs398225) 3p25.3 SRGAP3, RAD18 0.18 0.21 0.21 0.20
5 SNP_A-8463467 (rs17164474) 7q35 OR2F2, OR2F1 0.17 0.17 0.23 0.19
6 SNP_A-2307481 (rs716591) 15q26.2 MCTP2, LOC400456 0.21 0.17 0.19 0.19
7 SNP_A-1894705 (rs986324) Xp22.11 DDX53, ZNF645 0.18 0.20 0.17 0.18
8 SNP_A-2071005 (rs4687210) 3q28 UTS2D 0.16 0.22 0.17 0.18
9 SNP_A-1998023 (rs9722212) 9q34.11 PTGES, TOR1B 0.15 0.19 0.19 0.18
10 SNP_A-8652129 (rs2479084) 1p36.21 FHAD1 0.13 0.18 0.22 0.18
11 SNP_A-8696273 (rs1003533) 5q31.1 C5orf56 0.29 0.16 0.07 0.17
12 SNP_A-1862496 (rs17578280) 1p31.1 LRRIQ3, NEGR1 0.18 0.17 0.17 0.17
13 SNP_A-2040586 (rs17097827) 14q32.2 C14orf177, BCL11B 0.23 0.10 0.18 0.17
14 SNP_A-1932077 (rs220030) 15q11.2 SNRPNa 0.18 0.18 0.15 0.17
15 SNP_A-2107106 (rs987377) 6q21 AIM1a, ATG5 0.16 0.15 0.20 0.17
a Known imprinted gene




microarrays—these do not interrogate the whole genome, and
can only assess pools of DNA molecules. Allelic patterns of
DNA methylation across individual DNA molecules cannot be
directly assessed using this approach, as would be possible
using bisulﬁte-sequencing methods. Furthermore, our thresh-
old for calling allelic imbalances in DNA methylation is
Table 5. Top 15 tissue-speciﬁc ASM sites, deﬁned by highly variable ASM scores across cerebellum, whole blood, and cortex (BA9).
Rank SNP ID Location Associated gene (s) Cerebellum ASM score Blood ASM score BA9 ASM score SD
1 SNP_A-4255628 (rs959246) 18q12.3 SLC14A2, SETBP1 ¡0.30 ¡0.03 ¡0.05 0.15
2 SNP_A-1946136 (rs927000) 20q13.12 STK4 ¡0.04 0.23 0.01 0.15
3 SNP_A-8438077 (rs585451) 15q21.2 ATP8B4, DTWD1 0.01 ¡0.25 0.00 0.15
4 SNP_A-8397727 (rs1123514) 5q13.3 ENC1, RGNEF ¡0.16 0.11 ¡0.01 0.13
5 SNP_A-2273834 (rs2252267) 14q23.1 PRKCH 0.19 ¡0.03 ¡0.05 0.13
6 SNP_A-4264458 (rs1358229) 4q27 TRPC3, KIAA1109 ¡0.23 0.01 0.00 0.13
7 SNP_A-8643616 (rs11700515) 21q22.3 COL6A1, PCBP3 0.20 ¡0.01 ¡0.03 0.13
8 SNP_A-2180729 (rs10276966) 7p15.2 HIBADH, EVX1b ¡0.01 ¡0.25 ¡0.03 0.13
9 SNP_A-4210659 (rs10517764) 4q32.2 NAF1, FSTL5 0.07 ¡0.14 ¡0.15 0.13
10 SNP_A-1997061 (rs10512149) 9q21.33 SLC28A3, NTRK2 ¡0.19 0.02 0.05 0.13
11 SNP_A-2160121 (rs7205794) 16q23.3 CDH13, MPHOSPH6 ¡0.24 ¡0.01 ¡0.01 0.13
12 SNP_A-8667432 (rs519782) 1p36.11 C1orf201 0.19 ¡0.04 ¡0.01 0.13
13 SNP_A-1787058 (rs10951911) 7p12.3 TNS3, C7orf65 ¡0.20 ¡0.01 0.04 0.13
14 SNP_A-1931666 (rs6707698) 2q34 IKZF2, ERBB4 ¡0.22 ¡0.03 0.02 0.13
15 SNP_A-8502638 (rs10989120) 9q31.1 TMEFF1, C9orf30 0.04 ¡0.20 ¡0.15 0.13
b Suspected imprinted gene
Figure 3. A number of loci are characterized by allelic-skewing of DNA methylation in only one tissue with minimal ASM present in any of the other tissues examined.
Heatmaps display allele signal intensities for genomic DNA (G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A and B denote the
2 alleles of the SNP and brightness represents the quantile normalized signal intensity, with the scale displayed below the heatmap. Two of the top-ranked cerebellum-
speciﬁc ASM signals are (A) rs959246 (informative for individual 3) and (B) rs2252267 (informative for individual 2). The tissue-speciﬁc patterns of DNA methylation in
these 2 loci were validated by clonal bisulﬁte sequencing, conﬁrming the ﬁndings from the MSNP assay (C,D). Each row represents a single DNA molecule, with black
dots depicting methylated cytosines and white dots depicting unmethylated cytosines. The percentage of methylated cytosines for each sample is displayed below the
plots. The amplicon spanning the DMR associated with rs959246 in (C) did not encompass a SNP enabling us to distinguish between the 2 alleles, however the methyla-
tion pattern shows evidence for tissue-speciﬁc intermediate methylation (IM) in the cerebellum. G and A in (D) denote the 2 alleles determined by SNP variation within
the amplicon in heterozygous individual 2. Cerebellum-speciﬁc hypomethylation of the A allele is observed surrounding rs2252267, with individual 3 (homozygous for





somewhat arbitrary; it is likely that our data is confounded by
both false positives and negatives. We did, however, ﬁnd very
consistent overlap in whole blood ASM data with that reported
in our previous study using the same laboratory and analysis
methods,7 conﬁrming the validity of the MSNP approach. Fur-
thermore, we validated our ﬁndings using 2 independent plat-
forms: clonal bisulﬁte sequencing and the Illumina 450K
Human methylation array. Using the latter, we were able to
show that variable ASM sites are located in an extended context
of intermediate DNA methylation, supporting a regional regu-
latory role of DNA methylation in these domains, which is
potentially driving intermediate expression levels in a quantita-
tive manner across gene regulation clusters.12 In addition, we
observed a signiﬁcant enrichment of ASM in regions
Table 6. Top 15 variable ASM sites, deﬁned by average range of ASM scores between individuals across cerebellum, whole blood, and cortex (BA9).
Rank SNP ID Location Associated gene(s) Cerebellum range Blood range BA9 range Average range
1 SNP_A-8579417 (rs1538116) 1q24.1 MGST3, LOC400794 0.24 0.35 0.32 0.30
2 SNP_A-2019421 (rs2244352) 21q22.2 WRB 0.36 0.24 0.29 0.30
3 SNP_A-4219174 (rs2346019) 5q31.1 TGFBI, VTRNA2b 0.23 0.23 0.30 0.25
4 SNP_A-4208914 (rs927651) 20q13.2 CYP24A1 0.25 0.23 0.17 0.22
5 SNP_A-8717059 (rs12713666) 2p13.3 ARHGAP25 0.26 0.15 0.21 0.21
6 SNP_A-8692937 (rs4605656) 4q24 CXXC4, TACR3 0.16 0.18 0.25 0.20
7 SNP_A-8634251 (rs1209228) 14q24.2 RGS6, SIPA1L1 0.19 0.15 0.24 0.19
8 SNP_A-8329713 (rs16825906) 3q13.31 LSAMP, IGSF11, LOC285194 0.21 0.13 0.22 0.19
9 SNP_A-8713358 (rs16890883) 4p15.33 CPEB2, LOC152742 0.24 0.14 0.17 0.19
10 SNP_A-8638348 (rs4525744) 2p21 SRBD1 0.20 0.18 0.17 0.18
11 SNP_A-1855770 (rs3764124) 13q34 CUL4A 0.16 0.23 0.15 0.18
12 SNP_A-4259064 (rs7766133) 6p22.3 MBOAT1 0.17 0.17 0.20 0.18
13 SNP_A-2118217 (rs1695824) 1p36.33 VWA1, TMEM88B 0.25 0.16 0.13 0.18
14 SNP_A-1880775 (rs6116750) 20p12.3 PROKR2 0.23 0.13 0.18 0.18
15 SNP_A-8424056 (rs3922835) 18q12.1 CDH2b, CHST9 0.18 0.04 0.32 0.18
b Suspected imprinted gene
Figure 4. Cases of allelic-ﬂipping of DNA methylation between individuals are found both in known imprinted gene clusters as well as regions not previously
conﬁrmed as being imprinted. The heatmaps show allele signal intensities for genomic DNA (G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U)
in all tissues. A and B denote the 2 alleles of the SNP and brightness represents the quantile normalized signal intensity, with the scale displayed below the heatmap. (A)-
(C) Three probes in the vicinity of the known imprinted cluster on chromosome 15q11.2 show variable ASM and allelic-ﬂipping in cerebellum [(A) rs940596, (B)
rs11633486, (C) rs11854691]. (D) Allelic-ﬂipping of DNA methylation across all tissues is observed in the vicinity of WRB (rs2244352), which has not been reported as
imprinted previously.




characterized by DHS peaks across several tissues. This enrich-
ment of ASM in the vicinity of markers of open chromatin sup-
ports the involvement of ASM in transcriptional activity.
To conclude, we explored inter- and intra-individual varia-
tion in ASM across several regions of the human brain and
whole blood frommultiple individuals. Consistent with previous
studies, we ﬁnd relatively widespread ASM, observing allelically-
skewed DNA methylation ﬂanking known imprinted regions,
and show that ASM sites are often located in an extended geno-
mic context of intermediate DNAmethylation. Interestingly, we
detect cases of genotype-driven ASM, which are also tissue-spe-
ciﬁc. These ﬁndings contribute to our understanding about the
nature of differential DNA methylation across tissues and have
important implications for genetic studies of complex disease.
As a resource to the community, ASM patterns across each of
the tissues studied are available in a searchable online database:
http://epigenetics.essex.ac.uk/ASMBrainBlood.
Materials and methods
Genome-wide analysis of allelically-skewed DNA
methylation
Post-mortem brain and pre-mortem whole blood samples from 2
female and one male donors were provided by the MRC London
Neurodegenerative Disease Brain Bank (http://www.kcl.ac.uk/
ioppn/depts/bcn/Our-research/Neurodegeneration/brain-bank.
aspx). Subjects were approached in life for written consent for
Figure 5. Regions around variable ASM sites are enriched for genomic domains characterized by intermediate DNA methylation. Flanking regions (1 kb) of variable ASM
sites show a signiﬁcant enrichment in intermediately methylated probes on the Illumina 450K Human Methylation Array (P range D 6.82 £ 10¡11 – 0.005). The scatter
plots (A)-(D) show the location of genes and imprinting control regions (ICR) if overlapping the plotting window, as well as the location of the SNP from the MSNP assay
(gray vertical line). These intermediate DNA methylation patterns span several known imprinted regions, for example (A) a ﬂanking region of rs220030 in the SNRPN
imprinted DMR, and (B) a region around rs2735971 in the imprinted gene H19. (C) Other sites showing allelic-ﬂipping and intermediately methylated ﬂanking regions lie
in areas not previously known to be imprinted, for example rs2244352, which lies in an intron of WRB. (D) A polymorphic ASM pattern is observed in a ﬂanking region
around rs2346019, a downstream gene variant of VTRNA2-1, in which the majority of samples display intermediate DNA methylation in cortex (BA9) and whole blood. Of
note, 4 samples show consistent hypomethylation across this region.
Table 7. Enrichment in intermediate methylation (IM) near ASM regions.
IM rate O/E P
Bloodd 5.88% 0.98 0.576
Cerebellumd 11.49% 1.75 0.059
BA9d 13.29% 1.45 0.065
Cross-tissue 8.11% 0.87 0.741
Tissue-speciﬁc 8.00% 0.85 0.701
Variable 38.46% 4.10 9.56 £ 10¡11
Variable (BA9)d 37.50% 4.09 8.86 £ 10¡9
Variable (cerebellum)d 16.95% 2.58 0.005
Variable (blood)d 34.48% 5.77 6.82 £ 10¡11
c IM is deﬁned as an average methylation between 0.4 and 0.6, enrichment P val-
ues are based on a hypergeometric test based on the background distribution of
IM.






brain banking, and all tissue donations were collected and stored
following legal and ethical guidelines (NHS reference number 08/
MRE09/38; the HTA license number for the LBBND brain bank
is 12293). All samples were free from neuropathological and neu-
ropsychiatric disease. A detailed list of brain regions obtained for
each individual is provided in Table S18. Genomic DNA was iso-
lated from all tissue samples using a standard phenol-chloroform
protocol and assessed for purity and degradation prior to analysis
(see Davies et al.22 for additional information about the samples
used in this study). The MSNP method, described previously,6,7
was used to quantitatively assess allelic-skewing of DNAmethyla-
tion across the genome. Brieﬂy, Affymetrix Genome-wide
Human SNP 6.0 Arrays were used to genotype a) DNA from
each tissue sample digested with a cocktail of MSREs (HpaII:
50 -C^ C G G-30, HhaI: 50 -G C G^ C-30, and AciI: 50 -C^C G C-30)
(D arrays), b) unmethylated whole-genome-ampliﬁed DNA for
each individual digested with the same cocktail of MSREs to con-
trol for possible confounding effects of DNA sequence polymor-
phisms located at MSRE cut-sites (U arrays), and c) genomic
DNA from each of the 3 individuals to identify heterozygous
(informative) SNPs (G arrays). Unmethylated DNA was pro-
duced by whole-genome amplifying 100 ng cerebellum DNA
using the Qiagen RepliG kit (Qiagen, Crawley, UK) using the
manufacturer’s protocol. In total 28 genotyping arrays were
processed: 22 D arrays (DNA from between 6 and 7 brain regions
plus whole blood, for each individual), 3 U arrays (one for each
individual), and 3 G arrays (one for each individual). Additional
methodological details are available in Schalkwyk et al.7
Selection of informative SNPs and quantiﬁcation of ASM
To be informative in the ASM assay, SNPs must be heterozy-
gous, and the amplicon must contain an MSRE cut site.6,7 To
guard against poorly performing SNP probes we also removed
consistently low signal intensity SNPs across the 22 G arrays,
and those yielding a highly variable U/G signal ratio
(SD > 0.077) across all samples. A total of 220,449 SNPs passed
our stringent ﬁltering criteria and were classiﬁed as informative
and heterozygous in at least one individual. The number of
informative SNPs in each of the individual samples proﬁled by
theMSNPmethod is shown in Table S19. Quantitative measures
of ASM were derived by comparing signal intensities between
the D (MSRE digested) and G (genomic DNA) arrays using the
SNPMaP package (v1.02) in R that was developed for the esti-
mation of allele frequencies in DNA pools genotyped on SNP
arrays.46 Brieﬂy, relative allele score (RAS) values were gener-
ated for all SNPs on the array, which are deﬁned as A/(A C B),
where A and B are the intensities of the probes for the 2 alleles of
Figure 6. Regions around variable ASM are enriched in intermediate DNA methylation. The distributions of DNA methylation at the 65 Illumina 450K Human Methylation
Array probes within 1 kb of the top 100 variable ASM sites (Table S14) show an enrichment in intermediately methylated probes compared to DNA methylation levels
across the whole array (shown in gray) in (A) cortex (BA9), (B) cerebellum, and (C) whole blood).
Figure 7. Genotype-driven ASM can be tissue-speciﬁc. (A) The tissue-speciﬁc ASM site rs1009014, located in an intron of SYNJ2, shows allelic-skewing of DNA methylation
in cerebellum (ASM score D 0.16) but not in cortex (ASM score D 0.04) or whole blood (ASM score D 0.03). (B) DNA methylation levels for Illumina 450K Human Methyla-
tion Array probes in cerebellum across a ﬂanking region of this locus exhibit a genotype-driven tissue-speciﬁc DNA methylation pattern. The scatter plot shows the loca-
tion of SYNJ2 (transcript variant 1), as well as the location of the informative SNP from the MSNP assay (gray vertical line).




a given SNP. For a given SNP in a heterozygous individual, ASM
(or allelic-skewing of DNA methylation) is detected as a differ-
ence in RAS between the G and D arrays. We call this difference
in RAS “ASM score” and deﬁne probes showing an absolute
ASM score ! 0.10 as “allelically-skewed.” A UCSC custom
annotation track showing the location of all 220,449 loci and the
degree of allelic-skewing in DNA methylation across each tissue
and individual is available for download from our website
(http://epigenetics.essex.ac.uk/ASMBrainBlood). Enrichment
analyses were performed using a Kruskal-Wallis rank-sum test
for ASM rank differences between the annotated genic regions.
This non-parametric method tests whether multiple samples
were drawn from the same distribution and is the multivariate
extension of the better-known Wilcoxon rank-sum test. This
test allowed us to avoid selecting a speciﬁc threshold for ASM
scores and does not assume a normal distribution of residuals.
Of the 220,449 informative probes, 219,921 could be annotated
to speciﬁc deﬁned genic regions. Annotations were based on
the Homo sapiens hg19 build from UCSC using the Annota-
tionHub Bioconductor package47 classifying probes as residing
in introns (n D 100,254), 50UTRs (n D 347), 30UTRs (n D
2,341), coding regions (n D 2,569), intergenic regions (n D
110,186) and promoters (n D 4,224). A Nemenyi test for pair-
wise multiple comparisons of mean rank sums as implemented
in the PMCMR R package48 was used for post-hoc compari-
sons. ENCODE tracks for DHS peaks in frontal cortex, frontal
cerebrum, cerebellum, CD14C monocytes, na€ıve B cells, H1
human embryonic stem cells (H1-hesc), heart, and ﬁbroblasts
were obtained from the UCSC genome browser (http://hgdown
load.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeO
penChromDnase/). For the DHS enrichment analyses we tested
whether the rank-sums for ASM scores differed signiﬁcantly in
informative probes deﬁned by the presence or absence of DHS
peaks using a Wilcoxon rank-sum test. Informative probes
were ranked according to ASM scores with higher absolute
ASM scores corresponding to lower ranks.
Clonal bisulﬁte sequencing
Two regions were subsequently selected for clonal bisulﬁte
sequencing analysis to further verify our ﬁndings and deter-
mine the precise allele-speciﬁc patterns of DNA methylation.
Following sodium bisulﬁte treatment and bisulﬁte-PCR ampli-
ﬁcation, amplicons were cloned using the TOPO TA cloning
method (Invitrogen, Paisley, UK) and sequenced with BigDye
v1.1 sequencing chemistry (Applied Biosystems) (Table S20).
Sequencing traces were visualized, quality controlled, and
aligned using BiQ Analyzer.49 All data were tested for complete
sodium bisulﬁte conversion, with an overall conversion rate
> 99.9% estimated by BiQ Analyzer.
Validation of ASM on the llumina 450K HumanMethylation
microarray
Further analysis of ASM sites was undertaken on a larger col-
lection of post-mortem brain samples (n D 34), comprising
BA9, BA21, BA28/34, and cerebellum, which were also free of
any neuropathology and neuropsychiatric disease. Additionally
we analyzed matched pre-mortem whole blood samples, which
were available for a subset (n D 8), as well as 5 unmatched
blood samples (see Table S18). The 3 individuals proﬁled by
MSNP were included in this analysis. DNA (500 ng) from each
sample was treated with sodium bisulﬁte in duplicate, using the
EZ-96 DNA methylation kit (Zymo Research, CA, USA). DNA
methylation was quantiﬁed using the Illumina Inﬁnium
HumanMethylation450 BeadChip (Illumina Inc., CA, USA)
run on an Illumina HiScan System (Illumina) using the manu-
facturers’ standard protocol, with pre-processing and stringent
quality control performed as previously described.50 We used
the GenomicRanges package51 to extract data for all CpG sites
within 1 kb of candidate ASM SNPs and examined patterns of
DNA methylation across the 3 tissues. Intermediate DNA
methylation was deﬁned as an average methylation value
between 0.4 and 0.6 across all individuals. To test for statistical
signiﬁcance of enrichment in intermediately methylated probes
we used a hypergeometric distribution based on the number of
probes tested and the background of intermediately methylated
probes across the whole array. Annotation of genes in the
methylation plots (Fig. 5 and Fig. 7B) was obtained from the
UCSC Genome Browser hg19 assembly. Imprinting control
region (ICR) annotation was obtained from the web resource
on human DMRs provided by the Department of Medical and
Molecular Genetics, Kings College London (https://atlas.genet
ics.kcl.ac.uk) and lifted over from hg18 to hg19.
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4.2. Supplementary Material 
 
 
Supplementary Figure 1 
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Figure 4-8. The overall distribution of ASM score is similar across brain regions and whole 
blood samples. The distribution of ASM scores (A) and absolute ASM scores (B) is similar 
across cortex (BA9), cerebellum and whole blood. However, histograms of absolute ASM score 
using a threshold of ≥ 0.10 (C) and ≥ 0.20 (D) indicate a large number of loci characterized by 
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Supplementary Figure 2 
	
Figure 4-9. ASM scores in whole blood overlap with those identified in a previous study. 
Across probes informative in both studies there is a significant correlation between whole blood 
ASM scores identified in the current study and previously by Schalkwyk et al (2010) (r = 0.21, P 
< 1.0 × 10-50). 9 of the 15 top-ranked blood ASM sites in our current study (Table 1) were 





Supplementary Figure 3 
 
	
Figure 4-10. Large allelic asymmetries in DNA methylation are more prevalent in 
cerebellum and whole blood than cortex. The average percentage of informative amplicons 
showing an ASM score ≥ 0.20 for the six cortical regions profiled as well as averaged across the 
cortical areas (Ctx) is consistently lower than in cerebellum (Cer) or blood. Standard errors are 





Supplementary Figure 4 
 
 
Figure 4-11. ASM scores are highly correlated across cortical regions. Lower triangular 
matrix: scatterplots of ASM scores, with probes characterized by absolute ASM scores ≥ 0.10 
colored in red. Upper triangular matrix: correlations of ASM scores filtered for loci with at least 





Supplementary Figure 5 
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Figure 4-12.	 Informative probes annotated to genic promoter regions are enriched for 
elevated ASM scores. A Kruskal-Wallis non-parametric test showed a significantly different 
distribution of ranked ASM scores between coding, 5’UTR, intergenic, intronic, promoter and 3’ 
UTR regions in informative cortex, cerebellum, blood and cross-tissue MSNP probes (P range = 
2.21 ×1026 - 2.06 ×1012). Post-hoc analysis showed that the differences were primarily driven 
by an enrichment of elevated ASM scores in annotated promoter regions for (A) cortex (BA9), (B) 
cerebellum, (C) whole blood and (D) cross-tissue ASM scores. The mean number of informative 
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Figure 4-13. DNase I hypersensitive (DHS) sites are enriched for loci characterized by high 
ASM scores. DHS peaks overlapping informative MSNP probes are enriched for elevated ASM 
scores (see Supplementary Table 3). The histograms show the distribution of ASM score ranks 
for informative probes residing in ENCODE DHS peaks from frontal cortex (A), cerebellum (B) 
and monocyte-CD14+ cells (C). Shown is the distribution of ASM score ranks identified in cortex 
(BA9) (blue, top left), cerebellum (green, top right), whole blood (red, bottom left) and in the cross-
tissue analysis (black, bottom right) across informative MSNP probes within ENCODE DHS 
peaks. All histograms show a clear peak in lower ranks with a uniform distribution across the rest 
of the rank spectrum, illustrating the higher than expected prevalence of probes with high ASM 



















































Supplementary Figure 7 
 
	
Figure 4-14. Individuals are more highly correlated for loci characterized by high ASM 
scores. ASM scores are significantly correlated between individuals, particularly at loci with an 
ASM score ≥ 0.10 for at least one of the two compared individuals (subset correlation r’).  (A)-(C) 
Scatterplots of ASM scores across individuals plotted for each informative probe in cortex (BA9), 
cerebellum and whole blood. 
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Supplementary Figure 8 
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Figure 4-15. Figure 8. Several ASM sites were identified in known or suspected imprinted 
regions. Heatmaps display allele signal intensities for genomic DNA (G), MSRE-digested DNA 
(D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A and B denote the two alleles 
of the SNP and brightness represents the quantile normalized signal intensity, with the scale 
displayed below the heatmap. Shown are data from probes in the vicinity of known imprinted 
genes: (A) rs220030 (SNRPN), (B) rs10481354 (DLGAP2), (C) rs987377 (AIM1), (D) rs7158663 
(MEG3), (E) rs4810805 (BLCAP) and (F) rs2237453 (GRB10). Also shown are data from probes 




Supplementary Figure 9 
 
	
Figure 4-16. Some sites showing allelic-flipping in ASM are not located near known or 
suspected imprinted regions. The heatmap displays allele signal intensities for genomic DNA 
(G), MSRE-digested DNA (D) and fully unmethylated, MSRE-digested DNA (U) in all tissues. A 
and B denote the two alleles of the SNP and brightness represents the quantile normalized signal 
intensity, with the scale displayed below the heatmap. The heatmap shows rs941540 (ITPKI), 
which is located in a region not previously shown to be genomically imprinted. 
 
	 152	
Supplementary Table 1 
 
Table 4-8. Average absolute ASM scores for each sample. 
 BA8 BA9 BA10 BA17 BA21 BA28/34 Cerebellum Blood Average 
Individual 1 0.026 0.025 0.028  0.023 0.027 0.023 0.028 0.026 
Individual 2 0.023 0.027 0.024   0.026 0.028 0.026 0.025 
Individual 3 0.025 0.027 0.025 0.024 0.023 0.023 0.030 0.024 0.025 
Average 0.025 0.026 0.026 0.024 0.023 0.025 0.027 0.026 0.025 
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Supplementary Table 2 
 
Table 4-9. Percentage of amplicons characterized by an ASM score ≥ 0.10 for each sample. 
 BA8 BA9 BA10 BA17 BA21 BA28/34 Cerebellum Blood Average 
Individual 1 0.68% 0.40% 0.84%  0.37% 0.80% 0.56% 0.97% 0.66% 
Individual 2 0.42% 0.64% 0.44%   0.64% 1.36% 1.03% 0.76% 
Individual 3 0.47% 0.73% 0.55% 0.43% 0.31% 0.34% 1.50% 0.51% 0.60% 
Average 0.52% 0.59% 0.61% 0.43% 0.34% 0.59% 1.14% 0.84% 0.63% 
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Supplementary Table 3 
 
Table 4-10. Enrichment of high ASM scores in DNase I hypersensitivity peaks spanning 







Enrichment P value* 









Frontal cortex 7746 4.59 ×10-38 5.69 ×10-58 1.41 ×10-43 1.19 ×10-81 
Cerebrum frontal 8294 8.84 ×10-51 1.75 ×10-80 3.19 ×10-42 2.92 ×10-107 
Cerebellum 7228 2.10 ×10-47 3.51 ×10-220 1.09 ×10-27 4.74 ×10-181 
Monocytes - CD14+ 8316 4.98 ×10-15 4.13 ×10-24 7.41 ×10-52 5.43 ×10-53 
Naïve B cell 3908 4.71 ×10-31 2.10 ×10-37 2.99 ×10-96 1.35 ×10-99 
Heart 7268 5.05 ×10-42 1.19 ×10-54 1.78 ×10-55 3.86 ×10-93 
Fibroblast 4316 7.50 ×10-25 1.67 ×10-24 1.85 ×10-20 2.07 ×10-42 
H1-hesc 7208 2.92 ×10-44 8.77 ×10-67 3.52 ×10-56 1.98 ×10-93 
* P values are based on a Wilcoxon rank-sum test comparing ASM ranks in DHS and non-DHS informative probes 
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Supplementary Table 4 
 
Table 4-11. Correlations of ASM scores between individuals. 
 Correlation (r)  Subset correlation (r’)*  
 BA9 Cerebellum Blood All tissues+ BA9 Cerebellum Blood All tissues+ 
Individual 1 vs. 2 0.15 0.19 0.12 0.15 0.45 0.51 0.41 0.45 
Individual 1 vs. 3 -0.01 0.23 0.14 0.12 0.12 0.55 0.41 0.38 
Individual 2 vs. 3 0.15 0.28 0.17 0.21 0.34 0.52 0.53 0.48 
* The subset correlation r’ is calculated using only probes for which at least one of the two compared individuals exhibit an ASM score ≥ 0.10 in the 
given tissue. 
+ Cerebellum, cortex (BA9) and whole blood 
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Supplementary Table 5 
 
Table 4-12. Top 20 variable ASM sites in whole blood, defined by range of ASM scores. 
Rank SNP ID Location Associated gene(s) Blood ASM scores Range per tissue  
    Ind 1 Ind 2 Ind 3 Blood Cerebellum BA9 
1 SNP_A-8579417 
(rs1538116) 
1q24.1 MGST3, LOC400794 - -0.29 0.06 0.35 0.24 0.32 
2 SNP_A-8312502 
(rs17469830) 
14q12 ARHGAP5, NUBPL, 
C14orf128 
-0.07 0.21 - 0.28 0.12 0.03 
3 SNP_A-1802351 
(rs509062) 
20q13.32 PPP4R1L -0.16 - 0.08 0.25 0.13 0.05 
4 SNP_A-2019421 
(rs2244352) 
21q22.2 WRB -0.19 0.05 - 0.24 0.36 0.29 
5 SNP_A-8324660 
(rs6438837) 
3q21.2 KALRN -0.14 0.09 -0.06 0.24 0.16 0.10 
6 SNP_A-4232094 
(rs8179356) 
1p21.2 FRRS1 - 0.08 -0.16 0.23 0.11 0.07 
7 SNP_A-1855770 
(rs3764124) 
13q34 CUL4A -0.11 0.12 0.06 0.23 0.16 0.15 
8 SNP_A-4219174 
(rs2346019) 
5q31.1 TGFBI, VTRNA2b 0.04 0.07 -0.16 0.23 0.23 0.30 
9 SNP_A-4208914 
(rs927651) 
20q13.2 CYP24A1 0.15 -0.08 0.00 0.23 0.25 0.17 
10 SNP_A-2275375 
(rs7694398) 




20p11.23 RIN2, SLC24A3 0.01 -0.20  0.21 0.04 0.09 
12 SNP_A-8448479 
(rs12837024) 
Xq22.3 CLDN2, RIPPLY1 -0.06 - 0.15 0.21 0.10 0.15 
13 SNP_A-2074691 
(rs7065328) 
Xq13.1 TEX11 -0.10 - 0.10 0.21 0.08 0.01 
14 SNP_A-8330843 
(rs896040) 





0.13 - -0.07 0.20 0.05 0.01 
16 SNP_A-8633376 
(rs318657) 
5p15.33 LOC285577, C5orf38 -0.11 0.09 - 0.20 0.11 0.08 
17 SNP_A-4239614 
(rs1890070) 
1q41 HHIPL2, DUSP10 -0.16 0.04 - 0.20 0.02 0.02 
18 SNP_A-2256850 
(rs1164193) 
3q13.13 PVRL3, FLJ25363 0.08 -0.12 - 0.20 0.01 0.08 
19 SNP_A-1869018 
(rs1984713) 
4p12 CNGA1 - -0.18 0.02 0.20 0.15 0.14 
20 SNP_A-8436908 
(rs4810805) 
20q11.23 CTNNBL1, BLCAPa -0.14 0.05 0.06 0.20 0.05 0.07 
a Known imprinted gene 




Supplementary Table 6 
 
Table 4-13. Top 20 variable ASM sites in cerebellum, defined by range of ASM scores. 
Rank SNP ID Location Associated 
gene(s) 
Cerebellum ASM scores Range per tissue 
   Ind 1 Ind 2 Ind 3 Cerebellum  Blood  BA9  
1 SNP_A-2019421 
(rs2244352) 
21q22.2 WRB -0.22 0.14 - 0.36 0.24 0.29 
2 SNP_A-8492800 
(rs2237453) 
7p12.1 GRB10a - 0.06 -0.23 0.30 0.11 0.08 
3 SNP_A-8291694 
(rs941540) 
14q32.12 ITPK1 - 0.10 -0.17 0.27 0.07 0.13 
4 SNP_A-8717059 
(rs12713666) 
2p13.3 ARHGAP25 -0.08 0.18 0.04 0.26 0.15 0.21 
5 SNP_A-4208914 
(rs927651) 



























































- 0.12 -0.11 0.23 0.13 0.18 
18 SNP_A-2244974 
(rs941483) 










-0.07 0.11 0.16 0.22 0.06 0.15 
a Known imprinted gene 
b Suspected imprinted gene 
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Supplementary Table 7 
 
Table 4-14. Top 20 variable ASM sites in cortex (BA9), as defined by range of ASM scores. 
Rank SNP ID Location Associated 
gene(s) 
BA9 ASM scores Range per tissue 





- -0.24 0.08 0.32 0.24 0.35 
2 SNP_A-8424056 
(rs3922835) 
18q12.1 CDH2b, CHST9 -0.15 - 0.17 0.32 0.18 0.04 
3 SNP_A-4219174 
(rs2346019) 
5q31.1 TGFBI, VTRNA2 0.10 0.13 -0.17 0.30 0.23 0.23 
4 SNP_A-2019421 
(rs2244352) 
21q22.2 WRB -0.15 0.14 - 0.29 0.36 0.24 
5 SNP_A-8448997 
(rs17346747) 
8p23.2 CSMD1 -0.11 0.01 0.15 0.26 0.10 0.03 
6 SNP_A-8692937 
(rs4605656) 
4q24 CXXC4, TACR3 -0.19 - 0.06 0.25 0.16 0.18 
7 SNP_A-8658815 
(rs9807659) 
18q11.2 LAMA3 -0.08 0.02 0.17 0.24 0.12 0.10 
8 SNP_A-8311269 
(rs403594) 
1p32.3 ACOT11 -0.12 0.03 0.12 0.24 0.11 0.02 
9 SNP_A-8634251 
(rs1209228) 




6p24.2 NEDD9 - 0.03 -0.19 0.23 0.07 0.07 
11 SNP_A-8487535 
(rs503755) 
2q21.3 TMEM163 - 0.10 -0.12 0.22 0.01 0.09 
12 SNP_A-8329713 
(rs16825906) 
3q13.31 LSAMP, IGSF11, 
LOC285194 
-0.04 0.04 0.19 0.22 0.21 0.13 
13 SNP_A-8301613 
(rs4380126) 
18q23 C18orf62, TSHZ1 0.10 -0.02 -0.12 0.22 0.17 0.10 
14 SNP_A-8368457 
(rs7307323) 





-0.08 -0.02 0.13 0.21 0.15 0.03 
16 SNP_A-8717059 
(rs12713666) 





-0.03 - 0.18 0.21 0.15 0.10 
18 SNP_A-8613922 
(rs1009800) 





-0.11 0.10 0.05 0.21 0.15 0.08 
20 SNP_A-2246435 
(rs7070457) 
10q21.1 ZWINT 0.12 - -0.09 0.20 0.19 0.13 
b Suspected imprinted gene 
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Supplementary Table 8 
 
Table 4-15. Illumina 450K probes within 1kb of 100 top-ranked ASM sites. 
Top 100 ASM sites SNPs CpG sites 
Blood ASM 27 102 
Cerebellum ASM 20 87 
BA9 ASM 40 143 
Cross-tissue ASM 34 148 
Tissue-specific ASM 22 50 
Variable ASM 22 65 
Variable ASM (blood) 19 58 
Variable ASM (cerebellum) 18 59 
Variable ASM (BA9) 20 56 
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Supplementary Table 9 
 
Table 4-16. Illumina 450K probes within 1kb of the top 100 ASM SNPs in whole blood. 
Rank 
ASM in 
blood SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
3 0.23 rs10234308 7 22528590 cg10016647 22528033 557 
4 0.23 rs927000 20 43598705 cg17104026 43598376 329 
10 0.22 rs4687210 3 191046770 cg25342125 191046380 390 
     cg19066520 191046547 223 
     cg23528751 191046721 49 
     cg00473167 191046872 102 
     cg17596905 191046949 179 
     cg23817170 191046997 227 
     cg09688588 191047460 690 
     cg14972328 191046866 96 
     cg26325444 191047058 288 
12 0.22 rs12978286 19 17861868 cg22317846 17862385 517 
     cg02639359 17862017 149 
     cg26307105 17861017 851 
     cg08206267 17862104 236 
     cg11737334 17862210 342 
     cg24783510 17862150 282 
13 0.22 rs10481354 8 1704030 cg19131313 1704013 17 
     cg17159058 1704075 45 
14 0.21 rs1542180 2 177028767 cg12634591 177028606 161 
     cg06145336 177027931 836 
     cg10304824 177028804 37 
     cg13316854 177027856 911 
     cg09387749 177028680 87 
     cg25938806 177028162 605 
     cg01128482 177028621 146 
     cg00005847 177029073 306 
     cg24541426 177029459 692 
     cg23981871 177028714 53 
     cg05021643 177029608 841 
25 0.20 rs17312325 X 68442113 cg00427681 68441389 724 
     cg03350825 68442327 214 
     cg22337892 68441690 423 
27 0.20 rs1024611 17 32579788 cg13648045 32579022 766 
30 0.20 rs12493005 3 176912899 cg03356026 176912588 311 
37 0.19 rs12510921 4 185189278 cg04960065 185189300 22 
43 0.19 rs906805 2 28604879 cg01273330 28605224 345 
44 0.18 rs220030 15 25199768 cg21746532 25198793 975 
     cg26875073 25200490 722 
     cg02152271 25199270 498 
     cg02125271 25200406 638 
     cg03858387 25199164 604 
     cg01432432 25199028 740 
     cg08372135 25199057 711 
     cg18506672 25200253 485 
     cg12298755 25199713 55 
	 164	
48 0.18 rs2252397 7 140225750 cg01499591 140226367 617 
50 0.18 rs999556 5 150473674 cg23290159 150474234 560 
56 0.18 rs9526072 13 32883583 cg26941801 32882845 738 
     cg11448807 32884114 531 
57 0.18 rs7010076 8 105342827 cg13045555 105342365 462 
     cg04554929 105342491 336 
     cg15172053 105342214 613 
     cg23108931 105342351 476 
     cg17696517 105343133 306 
58 0.18 rs485219 8 70065359 cg05959464 70064456 903 
62 0.18 rs7210715 17 7196390 cg00901493 7197375 985 
64 0.17 rs17366322 2 11272784 cg05517905 11273075 291 
     cg09045196 11272424 360 
     cg12453288 11273229 445 
     cg10334385 11272868 84 
     cg03251967 11273291 507 
     cg15704155 11272399 385 
     cg27641709 11272899 115 
67 0.17 rs16942894 12 114026006 cg12492938 114025383 623 
70 0.17 rs9314433 8 1467648 cg00598912 1468625 977 
71 0.17 rs2071780 X 47341821 cg26176649 47342033 212 
     cg02124059 47341898 77 
     cg22238863 47342101 280 
     cg22713892 47342160 339 
     cg23534593 47342469 648 
     cg21161328 47342498 677 
     cg24559073 47342471 650 
     cg19867709 47342478 657 
     cg04302192 47341740 81 
     cg04575501 47342663 842 
     cg14388993 47342690 869 
     cg01887353 47342480 659 
78 0.17 rs2332036 3 121714391 cg20356878 121714668 277 
     cg11854227 121714109 282 
83 0.17 rs4810485 20 44747947 cg21601405 44747006 941 
     cg16686951 44747351 596 
86 0.16 rs10883857 10 105127587 cg23418095 105128462 875 
     cg14125903 105126693 894 
     cg00245789 105128183 596 
     cg20188621 105127192 395 
     cg11667101 105127581 6 
     cg10301212 105126702 885 
     cg26978691 105128013 426 
     cg18732587 105127670 83 
     cg25713684 105127687 100 
     cg18586343 105127615 28 
     cg20684973 105127632 45 
     cg16500454 105127701 114 
     cg01360325 105127811 224 
88 0.16 rs4075600 16 86929340 cg07824497 86930033 693 
     cg08569253 86930198 858 
	 165	
     cg05490489 86930336 996 
90 0.16 rs10411704 19 35800662 cg22238209 35800743 81 
     cg07918620 35800925 263 
     cg15761414 35801014 352 
     cg02776658 35800589 73 
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Supplementary Table 10 
 
Table 4-17. Illumina 450K probes within 1kb of the top 100 ASM SNPs in cerebellum. 
Rank 
Cerebellum 
ASM score SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
2 0.29 rs1003533 5 131755651 cg03347934 131754928 723 
3 0.26 rs7959070 12 92805682 cg25400182 92806045 363 
4 0.25 rs10234308 7 22528590 cg10016647 22528033 557 
6 0.24 rs12493005 3 176912899 cg03356026 176912588 311 
7 0.24 rs1542180 2 177028767 cg13316854 177027856 911 
     cg06145336 177027931 836 
     cg25938806 177028162 605 
     cg12634591 177028606 161 
     cg01128482 177028621 146 
     cg09387749 177028680 87 
     cg23981871 177028714 53 
     cg10304824 177028804 37 
     cg00005847 177029073 306 
     cg24541426 177029459 692 
     cg05021643 177029608 841 
9 0.24 rs3098382 5 71462632 cg20954533 71462729 97 
12 0.23 rs7158663 14 101319424 cg19509303 101318703 721 
     cg07460524 101319526 102 
21 0.21 rs12413873 10 71212091 cg13358349 71211210 881 
     cg12712771 71211212 879 
     cg26465120 71211268 823 
     cg11279933 71211301 790 
     cg01566955 71211468 623 
     cg18382422 71211551 540 
     cg12610070 71211762 329 
     cg14388049 71211838 253 
24 0.21 rs2546890 5 158759900 cg07622001 158758903 997 
45 0.19 rs10861495 12 106142981 cg23539745 106142108 873 
63 0.18 rs971649 8 124732275 cg13177458 124732088 187 
65 0.18 rs7247675 19 28285519 cg17155612 28284698 821 
     cg02942594 28284741 778 
     cg03170611 28284813 706 
     cg22473312 28284823 696 
     cg08220598 28284952 567 
     cg17871739 28284973 546 
     cg24415565 28284988 531 
     cg25246092 28285128 391 
     cg03751272 28285308 211 
     cg06949053 28285395 124 
72 0.18 rs3762199 20 18487792 cg26234223 18487771 21 
     cg01866064 18487951 159 
	 167	
     cg27634549 18487976 184 
     cg23490046 18487999 207 
     cg15613982 18488017 225 
     cg16156954 18488094 302 
     cg07973146 18488185 393 
     cg02081051 18488312 520 
     cg22243844 18488366 574 
     cg13313269 18488622 830 
73 0.18 rs220030 15 25199768 cg21746532 25198793 975 
     cg01432432 25199028 740 
     cg08372135 25199057 711 
     cg03858387 25199164 604 
     cg02152271 25199270 498 
     cg12298755 25199713 55 
     cg18506672 25200253 485 
     cg02125271 25200406 638 
     cg26875073 25200490 722 
76 0.18 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
84 0.18 rs9469529 6 33587443 cg08355863 33587496 53 
     cg24603235 33588219 776 
     cg19889152 33588278 835 
     cg14639225 33588302 859 
85 0.18 rs1342331 6 144066159 cg06759993 144065203 956 
     cg08482167 144066847 688 
86 0.18 rs7185244 16 86546887 cg08142918 86546374 513 
     cg03697918 86546628 259 
     cg24908603 86546631 256 
     cg07056644 86546785 102 
     cg27453745 86546938 51 
     cg09338251 86546979 92 
     cg06834912 86547203 316 
     cg04787888 86547322 435 
     cg01243371 86547386 499 
     cg00551679 86547530 643 
     cg02783918 86547544 657 
87 0.18 rs12582221 12 125323240 cg17534092 125322578 662 
99 0.17 rs6713344 2 112814045 cg09071112 112813174 871 
     cg06723287 112813613 432 
     cg11931949 112814041 4 
     cg19917083 112814452 407 
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Table 4-18. Illumina 450K probes sites within 1kb of the top 100 ASM SNPs in BA9. 
Rank 
BA9 ASM 
score SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
1 0.24 rs12493005 3 176912899 cg03356026 176912588 311 
3 0.23 rs10234308 7 22528590 cg10016647 22528033 557 
7 0.19 rs3098382 5 71462632 cg20954533 71462729 97 
9 0.19 rs3121125 1 145382124 cg23685870 145382340 216 
     cg07117663 145382963 839 
10 0.19 rs1542180 2 177028767 cg13316854 177027856 911 
     cg06145336 177027931 836 
     cg25938806 177028162 605 
     cg12634591 177028606 161 
     cg01128482 177028621 146 
     cg09387749 177028680 87 
     cg23981871 177028714 53 
     cg10304824 177028804 37 
     cg00005847 177029073 306 
     cg24541426 177029459 692 
     cg05021643 177029608 841 
14 0.18 rs17303015 5 43194137 cg10641714 43193681 456 
15 0.18 rs4871852 8 23020396 cg23051664 23020966 570 
     cg10964421 23021093 697 
     cg01456571 23021325 929 
20 0.18 rs6874600 5 73945738 cg20658167 73944869 869 
25 0.18 rs7073504 10 60271987 cg07567376 60271505 482 
     cg09696939 60272079 92 
     cg07857251 60272754 767 
     cg19940537 60272938 951 
29 0.17 rs6929846 6 26458265 cg03553910 26457928 337 
     cg00369351 26458121 144 
     cg27318050 26458189 76 
     cg22814929 26458213 52 
     cg01542644 26458326 61 
     cg11239695 26458489 224 
30 0.17 rs971649 8 124732275 cg13177458 124732088 187 
33 0.17 rs1139405 17 79478019 cg12793711 79477853 166 
     cg26857837 79477974 45 
     cg06713261 79478173 154 
     cg15906692 79478715 696 
     cg17317962 79478839 820 
37 0.17 rs4687210 3 191046770 cg25342125 191046380 390 
     cg19066520 191046547 223 
     cg23528751 191046721 49 
     cg14972328 191046866 96 
     cg00473167 191046872 102 
	 169	
     cg17596905 191046949 179 
     cg23817170 191046997 227 
     cg26325444 191047058 288 
     cg09688588 191047460 690 
38 0.17 rs1774846 1 202994374 cg03639170 202993923 451 
     cg00501542 202995246 872 
39 0.17 rs12629627 3 73629548 cg14228812 73630106 558 
41 0.17 rs6466131 7 106408569 cg09735627 106407970 599 
42 0.17 rs1054497 4 174089048 cg27433088 174089019 29 
     cg10817093 174089402 354 
     cg06965122 174089515 467 
     cg05897918 174089748 700 
     cg18029791 174089755 707 
     cg08422745 174089978 930 
43 0.17 rs17366322 2 11272784 cg15704155 11272399 385 
     cg09045196 11272424 360 
     cg10334385 11272868 84 
     cg27641709 11272899 115 
     cg05517905 11273075 291 
     cg12453288 11273229 445 
     cg03251967 11273291 507 
44 0.17 rs7305595 12 3562234 cg23794848 3563020 786 
45 0.16 rs3762199 20 18487792 cg26234223 18487771 21 
     cg01866064 18487951 159 
     cg27634549 18487976 184 
     cg23490046 18487999 207 
     cg15613982 18488017 225 
     cg16156954 18488094 302 
     cg07973146 18488185 393 
     cg02081051 18488312 520 
     cg22243844 18488366 574 
     cg13313269 18488622 830 
51 0.16 rs10883857 10 105127587 cg14125903 105126693 894 
     cg10301212 105126702 885 
     cg20188621 105127192 395 
     cg11667101 105127581 6 
     cg18586343 105127615 28 
     cg20684973 105127632 45 
     cg18732587 105127670 83 
     cg25713684 105127687 100 
     cg16500454 105127701 114 
     cg01360325 105127811 224 
     cg26978691 105128013 426 
     cg00245789 105128183 596 
     cg23418095 105128462 875 
52 0.16 rs1237543 13 24739364 cg03903831 24739249 115 
57 0.16 rs1673087 19 37264190 cg05616754 37263860 330 
	 170	
     cg03430717 37263925 265 
     cg27080211 37263997 193 
59 0.16 rs6713344 2 112814045 cg09071112 112813174 871 
     cg06723287 112813613 432 
     cg11931949 112814041 4 
     cg19917083 112814452 407 
62 0.16 rs266388 15 67239366 cg09482748 67239225 141 
64 0.16 rs9331942 8 27455114 cg01572979 27455004 110 
65 0.15 rs2735971 11 2021649 cg27372170 2021103 546 
     cg16574793 2022324 675 
     cg09452478 2022386 737 
72 0.15 rs11089197 22 18121334 cg16048163 18121127 207 
     cg03887534 18121194 140 
     cg24160660 18121281 53 
     cg19898043 18121309 25 
     cg23077364 18121349 15 
     cg10625092 18121415 81 
     cg24756391 18121424 90 
     cg16593229 18122303 969 
73 0.15 rs12085639 1 94478293 cg26904308 94477653 640 
75 0.15 rs553046 7 140776401 cg11344121 140776653 252 
79 0.15 rs986912 3 124284055 cg06218523 124284219 164 
82 0.15 rs7166128 15 66946530 cg24382249 66947171 641 
     cg09827761 66947392 862 
85 0.15 rs17146982 7 22528568 cg10016647 22528033 535 
88 0.15 rs10147026 14 62523148 cg25133706 62522891 257 
     cg18261657 62523785 637 
89 0.15 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
94 0.15 rs10499772 7 63766980 cg00834400 63767240 260 
     cg09382800 63767753 773 
     cg23849078 63767841 861 
96 0.15 rs1870172 10 97990101 cg03281335 97989507 594 
97 0.15 rs220030 15 25199768 cg21746532 25198793 975 
     cg01432432 25199028 740 
     cg08372135 25199057 711 
     cg03858387 25199164 604 
     cg02152271 25199270 498 
     cg12298755 25199713 55 
     cg18506672 25200253 485 
     cg02125271 25200406 638 
     cg26875073 25200490 722 
	 171	
99 0.14 rs10245302 7 70294323 cg18138580 70294264 59 
     cg19560710 70294511 188 
     cg25795398 70294525 202 
100 0.14 rs2143346 6 26198449 cg23407396 26197481 968 
     cg23601095 26197514 935 
     cg16219491 26197733 716 
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Table 4-19. Illumina 450K probes within 1kb of the top 100 cross-tissue ASM sites, as 
defined by average ASM score across individuals. 
Rank ASM SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
1 0.24 rs10234308 7 22528590 cg10016647 22528033 557 
2 0.22 rs12493005 3 176912899 cg03356026 176912588 311 
3 0.21 rs1542180 2 177028767 cg13316854 177027856 911 
     cg06145336 177027931 836 
     cg25938806 177028162 605 
     cg12634591 177028606 161 
     cg01128482 177028621 146 
     cg09387749 177028680 87 
     cg23981871 177028714 53 
     cg10304824 177028804 37 
     cg00005847 177029073 306 
     cg24541426 177029459 692 
     cg05021643 177029608 841 
8 0.18 rs4687210 3 191046770 cg25342125 191046380 390 
     cg19066520 191046547 223 
     cg23528751 191046721 49 
     cg14972328 191046866 96 
     cg00473167 191046872 102 
     cg17596905 191046949 179 
     cg23817170 191046997 227 
     cg26325444 191047058 288 
     cg09688588 191047460 690 
11 0.17 rs1003533 5 131755651 cg03347934 131754928 723 
14 0.17 rs220030 15 25199768 cg21746532 25198793 975 
     cg01432432 25199028 740 
     cg08372135 25199057 711 
     cg03858387 25199164 604 
     cg02152271 25199270 498 
     cg12298755 25199713 55 
     cg18506672 25200253 485 
     cg02125271 25200406 638 
     cg26875073 25200490 722 
19 0.17 rs3121125 1 145382124 cg23685870 145382340 216 
     cg07117663 145382963 839 
21 0.16 rs17366322 2 11272784 cg15704155 11272399 385 
     cg09045196 11272424 360 
     cg10334385 11272868 84 
     cg27641709 11272899 115 
     cg05517905 11273075 291 
     cg12453288 11273229 445 
     cg03251967 11273291 507 
25 0.16 rs3762199 20 18487792 cg26234223 18487771 21 
	 173	
     cg01866064 18487951 159 
     cg27634549 18487976 184 
     cg23490046 18487999 207 
     cg15613982 18488017 225 
     cg16156954 18488094 302 
     cg07973146 18488185 393 
     cg02081051 18488312 520 
     cg22243844 18488366 574 
     cg13313269 18488622 830 
26 0.16 rs6713344 2 112814045 cg09071112 112813174 871 
     cg06723287 112813613 432 
     cg11931949 112814041 4 
     cg19917083 112814452 407 
29 0.16 rs3098382 5 71462632 cg20954533 71462729 97 
30 0.16 rs17312325 X 68442113 cg00427681 68441389 724 
     cg22337892 68441690 423 
     cg03350825 68442327 214 
37 0.15 rs1237543 13 24739364 cg03903831 24739249 115 
38 0.15 rs7247675 19 28285519 cg17155612 28284698 821 
     cg02942594 28284741 778 
     cg03170611 28284813 706 
     cg22473312 28284823 696 
     cg08220598 28284952 567 
     cg17871739 28284973 546 
     cg24415565 28284988 531 
     cg25246092 28285128 391 
     cg03751272 28285308 211 
     cg06949053 28285395 124 
39 0.15 rs986912 3 124284055 cg06218523 124284219 164 
40 0.15 rs7210715 17 7196390 cg00901493 7197375 985 
42 0.15 rs7305595 12 3562234 cg23794848 3563020 786 
46 0.15 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
47 0.15 rs7073504 10 60271987 cg07567376 60271505 482 
     cg09696939 60272079 92 
     cg07857251 60272754 767 
     cg19940537 60272938 951 
49 0.15 rs10883857 10 105127587 cg14125903 105126693 894 
     cg10301212 105126702 885 
     cg20188621 105127192 395 
     cg11667101 105127581 6 
     cg18586343 105127615 28 
     cg20684973 105127632 45 
	 174	
     cg18732587 105127670 83 
     cg25713684 105127687 100 
     cg16500454 105127701 114 
     cg01360325 105127811 224 
     cg26978691 105128013 426 
     cg00245789 105128183 596 
     cg23418095 105128462 875 
52 0.15 rs17146982 7 22528568 cg10016647 22528033 535 
55 0.14 rs1139405 17 79478019 cg12793711 79477853 166 
     cg26857837 79477974 45 
     cg06713261 79478173 154 
     cg15906692 79478715 696 
     cg17317962 79478839 820 
56 0.14 rs971649 8 124732275 cg13177458 124732088 187 
60 0.14 rs2143346 6 26198449 cg23407396 26197481 968 
     cg23601095 26197514 935 
     cg16219491 26197733 716 
     cg07329467 26199075 626 
64 0.14 rs9331942 8 27455114 cg01572979 27455004 110 
66 0.14 rs6874600 5 73945738 cg20658167 73944869 869 
76 0.14 rs1673087 19 37264190 cg05616754 37263860 330 
     cg03430717 37263925 265 
     cg27080211 37263997 193 
78 0.14 rs6548026 2 30872366 cg08120035 30872901 535 
81 0.14 rs10499772 7 63766980 cg00834400 63767240 260 
     cg09382800 63767753 773 
     cg23849078 63767841 861 
89 0.13 rs7185244 16 86546887 cg08142918 86546374 513 
     cg03697918 86546628 259 
     cg24908603 86546631 256 
     cg07056644 86546785 102 
     cg27453745 86546938 51 
     cg09338251 86546979 92 
     cg06834912 86547203 316 
     cg04787888 86547322 435 
     cg01243371 86547386 499 
     cg00551679 86547530 643 
     cg02783918 86547544 657 
90 0.13 rs10454027 13 100259376 cg22853485 100258524 852 
     cg12175106 100258589 787 
     cg01726399 100258641 735 
     cg10972431 100258753 623 
     cg02168723 100258760 616 
     cg27435467 100258954 422 
     cg20863393 100259188 188 
     cg24980005 100259219 157 
     cg23862604 100259302 74 
94 0.13 rs10108150 8 145687475 cg13071208 145686887 588 
	 175	
     cg17328964 145687451 24 
     cg15189104 145687562 87 
     cg02108130 145687727 252 
     cg25390352 145688187 712 
     cg22601688 145688206 731 
98 0.13 rs8179387 1 22290156 cg27522078 22290005 151 
99 0.13 rs9645876 13 112330861 cg06567836 112330930 69 
     cg09984047 112330954 93 
     cg15453778 112331089 228 
     cg06996147 112331836 975 
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Table 4-20. Illumina 450K probes within 1kb of the top 100 tissue-specific ASM SNPs as 
defined by the high variability of ASM scores across tissues. 
Rank 
ASM 
SD SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
2 0.15 rs927000 20 43598705 cg17104026 43598376 329 
17 0.13 rs7959070 12 92805682 cg25400182 92806045 363 
18 0.12 rs8032903 15 25980875 cg16651441 25980367 508 
     cg02747151 25981177 302 
     cg09978546 25981255 380 
     cg14216870 25981322 447 
23 0.12 rs6853895 4 38070899 cg24826020 38070998 99 
24 0.12 rs7158663 14 101319424 cg19509303 101318703 721 
     cg07460524 101319526 102 
25 0.12 rs10783269 12 48995983 cg18467358 48995259 724 
27 0.12 rs12510921 4 185189278 cg04960065 185189300 22 
29 0.11 rs10481354 8 1704030 cg19131313 1704013 17 
     cg17159058 1704075 45 
31 0.11 rs1003533 5 131755651 cg03347934 131754928 723 
33 0.11 rs2252397 7 140225750 cg01499591 140226367 617 
38 0.11 rs12978286 19 17861868 cg26307105 17861017 851 
     cg02639359 17862017 149 
     cg08206267 17862104 236 
     cg24783510 17862150 282 
     cg11737334 17862210 342 
     cg22317846 17862385 517 
46 0.11 rs10411704 19 35800662 cg02776658 35800589 73 
     cg22238209 35800743 81 
     cg07918620 35800925 263 
     cg15761414 35801014 352 
49 0.11 rs1009014 6 158487143 cg18559896 158487541 398 
     cg03544657 158487564 421 
     cg07549551 158487608 465 
51 0.10 rs3098382 5 71462632 cg20954533 71462729 97 
56 0.10 rs9469529 6 33587443 cg08355863 33587496 53 
     cg24603235 33588219 776 
     cg19889152 33588278 835 
     cg14639225 33588302 859 
62 0.10 rs14067 13 114110660 cg05314639 114109729 931 
     cg04870949 114109857 803 
     cg03557916 114109949 711 
64 0.10 rs11603592 11 20023522 cg09261702 20023953 431 
70 0.10 rs7268068 20 62199258 cg23352030 62198469 789 
     cg15262954 62198872 386 
     cg17593958 62199034 224 
     cg11779113 62199156 102 
     cg06064964 62199181 77 
     cg09844573 62199190 68 
     cg17864091 62200091 833 
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     cg04300115 62200199 941 
83 0.10 rs17539168 9 134485090 cg14485643 134484581 509 
84 0.10 rs16843471 1 198590421 cg10768932 198590738 317 
89 0.10 rs1774846 1 202994374 cg03639170 202993923 451 
     cg00501542 202995246 872 
95 0.10 rs10861495 12 106142981 cg23539745 106142108 873 
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Table 4-21. Illumina 450K probes within 1kb of the top 100 variable ASM sites, as defined 
by average range of ASM scores between individuals across tissues. 
Rank 
ASM 
Range SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CG Distance 
2 0.30 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
3 0.25 rs2346019 5 135415726 cg11852404 135414858 868 
     cg00308130 135415190 536 
     cg15837280 135415258 468 
     cg07158503 135415693 33 
     cg04515200 135415762 36 
     cg13581155 135415781 55 
     cg11978884 135415819 93 
     cg11608150 135415948 222 
     cg06478886 135416029 303 
     cg04481923 135416205 479 
     cg18678645 135416331 605 
     cg06536614 135416381 655 
     cg26328633 135416394 668 
     cg25340688 135416398 672 
     cg26896946 135416405 679 
     cg00124993 135416412 686 
     cg08745965 135416529 803 
     cg16615357 135416594 868 
     cg18797653 135416613 887 
7 0.19 rs1209228 14 72231880 cg15926477 72231668 212 
13 0.18 rs1695824 1 1365570 cg04865726 1365911 341 
     cg12407057 1366206 636 
     cg11156891 1366274 704 
18 0.17 rs578597 9 104185258 cg14048797 104186172 914 
23 0.16 rs3759917 15 92935447 cg18646851 92934809 638 
     cg08152839 92936232 785 
     cg05501584 92936306 859 
26 0.16 rs11231646 11 63702635 cg05766107 63702235 400 
28 0.16 rs1984713 4 47956556 cg06587443 47955755 801 
     cg19000186 47956011 545 
33 0.16 rs26835 16 2237549 cg07094340 2236773 776 
     cg10118998 2236938 611 
     cg07109743 2237020 529 
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     cg08938612 2237221 328 
35 0.16 rs10952289 7 150524681 cg05405275 150525013 332 
50 0.15 rs11611523 12 118018891 cg05738715 118018768 123 
51 0.15 rs2400135 6 106253120 cg01182171 106252695 425 
54 0.15 rs2377983 10 50352720 cg14620932 50353359 639 
69 0.14 rs6779820 3 191046793 cg25342125 191046380 413 
     cg19066520 191046547 246 
     cg23528751 191046721 72 
     cg14972328 191046866 73 
     cg00473167 191046872 79 
     cg17596905 191046949 156 
     cg23817170 191046997 204 
     cg26325444 191047058 265 
     cg09688588 191047460 667 
71 0.14 rs509062 20 56882238 cg21532801 56881949 289 
76 0.14 rs8179356 1 100215981 cg17222434 100215737 244 
80 0.14 rs7911580 10 7516306 cg03421195 7517215 909 
84 0.14 rs2294490 1 15723843 cg00582948 15724194 351 
87 0.14 rs4289794 8 141106204 cg12844366 141105335 869 
     cg00085199 141106596 392 
     cg05524387 141107113 909 
91 0.14 rs6045166 20 18035837 cg02113429 18036013 176 
94 0.13 rs12525580 6 74288782 cg05488681 74289464 682 
98 0.13 rs3109398 3 182402101 cg09391284 182401187 914 
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Table 4-22. Illumina 450K probes within 1kb of the top 100 variable ASM SNPs in whole 
blood as defined by range of ASM score between individuals. 
Rank 
Blood 
range SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
3 0.25 rs509062 20 56882238 cg21532801 56881949 289 
4 0.24 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
6 0.23 rs8179356 1 100215981 cg17222434 100215737 244 
8 0.23 rs2346019 5 135415726 cg11852404 135414858 868 
     cg00308130 135415190 536 
     cg15837280 135415258 468 
     cg07158503 135415693 33 
     cg04515200 135415762 36 
     cg13581155 135415781 55 
     cg11978884 135415819 93 
     cg11608150 135415948 222 
     cg06478886 135416029 303 
     cg04481923 135416205 479 
     cg18678645 135416331 605 
     cg06536614 135416381 655 
     cg26328633 135416394 668 
     cg25340688 135416398 672 
     cg26896946 135416405 679 
     cg00124993 135416412 686 
     cg08745965 135416529 803 
     cg16615357 135416594 868 
     cg18797653 135416613 887 
10 0.22 rs7694398 4 6733947 cg00966522 6734722 775 
17 0.20 rs1890070 1 222628509 cg15078329 222628324 185 
     cg11661340 222628632 123 
     cg17836114 222628702 193 
19 0.20 rs1984713 4 47956556 cg06587443 47955755 801 
     cg19000186 47956011 545 
23 0.19 rs10186949 2 237755950 cg04787916 237755762 188 
30 0.19 rs849322 7 28331586 cg26353161 28331380 206 
38 0.18 rs578597 9 104185258 cg14048797 104186172 914 
46 0.18 rs165342 5 150884793 cg22672639 150884813 20 
62 0.17 rs11231646 11 63702635 cg05766107 63702235 400 
64 0.17 rs2072019 6 112460541 cg12188410 112460467 74 
66 0.17 rs2357928 10 18549641 cg25091573 18549036 605 
     cg24422029 18549378 263 
	 181	
     cg14716734 18549397 244 
     cg05205813 18549413 228 
     cg09987620 18549439 202 
     cg26803268 18549536 105 
     cg18959207 18549686 45 
     cg02635932 18549778 137 
     cg14357089 18550033 392 
     cg26576398 18550135 494 
     cg15720089 18550223 582 
86 0.17 rs12938106 17 29926633 cg00351813 29926184 449 
     cg25208821 29926356 277 
89 0.17 rs7174808 15 52048251 cg02253142 52048211 40 
91 0.17 rs1464172 3 124873295 cg17478992 124873768 473 
     cg01432055 124873848 553 
92 0.17 rs875981 11 130903093 cg01464703 130903135 42 
96 0.17 rs10116248 9 132568500 cg14222752 132569372 872 
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Table 4-23. Illumina 450K probes within 1kb of the top 100 variable ASM SNPs in 
cerebellum as defined by range of ASM score between individuals. 
Rank 
Cerebellum 
range SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
1 0.36 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
8 0.25 rs1695824 1 1365570 cg04865726 1365911 341 
     cg12407057 1366206 636 
     cg11156891 1366274 704 
11 0.24 rs4289794 8 141106204 cg12844366 141105335 869 
     cg00085199 141106596 392 
     cg05524387 141107113 909 
13 0.24 rs3759917 15 92935447 cg18646851 92934809 638 
     cg08152839 92936232 785 
     cg05501584 92936306 859 
15 0.23 rs2346019 5 135415726 cg11852404 135414858 868 
     cg00308130 135415190 536 
     cg15837280 135415258 468 
     cg07158503 135415693 33 
     cg04515200 135415762 36 
     cg13581155 135415781 55 
     cg11978884 135415819 93 
     cg11608150 135415948 222 
     cg06478886 135416029 303 
     cg04481923 135416205 479 
     cg18678645 135416331 605 
     cg06536614 135416381 655 
     cg26328633 135416394 668 
     cg25340688 135416398 672 
     cg26896946 135416405 679 
     cg00124993 135416412 686 
     cg08745965 135416529 803 
     cg16615357 135416594 868 
     cg18797653 135416613 887 
18 0.23 rs941483 14 94422623 cg00839873 94421989 634 
     cg18572214 94423192 569 
     cg01956154 94423399 776 
28 0.21 rs578597 9 104185258 cg14048797 104186172 914 
35 0.20 rs2377983 10 50352720 cg14620932 50353359 639 
40 0.19 rs1209228 14 72231880 cg15926477 72231668 212 
	 183	
42 0.19 rs7426865 3 149058065 cg06305422 149057820 245 
60 0.18 rs12412942 10 2357702 cg23939236 2357224 478 
     cg03163525 2357283 419 
     cg17246535 2357363 339 
     cg03946168 2357461 241 
     cg18730194 2357587 115 
68 0.18 rs1708337 3 124886822 cg24838136 124887734 912 
76 0.17 rs4253747 22 46613237 cg06467025 46614169 932 
77 0.17 rs17146982 7 22528568 cg10016647 22528033 535 
88 0.17 rs9348131 6 166850798 cg11314174 166850928 130 
     cg02624984 166851100 302 
     cg21313980 166851372 574 
90 0.17 rs26835 16 2237549 cg07094340 2236773 776 
     cg10118998 2236938 611 
     cg07109743 2237020 529 
     cg08938612 2237221 328 
96 0.17 rs7911580 10 7516306 cg03421195 7517215 909 
97 0.17 rs3735715 8 102679909 cg25876227 102680096 187 
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Table 4-24. Illumina 450K probes within 1kb of the top 100 variable ASM SNPs in cortex 
(BA9) as defined by range of ASM score between individuals. 
Rank 
BA9 
range SNP Chr 
Mapinfo 
SNP CpG site 
Mapinfo 
CpG Distance 
3 0.30 rs2346019 5 135415726 cg11852404 135414858 868 
     cg00308130 135415190 536 
     cg15837280 135415258 468 
     cg07158503 135415693 33 
     cg04515200 135415762 36 
     cg13581155 135415781 55 
     cg11978884 135415819 93 
     cg11608150 135415948 222 
     cg06478886 135416029 303 
     cg04481923 135416205 479 
     cg18678645 135416331 605 
     cg06536614 135416381 655 
     cg26328633 135416394 668 
     cg25340688 135416398 672 
     cg26896946 135416405 679 
     cg00124993 135416412 686 
     cg08745965 135416529 803 
     cg16615357 135416594 868 
     cg18797653 135416613 887 
4 0.29 rs2244352 21 40757973 cg01322405 40757317 656 
     cg00606841 40757691 282 
     cg22858667 40757750 223 
     cg26710963 40757899 74 
     cg09916765 40758208 235 
     cg21297395 40758325 352 
     cg21459460 40758346 373 
9 0.24 rs1209228 14 72231880 cg15926477 72231668 212 
10 0.23 rs9357087 6 11216700 cg05208582 11216594 106 
11 0.22 rs503755 2 135228060 cg05670240 135227167 893 
22 0.20 rs17008180 4 106406083 cg08987594 106405819 264 
     cg20364776 106405850 233 
33 0.19 rs2377983 10 50352720 cg14620932 50353359 639 
35 0.19 rs9395212 6 46726441 cg10669279 46726850 409 
47 0.18 rs633644 21 44783063 cg02260098 44782434 629 
     cg25191041 44782470 593 
     cg14081667 44782497 566 
     cg19318330 44782872 191 
49 0.18 rs985462 10 127769598 cg19997196 127769491 107 
     cg08295661 127769903 305 
51 0.18 rs10952289 7 150524681 cg05405275 150525013 332 
54 0.18 rs17573298 16 78218016 cg04344190 78218445 429 
56 0.18 rs6577101 13 113293717 cg14227911 113292824 893 
	 185	
     cg07014973 113292951 766 
57 0.18 rs12525580 6 74288782 cg05488681 74289464 682 
58 0.18 rs4784910 16 58298471 cg08638917 58299153 682 
72 0.18 rs17130554 1 68653137 cg22850128 68654112 975 
76 0.18 rs17432433 15 37174748 cg17921924 37174376 372 
     cg22444584 37174661 87 
     cg27042266 37175007 259 
     cg16890051 37175029 281 
     cg12288941 37175117 369 
90 0.17 rs10886631 10 85325650 cg12554194 85324700 950 
     cg04567661 85325001 649 
     cg24127335 85325062 588 
92 0.17 rs11135514 5 96790262 cg21913787 96789385 877 
98 0.17 rs2070682 7 100777267 cg17968347 100777740 473 
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Table 4-25. Sample information. Shown is demographic information for individuals profiled for ASM using our MSNP protocol and for DNA methylation using the 
Illumina Infinium HumanMethylation450 BeadChip (450K). PMD = Post-mortem delay (h). 
 Demographics Tissue       
ID Sex 
Age at 
death PMD BA8 BA9 BA10 BA 17 BA21 BA28/34 Cerebellum Blood 
1 F 82 43 MSNP MSNP MSNP  MSNP MSNP MSNP MSNP 
     450K   450K 450K 450K 450K 
2 M 78 NA MSNP MSNP MSNP   MSNP MSNP MSNP 
     450K   450K 450K 450K 450K 
3 F 92 17 MSNP MSNP MSNP MSNP MSNP MSNP MSNP MSNP 
     450K   450K 450K 450K 450K 
4 F 82 13  450K   450K 450K 450K 450K 
5 F 81 17  450K   450K 450K 450K  
6 M 86 7  450K   450K 450K 450K 450K 
7 F 80 3  450K   450K 450K 450K  
8 F 55 12  450K   450K 450K 450K  
9 M 79 47  450K   450K 450K 450K  
10 M 80 21  450K   450K 450K 450K  
11 M 86 6  450K   450K 450K 450K  
12 F 87 22  450K   450K  450K  
13 F 68 9     450K  450K  
14 M 59 50  450K   450K 450K 450K  
15 F 80 48  450K   450K 450K 450K  
16 M 40 40     450K  450K  
17 F 55 95  450K   450K  450K  
18 F 73 70  450K   450K    
19 M 80 60  450K   450K 450K 450K  
20 F 90 50  450K   450K 450K 450K  
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21 M 81 18  450K   450K 450K 450K  
22 M 66 52  450K   450K 450K 450K  
23 F 88 6  450K   450K 450K 450K  
24 M 86 21  450K   450K 450K 450K 450K 
25 F 90 56  450K   450K 450K 450K 450K 
26 F 92 23  450K   450K 450K 450K 450K 
27 M 97 44  450K   450K 450K 450K  
28 M 74 23  450K   450K 450K 450K  
29 M 77 11  450K   450K 450K 450K  
30 M 82 47  450K   450K 450K 450K  
31 M 73 23  450K   450K 450K 450K  
32 M 95 26  450K   450K 450K 450K  
33 F 79 56  450K   450K 450K 450K  
34 F 91 74  450K   450K 450K 450K  
35 M NA NA        450K 
36 F NA NA        450K 
37 F NA NA        450K 
38 F NA NA        450K 
39 M NA NA        450K 
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Table 4-26. Number of informative loci interrogated by the MSNP protocol for each sample. 
 BA8 BA9 BA10 BA17 BA21 BA28/34 Cerebellum Blood Total 
Individual 1 110004 110004 110004  110004 110004 110004 110004 110004 
Individual 2 107649 107649 107649   107649 107649 107649 107649 
Individual 3 108942 108942 108942 108942 108942 108942 108942 108942 108942 
Total 220449 220449 220449 108942 220449 177162 220449 220449  
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Supplementary Table 20 
 
Table 4-27. Primers used for clonal bisulfite sequencing. 
Assay Forward Primer Reverse Primer 
SNP_A-4255628 (rs959246) TGGTTTGGTAGGTGTTAGGTATTTAG CTCCCTATTCCCCAATAAAAATTTA 






5. A genome-wide study of 
H3K27ac identifies molecular 







Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that 
contributes substantially to the global burden of disease, affecting in excess of 
26 million people worldwide (Brookmeyer et al., 2007, Knapp et al., 2007).  AD is 
characterized by cognitive decline and memory loss, and associated with 
progressive neuropathology in the cortex, with areas surrounding the entorhinal 
cortex being particularly affected early in the disease (Wenk, 2003). The 
neuropathological hallmarks of the disease include the extracellular deposition of 
neurotoxic amyloid-β peptides in the form of amyloid plaques and an 
accumulation of intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau (Hardy and Selkoe, 2002, Hardy and Higgins, 1992). 
Despite progress in understanding risk factors contributing to AD progression, 
the mechanisms involved in disease progression are not fully understood and 
long-term treatments, reversing the cellular disease process, are elusive. 
There has been considerable success in identifying genetic risk factors for AD 
(Karch et al., 2014). While autosomal dominant mutations in three genes (APP, 
PSEN1, and PSEN2) can explain early-onset (< 65 years) familial AD, these 
account for only 1-5% of the total disease burden (Reitz et al., 2011). Most cases 
of AD are late-onset (> 65 years), non-Mendelian and highly sporadic, with 
susceptibility attributed to the action of highly prevalent genetic variants of low 
penetrance. In addition to the well-established risk associated with the APOE 
locus (Corder et al., 1993, Bu, 2009, Liu et al., 2013) there has been notable 
success in identifying novel AD-associated variants capitalising on the power of 
genome-wide association studies (GWAS) in large sample cohorts; a recent large 
GWAS meta-analysis of AD, incorporating 74,046 samples, identified 19 
genome-wide significant risk loci for sporadic AD (Lambert et al., 2013). Despite 
these advances, little is known about the functional mechanisms by which risk 
variants mediate disease susceptibility.  
Increased understanding about the functional complexity of the genome has led 
to growing recognition about the likely role of non-sequence-based regulatory 
variation in health and disease. Building on the hypothesis that epigenomic 
dysregulation is important in the aetiology and progression of neuropathology 
(Lunnon and Mill, 2013), we and others have recently performed the first genome-
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scale cross-tissue analyses of DNA methylation in AD identifying robust DNA 
methylation differences associated with AD neuropathology across multiple 
independent human post-mortem brain cohorts (Lunnon et al., 2014, De Jager et 
al., 2014). To date, however, no study has systematically examined other types 
of regulatory genomic variation in AD. In this study, we focus on the histone 
modification H3K27ac, a robust mark of active enhancers and promoters that is 
strongly correlated with gene expression and transcription factor binding 
(Creyghton et al., 2010, Rada-Iglesias et al., 2011, Spitz and Furlong, 2012). In 
addition, H3K27ac is characterized by elevated levels of inter-individual variability 
compared to other modifications, in particular when located in enhancer regions 
(Kasowski et al., 2013), making it an appropriate target for epidemiological 
profiling. Interestingly, histone deacetylase (HDAC) inhibitors have been shown 
to ameliorate symptoms of cognitive decline and synaptic dysfunction in mouse 
models of AD (Kilgore et al., 2010, Graff and Tsai, 2013b, Cuadrado-Tejedor et 
al., 2017) and are promising targets for novel human AD treatments (Graff and 
Tsai, 2013a, Fischer, 2014, Lu et al., 2015). Despite this, investigations into 
alterations of the global levels of histone acetylation in AD have thus far been 
inconclusive (Rao et al., 2012, Zhang et al., 2012, Lu et al., 2014, Narayan et al., 
2015). Few studies have systematically profiled H3K27ac across large numbers 
of samples in the context of complex disease, and optimal methods for these 
analyses are still being developed (Sun et al., 2016). 
We used chromatin immunoprecipitation combined with highly-parallel 
sequencing (ChIP-seq) to profile H3K27ac in post-mortem entorhinal cortex 
samples from AD patients and matched controls. We identify robust regulatory 
genomic signatures associated with AD, including variable H3K27ac across 
discrete regions annotated to genomic loci mechanistically implicated in the onset 
of both tau and amyloid pathology. This is the first study of variable H3K27ac yet 
undertaken for AD, and in addition to identifying molecular pathways associated 
with AD neuropathology, we present a framework for genome-wide studies of this 




5.2.1 Samples  
Post-mortem brain samples from 54 individuals - 27 characterized by Alzheimer’s 
disease neuropathology and 27 neuropathology-free brain samples - were 
provided by the MRC London Neurodegenerative Disease Brain Bank 
(http://www.kcl.ac.uk/ioppn/depts/cn/research/MRC-London-
Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-
Diseases-Brain-Bank.aspx). Ethical approval for the study was provided by the 
NHS South East London REC 3. Samples for this ChIP-seq study were selected 
from a larger collection of post-mortem entorhinal cortex (Brodmann area (BA) 
28/34) samples, based on Braak staging, a standardized measure of 
neurofibrillary tangle burden determined at autopsy (Braak and Braak, 1991). We 
prioritized cases with high Braak staging and controls with lower Braak scores 
(Table 5-1). Subjects were approached in life for written consent for brain 
banking, and all tissue donations were collected and stored following legal and 
ethical guidelines (NHS reference number 08/MRE09/38; the HTA license 
number for the LBBND brain bank is 12293). All samples were dissected by 
trained specialists, snap-frozen and stored at −80 °C. A detailed list of 
demographic and sample data for each individual included in the final analyses 
is provided in Table 5-1.  
 
 
Table 5-1. Demographic and phenotypic information for each individual sample included 


















1 Control 0 63 M 12% 1380 
2 Control 0 84 M 36% 3180 
3 Control 0 69 F 33% 2880 
4 Control 0 77 F 8% 1260 
5 Control 0 66 F 36% 3000 
6 Control 0 90 M 20% 2700 
7 Control 0 66 F 48% 4680 
8 Control 0 58 M 30% 3480 
9 Control 1 72 F 22% 2820 
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10 Control 1 65 M 18% 1560 
11 Control 1 67 M 46% 1500 
12 Control 2 80 M 45% 3300 
13 Control 2 76 F 41% 1320 
14 Control 2 85 F 37% 2700 
15 Control 2 67 F 15% 3720 
16 Control 2 80 M 45% 1860 
17 Control 2 68 M 29% 3600 
18 Control 2 85 M 33% 3300 
19 Control 2 83 F NA 2340 
20 Control 2 89 F 27% 2580 
21 Control 3 97 M 20% 2460 
22 Control 3 88 F 28% 2340 
23 Control 3 78 M 36% 1440 
24 AD 6 91 M 1% 4080 
25 AD 6 75 F 34% 720 
26 AD 6 84 M 32% 4020 
27 AD 6 65 F 10% 4200 
28 AD 6 62 M 40% 2940 
29 AD 6 74 M 21% 930 
30 AD 6 73 F 18% 5460 
31 AD 6 86 F 17% 1260 
32 AD 6 70 M 13% 5400 
33 AD 6 80 M 37% 2700 
34 AD 6 87 F 26% 1860 
35 AD 6 68 M 12% 1620 
36 AD 6 71 M 23% 1260 
37 AD 6 86 F 16% 660 
38 AD 6 94 F 30% 2520 
39 AD 6 83 M 21% 5760 
40 AD 6 76 M 30% 3300 
41 AD 6 87 F 17% 2400 
42 AD 6 62 M 17% 1380 
43 AD 6 83 M 42% 4260 
44 AD 6 79 F 8% 3780 
45 AD 6 81 F 11% 1200 
46 AD 6 88 F 33% 1080 
47 AD 6 81 F 60% 4800 
* Neuronal proportion estimates are derived from DNA methylation data generated on the same 
samples using the Illumina 450K HumanMethylation Array, calculated using the CETS R package 




5.2.2 Chromatin immunoprecipitation  
30 mg brain samples were homogenized in 1ml ice-cold phosphate buffered 
saline (PBS) buffer with protease inhibitor cocktail (PIC; Diagenode, Cat 
#C12010012). The suspension was centrifuged at 4,000 rpm for 5 minutes at 
4°C, discarding the supernatant. The pellets were resuspended in 1ml PBS 
containing 1% formaldehyde, rotating at room temperature for 8 minutes. The 
cross-linking process was terminated by adding 100μl glycine, followed by 5 
minutes of rotation. After 5 minutes of centrifugation at 4,000 rpm and 4°C, the 
pellet was washed twice with ice-cold PBS (suspend the pellet in 1ml PBS with 
PIC, centrifuge for 5 minutes at 4,000 rpm and 4°C, and discard the supernatant), 
then lysed in 10 mL ice-cold lysis buffer iL1 and iL2 (iDeal ChIP-seq kit; 
Diagenode, Cat #C01010050, Denville, NJ, USA), sequentially (suspend the 
pellet in 10ml lysis buffer, incubate mixing gently for 10 minutes at  4°C, centrifuge 
for 5 minutes at 4,000 rpm and 4°C, and discard the supernatant). The cross-
linked lysate was suspended in 1.8ml shearing buffer iS1 (iDeal ChIP-seq kit; 
Diagenode, Cat #C01010050, Denville, NJ, USA) containing PIC and sonicated 
in aliquots of 300μl for 10 minutes on a Bioruptor Pico (Diagenode, Denville, NJ, 
USA) with 30 seconds on/off cycles. After shearing, samples were centrifuged at 
14,000 rpm for 10 minutes, collecting the supernatant, containing the sheared 
chromatin. Sonication resulted in an average size range of 100-1000bp as 
visualized by agarose gel electrophoresis (Figure 5-1).  
 
Figure 5-1. Chromatin shearing resulted in an average size distribution of 100-1000bp. 10 
example agarose gel electrophoresis profiles, generated from DNA extracted after sonication, are 
shown.  
	 196	
Immunoprecipitation was performed using the iDeal ChIP-seq kit (Diagenode, 
Cat #C01010050, Denville, NJ, USA) on the SX-8G IP-Star robot (Diagenode, 
Liège, Belgium), following the manufacturer’s protocol. All samples were 
immunoprecipitated with H3K27ac polyclonal antibody (Diagenode, Cat 
#C15410196, Liège, Belgium). In addition, a randomly selected subgroup of 12 
samples – 6 cases and 6 controls – were immunoprecipitated with rabbit IgG 
antibody (iDeal ChIP-seq kit; Diagenode, Cat #C01010050, Denville, NJ, USA) 
as negative control. 1-1.5μl of H3K27ac or IgG antibody were first mixed with 
98.5-99μl ChIP buffer iC1 (iDeal ChIP-seq kit; Diagenode, Cat #C01010050, 
Denville, NJ, USA), 0.5μl PIC and 4μl of 5% bovine serum albumin (BSA; iDeal 
ChIP-seq kit; Diagenode, Cat #C01010050, Denville, NJ, USA), which was 
incubated with magnetic beads for 3 hours at 4°C. Next the antibody conjugate 
was added to 180μl chromatin for overnight (15h) immunoprecipitation at 4°C in 
an immunoprecipitation mix also containing 20μl ChIP buffer iC1, 1μl PIC and 4μl 
of 5% BSA. After immunoprecipitation, the beads were suspended in in 100μl 
elution buffer iE1 (iDeal ChIP-seq kit; Diagenode, Cat #C01010050, Denville, NJ, 
USA), to which 4μl elution buffer iE2 (iDeal ChIP-seq kit; Diagenode, Cat 
#C01010050, Denville, NJ, USA) was added. Cross-link reversal was performed 
on a PCR thermoblock for 4 hours at 65°C. DNA was extracted using columns 
(Diagenode Micro ChIP DiaPure columns, Cat No C03040001) according to the 
manufacturers protocol, eluding the DNA from the column matrix in 30μl DNA 
elution buffer (MicroChIP DiaPure columns; Diagenode, Cat #C03040001, 
Denville, NJ, USA). Quantitative PCR, using 1% input DNA, confirmed specific 
enrichment of H3K27ac at positive control genes (IEF4A2 and GAPDH) but not 




Libraries were prepared using the MicroPlex Library Preparation kit (Diagenode, 
Cat #C05010010, Denville, NJ, USA) according to the manufacturer’s protocol. 
DNA concentrations were measured on Qubit dsDNA HS Assay Kits (Invitrogen, 
Cat# Q32851, Carlsbad, CA, USA) on the Qubit 2.0 Fluorometer (Invitrogen) and 
library fragment profiles generated on the Agilent 2100 BioAnalyzer using Agilent 
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High Sensitivity DNA kits (Agilent Technologies, Cat# 5067-4626, Santa Clara, 
CA, USA). 7 samples were excluded from sequencing based on poor qPCR 
results after immunoprecipitation or low library concentration and a sample 
mismatch. The remaining 47 samples (from 24 cases and 23 controls) were 
sequenced on an Illumina HiSeq-2500 using single-end sequencing and a read 
length of 50bp.  
 
5.2.4 Data pre-processing and quality control  
Global sample anomalies were ruled out using fastqc (Andrews, 2010) summary 
measures.  All fastq files were aligned to the homo sapiens reference genome 
(hg19, Broad Institute) using Bowtie (Langmead et al., 2009). The output SAM 
files were converted to binary (BAM) format. All BAM files were sorted and 
indexed using samtools (Li et al., 2009). PCR duplicates were removed using 
Picard (http://broadinstitute.github.io/picard/). Samtools was used to additionally 
remove non-uniquely mapped reads as well as reads with a sequencing quality 
score q < 30. Final read counts after QC for all 47 samples are shown in Figure 
5-2. On average, we obtained 30,032,623 reads per sample (SD= 10,638,091; 
range=10,910,000-53,770,000) and individual read counts did not associate with 
disease status (P = 0.93). 
 
Figure 5-2. The number of ChIP-seq reads passing QC for each sample. On average, we 





























average = 30.03 million reads
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filtering and QC. There was no significant difference in the number of sequencing reads obtained 






Figure 5-3. PCA analysis confirms documented sex. (a) Load on the first principal components 
calculated on normalised read counts shows exact overlap in annotated sex and epigenetically 
predicted sex (1st PC). (b) Variance captured by the same first PCs is not associated with disease 
status. 
 
5.2.5 Peak calling and read counts 
All filtered BAM files were merged into one grouped file and converted to tagAlign 




























































































































merged file using MACS2 (Zhang et al., 2008), keeping all duplicates, since 
duplicates were removed from each sample previously and any remaining 
duplicates would result from the same read occurring in more than one sample. 
From the resulting peaks those located in unmapped contigs and mitochondrial 
DNA were filtered out as well as peaks that did not meet a significance threshold 
of P < 1.0´10-7 for peak calling. The bed file of peaks was converted to gff format 
using awk and R and reads for each individual sample were generated using 
HTSeq (Anders et al., 2015). Final filtering was performed using the Bioconductor 
package EdgeR (Robinson et al., 2010), excluding peaks with fewer than 2 
samples showing at least 1 read per million, resulting in a total of 182,065 peaks 
to be tested. Principal components analysis (PCA) in R using DESeq2 (Love et 
al., 2014) confirmed that the epigenetically predicted gender was identical to the 
recorded one (Figure 5-3) and load on the first two principal components was not 
related to the sample’s disease status.  
 
5.2.6 Peak validation  
We validated the 182,065 union peaks in two ways. First, we obtained the 
locations of H3K27ac peaks called in the cortex (BA9) and cerebellum from a 
recent paper by Sun and colleagues (Sun et al., 2016). Second, we downloaded 
H3K27ac profiles produced by the NIH Roadmap Epigenomics Consortium 
(Kundaje et al., 2015) from the Gene Expression Omnibus (GEO; 
https://www.ncbi.nlm.nih.gov/geo) for a range of cell-/tissue-types including 
several brain regions (mid frontal lobe (GSM773015), inferior temporal gyrus 
(GSM772995), middle hippocampus (GSM773020), substantia nigra 
(GSM997258), cingulate gyrus (GSM773011), H1-derived neuronal progenitor 
cells (HDNPs, GSM753429), lung (GSM906395), liver (GSM1112808) and 
skeletal muscle (GSM916064)). The downloaded files were in bed format, on 
which we performed peak calling using MACS2 and the same specifications as 
described for our own samples, discounting any duplicate reads. We calculated 
the overlap between each peak set and our peaks by quantifying the percentage 
of peaks from the external sample overlapping our peaks using the Bioconductor 






Figure 5-4.	 Factor-conversion of age and neuronal proportion estimates. Neuronal cell 
proportion estimates (derived from DNA methylation data using CETS (Guintivano et al., 2013)) 
and age at death were factorised, to adapt for use in the EdgeR statistical model. (a) The 
distribution of the samples’ age at death and neuronal proportion estimates based on CETS 
profiles are plotted together with the four breaks generated for the respective factor versions of 
the variable by the cut() function in R. (b) The distribution of the CETS variable highlights 
decreased neuronal proportion estimates in cases (AD) (average = 23.8%) compared to controls 




5.2.7 Differential Peak calling  
We used the quasi-likelihood F test (Lun et al., 2016) in EdgeR (Robinson et al., 
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to correct for potential confounders in the analysis of differential peaks. Our 
analyses accounted for additional phenotypic variation across the samples, 
including age at death and neuronal proportion estimates (CETS) based on DNA 
methylation profiles from the Illumina 450K HumanMethylation Array from the 
same samples, which were calculated using the CETS R package (Guintivano et 
al., 2013). We imputed the median CETS estimate for one individual with missing 
DNA methylation data. To include age at death and CETS estimate in the EdgeR 
differential peak calling method, these variables were converted to five-level 
factors using the R function cut(). The distribution of the age and CETS variable 
(including the imputed individual) with the respective bins of the factor variables 
are shown in Figure 5-4. We next calculated normalization factors based on 
sample-specific library compositions and estimated both sample and peak-
specific dispersions, specifically for a generalized linear model controlling for 
factorized CETS estimates and age at death. The quasi-likelihood F-test was 
conducted after fitting a quasi-likelihood model (Lun et al., 2016) using the 
glmQLFit() and glmQLFTest() functions respectively. We generated genome 
browser tracks on the UCSC Genome Browser using BAM files from three 
selected AD samples and three controls, as well as bed tracks for background 
and significantly hyper- and hypoacetylated peaks (FDR < 0.05). Effect sizes are 
reported as log fold change, a standard measure for quantifying sequencing read 
count differences between different conditions. Log fold change refers to the log2-
transformed ratio of normalized read counts between cases and controls, with 
positive values indicating higher normalized read counts in AD samples. 
 
5.2.8 Analysis of CpG island peaks and genomic locations 
First, we analysed the sequence content of all H3K27ac peaks using the hg19 
reference genome sequence. For each peak we quantified the GC content, as 
well as the observed vs expected number of CpG sites, defining peaks with > 
50% GC content and > 60% observed over expected CpG sites as CpG island 
peaks (Gardiner-Garden and Frommer, 1987). Second, we downloaded the 
location of all transcription start sites (TSS) of RefSeq genes in the hg19 
assembly and subsequently compared peaks that mapped within 2kb upstream 
of a TSS to those that didn’t. For both classification methods we compared the 
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distributions of differentially acetylated peaks to those of the non-significant 
background peaks using Fisher’s exact tests. 
	
5.2.9 Analysis of copy-number variation (CNV) and short tandem repeats 
(STRs) across H3K27ac peaks 
We downloaded published maps of CNVs (Zarrei et al., 2015) and STRs (Willems 
et al., 2014) to analyse the enrichment of these amongst differentially acetylated 
peaks. We overlapped the location of all H3K27ac peaks with these locations and 
tested for statistical enrichments of CNVs and STRs using Fisher’s exact test. 
	
5.2.10 Genomic annotation and enrichment analyses  
Peaks were annotated to genes using the Genomic Region Enrichment and 
Annotation Tools (GREAT) (McLean et al., 2010). In addition, we performed 
enrichment analyses to calculate statistical enrichments for ontological 
annotation (gene ontologies for molecular function and biological processes 
(Ashburner et al., 2000), human diseases (Osborne et al., 2009) as well as 
human phenotypes (Robinson and Mundlos, 2010)). Functional enrichment 
analyses were conducted for significantly hyper- and hypoacetylated peaks (FDR 
< 0.05) separately, using the basal plus extension option. Significance in the 
enrichment test is based on a hypergeometric test of genes annotated to the test 
set (hyper-/ hypoacetylated peaks) compared to the background set of genes 
annotated to all 182,065 peaks called across all samples. Results presented in 
Figure 5-19 are restricted to the top five non-redundant enrichments (separated 
by at least two nodes in the local directed acyclic graph visualizing the hierarchy 
of enriched terms from a single ontology) associated with at least three genes in 
the test set for the ontology categories biological process, molecular function, and 




5.2.11 Motif enrichment analysis  
Motif analysis was performed using the Regulatory Sequence Analysis Tools 
suite (RSAT) (Thomas-Chollier et al., 2012b, Thomas-Chollier et al., 2012a) at 
http://rsat.sb-roscoff.fr. Peak sequences were reduced to 500bp to each side of 
the peak centre, and motif discovery was conducted on 6 and 7mer 
oligonucleotides, comparing the statistically enriched sequences with known 
transcription factor motifs from JASPAR (Mathelier et al., 2016) (core 
nonredundant vertebrates) and Homer (Heinz et al., 2010) (Human TF motifs).  
Enrichments were computed relative to the background peak sequences (n = 
182,065 peaks) for significantly hyper- and hypoacetylated peaks (FDR < 0.05). 
 
5.2.11 Analysis of differential H3K27ac across AD regions from genome-
wide association studies (GWAS):  
The summary statistics for the stage 1 GWAS from (Lambert et al., 2013) were 
downloaded from http://web.pasteur-
lille.fr/en/recherche/u744/igap/igap_download.php. These results were clumped 
(p1 = 1e-4; p2 = 1e-4, r2 =0.1, window = 3000kb) using plink, which collapses 
multiple correlated signals (due to linkage disequilibrium (LD)) into regions which 
represent independent signals. LD relationships were inferred from a reference 
GWAS dataset from another study (Phase 1 from (Hannon et al., 2016a)). 
Neighbouring regions located within 250kb of each other on the same 
chromosome were subsequently merged. After clumping, each region was 
assigned the minimum P value for all SNPs contained in the region (from Lambert 
et al), and regions were then filtered to the genome-wide significance threshold 
(P < 5.0E-08). This yielded 11 LD blocks for the genome-wide significant findings 
from Lambert et al., which were then overlapped with our AD-associated 
differentially acetylated peaks using the Bioconductor package GenomicRanges 
(Lawrence et al., 2013). 
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5.2.12 Integrative analysis with DNA methylation and hydroxymethylation  
DNA methylation and hydroxymethylation data was available (unpublished) from 
entorhinal cortex DNA for 42 of the samples profiled in this study. DNA 
methylation and hydroxymethylation profiles were generated on the Illumina 
Infinium HumanMethylation450 BeadChip (Illumina Inc., CA, USA) (“Illumina 
450K array”) using the TrueMethyl Array kit (Cambridge Epigenetix, Cambridge, 
UK). Profiles for both modifications were pre-processed, normalized and filtered 
according to a stringent standardised quality control pipeline, as described 
previously (Lunnon et al., 2016) using the WateRmelon (Pidsley et al., 2013) 
package in R. We identified probes on the array within 1kb of differentially 
acetylated peaks (FDR < 0.05) using the Bioconductor package GenomicRanges 
(Lawrence et al., 2013). A total of 1,659 of the 4,162 FDR significant differentially 
acetylated peaks were located within 1kb of at least one CpG probe on the array, 
with a total of 6,838 probes mapping to the 1kb neighbourhood of these 1,649 
peaks. For each CpG-peak pair we compared the log fold change in H3K27ac 
between AD cases and controls to the difference in DNA methylation or 
hydroxymethylation in a linear model controlling for the same covariates as in the 
differential acetylation analysis. Moreover, we compared DNA methylation and 
hydroxymethylation between probes in vicinity of AD hyper- and hypoacetylated 
peaks, as well as those in vicinity of all background peaks and the whole 
microarray background using t-tests. We used a hypergeometric test to 
characterize enrichment in intermediate methylation values (beta in [0.4,0.6]) in 






5.3.1 Genome-wide profiling of inter-individual variation in H3K27ac in the 
entorhinal cortex 
We generated H3K27ac ChIP-seq data using post-mortem entorhinal cortex 
tissue dissected from 47 elderly individuals (average age = 77.43, SD = 9.66, 
range = 58-97) comprising both AD cases (n = 24) and matched low pathology 
controls (n = 23) (Table 5-1). After stringent quality control (QC) of the raw data 
(see Methods), we obtained an average of 30,032,623 sequencing reads (SD = 
10,638,091) per sample, with no difference in read-depth between cases and 
controls (P = 0.93, Figure 5-2). This represents, to our knowledge, the most 
extensive analysis of H3K27ac in the human entorhinal cortex yet undertaken. 
Using data from all 47 samples (see Methods) we identified 182,065 high 
confidence H3K27ac peaks; these are distributed across all 24 chromosomes 
(Table 5-2) spanning an average of 982bp (SD = 682bp) with a mean distance 
between neighbouring peaks of 15,536bp (SD = 116,040bp). We validated the 
identified peaks using two independent ChIP-seq datasets: first, we obtained 
locations for cortex (BA9) and cerebellum H3K27ac peaks from a recent 
publication by Sun and colleagues (Sun et al., 2016); second, we downloaded 
peak profiles for multiple cell- and tissue-types from the NIH Epigenomics 
Roadmap Consortium (Kundaje et al., 2015) (see Methods). There was a near 
perfect overlap between H3K27ac peaks called in other neocortical datasets and 
our ChIP-seq data, and a much lower overlap with H3K27ac data from non-
cortical tissues (Figure 5-5). As a resource to the community, our data are 




Table 5-2. Distribution of H3K27ac peaks across the 24 chromosomes. 






























Figure 5-5. H3K27ac peaks identified in our study overlap substantially with those identified in other brain ChIP-seq datasets. Shown is the percentage 
of the peaks from other H3K27ac datasets overlapping with peaks in our entorhinal cortex (EC; n = 182,065) ChIP-seq data. (a) 53,882 (95%) of the 56,503 
peaks identified by Sun et al (2016) in BA9 overlap our EC peaks, compared to 29,253 (77%) of the 38,069 cerebellum peaks. (b) Samples profiled by the 
Epigenomics Roadmap Consortium overlap our peaks in a tissue-specific manner with the highest overlap observed for cortical and sub-cortical datasets (mid 
frontal lobe (MFL): 97%, inferior temporal lobe (ITL): 97%, hippocampus: 97%, substantia nigra (99%), cingulate gyrus 70%, H1-derived neuronal progenitor 











































































Figure 5-6. A genome-wide analysis of variable H3K27ac in AD identified widespread 
differentially acetylated peaks. (a) Manhattan plot showing the –log10 P value against 
chromosomal location from the EdgeR quasi-likelihood test, controlling for age and derived 
neuronal proportion. 4,162 peaks were identified as being associated with AD (FDR < 0.05, red 
line). (b) Volcano plot showing the -log10 P value against log fold change for each entorhinal cortex 
H3K27ac peak (FDR < 0.05, red line). Of the associated peaks, 1,475 (35%) are hyperacetylated 
in AD (higher H3K27ac) and 2,687 (65%) are hypoacetylated in AD (lower H3K27ac). 
	
	
5.3.2 AD-associated differential acetylation in the entorhinal cortex 
We quantified read counts for each peak in each individual sample using HTSeq 
(Anders et al., 2015) and employed the quasi-likelihood F test, implemented in 
the Bioconductor package EdgeR (Robinson et al., 2010), to test for differences 
in H3K27 acetylation associated with AD compared to low pathology controls 
(see Methods). Our analysis model controlled for age at death and neuronal cell 
proportion estimates derived from DNA methylation data generated on the same 
samples using the CETS R package (Guintivano et al., 2013) (Table 5-1, Figure 
5-4). A total of 4,162 (2.3%) of the 182,065 peaks were characterized by 
differential acetylation associated with AD at a false discovery rate (FDR) < 0.05 
(Figure 5-6), with a significant enrichment of hypo-acetylated AD-associated 
peaks (2,687 (1.5%)) compared to hyper-acetylated AD-associated peaks (1,475 
(0.8%)) (P = 9.89E-80, exact binomial test) (Figure 5-6). The ten top-ranked 
hyper- and hypo-acetylated peaks associated with AD are shown in Table 5-3, 
with a full list given in Appendix B-1 (hyperacetylated peaks) and Appendix B-
2 (hypoacetylated peaks). Peaks were subsequently annotated to genes using 
GREAT (McLean et al., 2010), which takes into account the strength of proximal 
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and distal DNA-binding events. The most significant AD-associated 
hyperacetylated peak (chr13: 112101248-112102698; P = 2.04E-08; log fold 
change = 0.93) is annotated to SOX1 and TEX29 on chromosome 13 (Figure 
5-7, Table 5-3). H3K27ac data from the Epigenomics Roadmap Consortium 
show that this region is characterized by brain-specific enhancer activity (Figure 
5-8). The most significant AD-associated hypoacetylated peak (chr7: 64011549-
64012825; P = 1.66E-08; log fold change = -0.86) is located within intron 1 of 
ZNF680 on chromosome 7 (Figure 5-9, Figure 5-8, Table 5-3). Global clustering 
of samples by normalized read counts across all hyper- and hypo-acetylated 
peaks (FDR < 0.05) indicated that samples group primarily by disease status 
(Figure 5-10).  
AD-associated differentially acetylated peaks (FDR < 0.05) are significantly 
longer (1295bp vs 975bp, P < 1.00E-50) and characterized by higher read-depths 
(2.56 log counts per million (CPM) vs 1.59 log CPM, P < 1.00E-50) than non-
significant peaks (Figure 5-11). Of note, within AD-associated peaks, 
hypoacetylated peaks are significantly longer (1412bp vs 1081bp, P = 5.66E-31) 
and have higher read depths (2.21 log CPM vs 1.77 log CPM, P = 2.69E-50) 
compared to hyperacetylated peaks. 43% of the overall peaks are located in 
regions classified as CpG islands, with differentially acetylated peaks significantly 
depleted in CpG islands (38%; P = 1.25E-05). However, amongst differentially 
acetylated peaks, 73% of hyperacetylated peaks are characterized as CpG 
islands compared to only 19% of hypoacetylated peaks (P < 1.0E-50; Figure 
5-11). Conversely, differentially acetylated peaks are slightly enriched in regions 
mapping within 2kb upstream of protein coding genes (11%) compared to the 
background of non-significant peaks (9%; P = 5.13E-05), with no significant 
difference between hyper- and hypoacetylated peaks (Figure 5-11). 
Hyyperacetylated peaks show higher GC content (55%) than the background set 
of non-siginificant peaks (49%; P < 1.0E-50), while hypoacetylated peaks are 
depleted in GC content (44%; P < 1.0E-50) compared to the background (Figure 
5-11). Finally, we tested for enrichments in CNVs (Zarrei et al., 2015) and STRs 
(Willems et al., 2014) using Fisher’s exact test. While we found differentially 
acetylated peaks not to be enriched in CNVs (4% of differentially acetylated 
peaks overlap CNVs, compared to 6% in the non-significant background peak 
set), we observed an enrichment of STRs amongst AD-associated peaks (29%) 
compared to the non-significant background set of peaks (16%; P < 1.0E-50), 
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with STRs co-localizing with higher frequencies of CpG islands (47% CpG islands 
amongst STR peaks) compared to non-STR background peaks (42% CpG 
islands; P < 1.0E-50). 
We used RSAT (Thomas-Chollier et al., 2012a, Thomas-Chollier et al., 2012b) to 
identify enriched transcription factor binding motifs located within AD-associated 
differentially acetylated peaks (see Methods), observing a significant enrichment 
of binding motifs for specificity protein 1 (Sp1) (P < 1.0E-50) amongst AD-
hyperacetylated peaks (FDR < 0.05). Of note, previous publications have 
reported dysregulated expression of Sp1 and its co-localization with 
neurofibrillary tangles in AD (Santpere et al., 2006, Citron et al., 2008).  
 
Table 5-3. Differential H3K27ac associated with AD. Shown are the ten top-ranked hyper- and 
hypo-acetylated H3K27ac peaks, controlling for age at death and neuronal proportion estimates 
derived from DNA methylation data. 





1 13 112101248-112102698 2.04E-08 0.002 0.93 SOX1, TEX29 
2 13 42094789-42095919 6.31E-08 0.003 0.92 RGCC, VWA8 
3 22 50342521-50343567 1.02E-07 0.003 0.93 PIM3, CRELD2 
4 5 640598-642071 1.36E-07 0.003 0.88 CEP72, TPPP 
5 8 145180336-145181125 2.72E-07 0.004 1.12 FAM203A, 
MAF1 
6 17 19665361-19666514 3.86E-07 0.004 0.77 ALDH3A1, 
ULK2 
7 1 9392591-9393233 5.25E-07 0.004 0.83 SLC25A33, 
SPSB1 
8 17 19619421-19620832 5.43E-07 0.004 0.80 SLC47A2 
9 17 43925717-43927482 7.01E-07 0.005 0.71 MAPT, SPPL2C 
10 1 9341867-9342320 8.55E-07 0.005 1.05 SPSB1, H6PD 
Hypoacetylated peaks 
1 7 64011549-64012825 1.66E-08 0.002 -0.86 ZNF680, 
ZNF736 
2 21 29827289-29828201 5.70E-08 0.003 -0.85 N6AMT1 
3 1 179175226-179176637 7.03E-08 0.003 -0.70 ABL2, TOR3A 
4 1 241397411-241399621 9.73E-08 0.003 -0.75 GREM2, RGS7 
5 12 13627258-13629064 1.46E-07 0.003 -0.80 EMP1, GRIN2B 
6 8 3964265-3966191 2.44E-07 0.004 -0.57 CSMD1 
7 4 74088063-74089559 2.52E-07 0.004 -0.68 COX18, 
ANKRD17 
8 6 166401119-166402753 2.85E-07 0.004 -1.06 SDIM1, T 
9 7 107111795-107113029 2.88E-07 0.004 -0.90 DUS4L, GPR22 




Figure 5-7. The top-ranked AD-associated hyperacetylated peak is annotated to SOX1 and TEX29 on chromosome 13. Shown are normalized read counts (a) 
and a regional track of H3K27ac ChIP-seq profiles from three example cases (red) and controls (turquoise; b). (a) The most significant AD-hyperacetylated peak is 
characterized by a consistent increase of H3K27ac in diseased samples (P = 2.04E-08, log fold change = 0.93). (b) This peak is located on chromosome 13 and 
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Figure 5-8. Regional profiles of H3K27ac signals in multiple cell- and tissue types around 
the top-ranked AD-associated differentially acetylated peaks. H3K27ac ChIP-seq profiles for 
several NIH Epigenomics Roadmap Consortium samples are shown: mid frontal lobe (BMFL), 
inferior temporal lobe (BITL), middle hippocampus (BHM), substantia nigra (BSN), cingulate gyrus 
(BCG), H1-derived neuronal progenitor cells (HDNP), lung, liver (AL), skeletal muscle (SM) and 
the layered H3K27ac track based on multiple cell lines displayed by the UCSC Genome Browser 
in the default setting. (a) A region surrounding the most significantly upregulated peak (P = 2.04E-
08; highlighted by an asterix) on chromosome 13 is presented. The peak and its immediate 
neighbour are characterized by brain-specific H3K27ac profiles. (b) A region around the most 
significantly downregulated peak (P = 1.66E-08), located in an intron of ZNF680 on chromosome 
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Figure 5-9. The top-ranked AD-associated hypoacetylated peak is located in intron 1 of ZNF680 on chromosome 7. Shown are normalized read counts (a) and 
regional tracks of H3K27ac ChIP-seq profiles from three example cases (red) and controls (turquoise; b). (a) The most significant differentially acetylated peak (P = 
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Figure 5-10. Clustering of samples by H3K27ac at differentially acetylated peaks groups them primarily by disease status. Shown are two heatmaps clustering 
samples based on the 1,475 hyperacetylated peaks (a) and the 2,687 hypoacetylated peaks (b), respectively. (a) A heatmap, clustering samples by normalized read 
counts in all significant AD hyperacetylated peaks (FDR < 0.05), generates three distinct groups: one comprised of controls only (group 1, 13 samples, left), a pure 
group of cases (group 2, 20 samples, middle), and a mixed group containing both cases and controls (group 3, 14 samples, right). The differences in the disease 
status distribution across these three groups is significant (P = 1.89E-08, chi-square test with Yates’ continuity correction). Controls grouped together with cases in 
group 3 are characterized by significantly decreased neuronal proportion estimates, compared to those in the pure control group 1 (P = 7.10E-04, t-test). (b) A heatmap, 
clustering samples by all FDR significant AD hypoacetylated peaks, divides the samples into two main groups: group 1 is composed mainly of controls (17 samples, 
left), whereas group 2 contains more cases than controls (30 samples, right). Case-control differences between these two groups are significant (P = 1.74E-04, chi-
square test). Interestingly, controls classified into group 2 are characterized by lower neuronal proportion estimates than those in group 1 (P = 0.004, t-test). The 
clustering defined by hyper- or hypoacetylated peaks is not significantly associated with sex (P > 0.05, chi-square test) or age at death (P > 0.05, t-test). 
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Figure 5-11. Peak characteristics of differentially acetylated peaks. On average, FDR 
significant differentially acetylated peaks (a) are longer (P < 1.00E-50) and (b) have higher log 
counts per million (CPM; P < 1.00E-50) compared to the non-significant background peaks. 
Interestingly, amongst differentially acetylated peaks, those that are hypoacetylated are 
characterized by (a) being longer (P = 5.66E-31) and (b) having higher CPM (P = 2.69E-50) than 
the significantly hyperacetylated peaks. (c) Overall, differentially acetylated peaks are 



































































































1.25E-08). However, amongst differentially acetylated peaks, hyperacetylated peaks show a 
larger percentage of CpG island peaks compared to hypoacetylated peaks (P < 1.0E-50). (d) In 
contrast, differentially acetylated peaks are enriched in regions mapping within 2kb upstream of 
the TSS of protein coding genes (P = 5.13E-05) but there is no statistically significant difference 
between hyper- and hypoacetylated peaks (P = 0.08). (e) Compared to the background GC 
density (49%), hyperacteylated peaks are enriched in GC content (55%, P < 1.0E-50) and 
hypoacetylated peaks are depleted in GC content (44%, P < 1.0E-50).	
	
	
5.3.3 Increased H3K27ac is observed in regulatory regions annotated to 
genes previously implicated in both tau and amyloid neuropathology 
One of the top-ranked AD-associated hyper-acetylated peaks is located proximal 
to the gene encoding microtubule associated protein tau (MAPT) (chr17: 
43925717-43927482; P = 7.01E-07; log fold change = 0.71; Table 5-3), which is 
widely expressed in the nervous system acting to promote microtubule assembly 
and stability. Tau is believed to play a key role in AD neuropathology, with 
hyperphosphorilation of the tau protein precipitating the neurofibrillary tangles 
associated with the pathogenesis of AD (Ittner and Gotz, 2011, Spillantini and 
Goedert, 2013). Closer inspection of the region around this AD-associated peak 
highlighted an extended cluster of six hyper-acetylated H3K27ac peaks (FDR < 
0.05) spanning 36 kb (chr17: 43925717 - 43961546) located within a MAPT 
antisense transcript (MAPT_AS1) ~10kb upstream of the MAPT transcription 
start site (Figure 5-12; Table 5-4). H3K27ac ChIP-seq data from the NIH 
Epigenomics Roadmap Consortium show that this region is characterized by 
brain-specific H3K27ac signatures (Figure 5-12), with ChromHMM (Ernst and 
Kellis, 2012) identifying the region as an active chromatin domain in brain, 
comprised of enhancers and blocks of weak transcription (Figure 5-13). 
Strikingly, AD-associated differentially-acetylated peaks were also found in the 
vicinity of other genes known to play a direct mechanistic role in AD. We identified 
a significantly hypoacetylated peak (chr21:27160993-27161475; P = 3.94E-04; 
log fold change = -0.72) on chromosome 21, located ~100 kb downstream of the 
amyloid precursor protein gene (APP), which encodes the precursor molecule to 
Ab, the main component of amyloid plaques (Rovelet-Lecrux et al., 2006, 
Scheuner et al., 1996, Goate et al., 1991, Jonsson et al., 2012, Cruchaga et al., 
2012) (Figure 5-14). We also identified significant hyperacetylation in the vicinity 
of the presenilin genes PSEN1 and PSEN2, which encode integral components 
of the gamma secretase complex and play a key role in generation of Aβ 
from APP (De Strooper et al., 1998). In PSEN1 we found significantly elevated 
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H3K27ac across a peak within intron 6 (chr14:73656445-73656860; P = 3.44E-
04; log fold change = 0.68; Figure 5-15). In PSEN2 we identified consistent 
hyperacetylation in AD cases across nine H3K27ac peaks (FDR < 0.05) spanning 
a ~57 kb region upstream of the transcription start-site (chr1:226957425-
227014019; Figure 5-16, Figure 5-13 and Table 5-5). Of note, highly-penetrant 
mutations in APP, PSEN1, and PSEN2 are associated with familial forms AD 
(Goate and Hardy, 2012, Tanzi, 2012, Schellenberg and Montine, 2012). The 
identification of altered regulation of these loci in late-onset sporadic AD brain 





Table 5-4. Association statistics for the nine peaks overlapping the differentially acetylated 
region on chromosome 17, annotated to MAPT and SPPL2C. 
Start - end P-value P FDR Log FC 
43925717-43927482 7.01E-07 0.005 0.71 
43928851-43929350 7.68E-04 0.043 0.60 
43929961-43930229 1.08E-03 0.049 0.59 
43935330-43936111 1.72E-04 0.024 0.54 
43938147-43939070 0.842 0.941 0.02 
43943325-43946054 0.165 0.454 0.20 
43947431-43948194 8.84E-04 0.046 0.45 
43954021-43954371 0.052 0.263 0.46 





Figure 5-12. A region annotated to MAPT comprising six H3K27ac peaks is characterized by significant hyperacetylation in AD. A cluster of nine 
H3K27ac peaks was identified on chromosome 17. All nine peaks show consistent effect directions (mean log fold change = 0.46; Table 5-4), with H3K27ac 
upregulated in cases. (a) For six of the nine peaks this increase in H3K27ac associated with AD is significant (FDR < 0.05).  (b) The whole region is located 
10kb upstream of MAPT (c) and is characterized by brain specific acetylation profiles. The boundaries of the significantly differentially acetylated peak region 
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Figure 5-13. Chromatin state tracks for the MAPT and PSEN2 hyperacetylated peak clusters. The tracks show the locations of H3K27ac peaks across 
the plotted window (black) as well as the peaks showing significant increase of H3K27ac in AD (FDR < 0.05; green). ChromHMM chromatin states from the 
Roadmap Epigenomics Consortium for a range of brain tissues (mid frontal lobe, inferior temporal gyrus, hippocampus middle, substantia nigra and cingulate 
gyrus) as well as non-brain tissue (H1-derived neuronal progenitor cells, lung, liver and skeletal muscle). Plots were produced on the WashU Epigenome 
Browser v42 using the core 15-state ChromHMM model. Chromatin states matching the colours shown include red - active TSS, green – strong transcription, 
dark green – weak transcription, yellow – enhancer, gray – repressed polycomb, light gray – weak repressed polycomb, pale turquoise – heterochromatin, and 
white – quiescent. (a) A cluster of six AD-hyperacetylated H3K27ac peaks was identified upstream of MAPT. Chromatin state annotation shows that this region 
is characterized primarily by brain-specific enhancers and blocks of weak transcription. (b) A second cluster spanning nine significantly hyperacetylated peaks 
was identified upstream of PSEN2. ChromHMM identified two active chromatin domains in brain, also comprised of enhancers and blocks of weak transcription. 
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Figure 5-14. A H3K27ac peak located downstream of APP is characterized by significant 
hypoacetylation in AD. We identified one significantly hypoacetylated peak (FDR < 0.05) on 
chromosome 21, located < 100 kb downstream of APP (chr21:27160993-27161475; P = 3.94E-





Figure 5-15. A H3K27ac peak located in an intron of PSEN1 is characterized by significant 
hyperacetylation in AD. We identified one significantly hyperacetylated peak (FDR < 0.05) on 
chromosome 14, located in intron 6 of PSEN1 (chr14:73656445-73656860; P = 3.44E-04; log fold 









































Figure 5-16. A region annotated to PSEN2 spanning nine H3K27ac peaks is characterized by significant hyperacetylation in AD. A cluster of 14 
H3K27ac peaks was identified on chromosome 1. All 14 peaks show consistent effect directions (mean log fold change = 0.52; Supplementary Table 6), with 
H3K27ac upregulated in cases. (a) For nine of the 14 peaks this increase in H3K27ac associated with AD is significant (FDR < 0.05).  (b) The whole region is 
located 44kb upstream of PSEN2 (c) and is characterized by predominantly acetylation peaks in brain. The boundaries of the significantly differentially acetylated 
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Table 5-5. Association statistics for the 14 peaks overlapping the differentially acetylated 
region on chromosome 1, annotated to PSEN2 and ITPKB. 
Start - end P-value P FDR Log FC 
226957424-226958029 2.19E-05 0.013 0.84 
226959991-226961572 8.10E-04 0.044 0.46 
226969195-226969518 2.57E-04 0.029 0.66 
226970654-226971677 3.40E-04 0.032 0.56 
226971888-226972730 0.014 0.144 0.39 
226974106-226975826 0.014 0.144 0.37 
226980648-226980894 0.144 0.426 0.34 
226986193-226988116 1.07E-06 0.005 0.60 
226996028-226997864 6.10E-05 0.018 0.53 
227001743-227003902 0.012 0.134 0.28 
227008727-227010081 2.48E-03 0.068 0.42 
227011597-227011851 3.47E-04 0.032 0.60 
227012069-227012797 1.67E-04 0.024 0.65 




5.3.4 Specific differentially-acetylated peaks also overlap known AD GWAS 
regions 
Using data from a large genome-wide association study (GWAS) of AD (Lambert 
et al., 2013) we tested for instances where there is an overlap between AD-
associated differential H3K27ac and genomic regions identified in GWAS. Briefly, 
we defined linkage-disequilibrium (LD) blocks around the 11 GWAS variants 
identified by Lambert and colleagues (Table 5-6) which contained a total of 292 
overlapping entorhinal cortex H2K27ac peaks (see Methods). Two of the 11 
GWAS LD blocks contained significant AD-associated H3K27ac peaks (FDR < 
0.05), although there was no overall enrichment of AD-associated differential 
acetylation at the 292 peaks (P = 0.364, Wilcoxon rank-sum test). Two peaks of 
AD-associated hyperacetylation were located within a GWAS region on 
chromosome 1, mapping to the gene body of CR1 (chr1:	207753457-207753813; 
P = 1.15E-06; log fold change = 0.99 and chr1:	207754916-207756572; P = 
5.40E-04; log fold change = 0.56; Figure 5-17). CR1 encodes a transmembrane 
glycoprotein expressed in microglia with a role in the innate immune system, 
promoting phagocytosis of immune complexes and cellular debris, in addition to 
Aβ (Crehan et al., 2012, Heppner et al., 2015, Villegas-Llerena et al., 2016). Two 
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other AD-associated differentially acetylated peaks were found to be located 
within a GWAS region on chromosome 19, including a hyperacetylated peak 
(chr19:45394441-	45395396; P = 2.13E-04; log fold change = 0.48) mapping to 
the gene body of TOMM40 in the immediate vicinity of APOE (Figure 5-18). 
Another H3K27ac peak in this LD block was hypoacetylated in AD (chr19:	
45639588-	45641733; P = 7.65E-04; log fold change = -0.33), mapping to intron 
1 of PPP1R37. 
 
Table 5-6. Shown are the locations, GWAS SNPs and P values for the 11 LD blocks 
constructed from the Lambert et al AD GWAS. 
CHR Start End Number 
of SNPs 
in GWAS 
Min P SNP Location P 
1 207372941 207875537 1144 rs1752684 207747296 3.65E-15 
2 127826533 127889932 255 rs7561528 127889637 6.54E-18 
6 47318885 47662484 981 rs9381563 47432637 5.30E-09 
7 143083661 143198249 278 rs10808026 143099133 1.42E-11 
8 27170788 27489959 869 rs7982 27462481 2.48E-17 
11 59826677 60105199 733 rs72924659 60103385 5.35E-13 
11 85636074 85874322 648 rs10792832 85867875 6.53E-16 
11 121423640 121517613 176 rs11218343 121435587 4.98E-11 
14 92926952 92941096 95 rs12590654 92938855 4.10E-08 
18 29088958 29088958 1 rs8093731 29088958 4.63E-08 




Figure 5-17. Two intragenic H3K27ac peaks located across CR1 are characterized by 
significant hyperacetylation in AD. We identified two significantly hyperacetylated peak (FDR 






































P = 1.15E-06; log fold change = 0.99 and (b) chr1: 207754916-207756572; P = 5.40E-04; log fold 
change = 0.56.   
a      b 
	
Figure 5-18. Two differentially acetylated peaks overlap the GWAS LD block on 
chromosome 19. (a) We identified one significantly hyperacetylated peak (FDR < 0.05) on 
chromosome 19, mapping to the gene body of TOMM49 and < 15 kb upstream of APOE 
(chr19:45394441- 45395396; P = 2.13E-04; log fold change = 0.48).  (b) A peak located in intron 
1 of PPP1R37 was hypoacetylated in AD (chr19: 45639588- 45641733; P = 7.65E-04; log fold 
change = -0.33). 
 
	
5.3.5 AD-associated differentially-acetylated peaks are enriched for 
functional processes related to neuropathology 
We used GREAT (McLean et al., 2010) to calculate statistical enrichments for 
ontological annotations, interrogating gene ontologies for molecular function and 
biological processes (Ashburner et al., 2000), human diseases (Osborne et al., 
2009) as well as human phenotypes (Robinson and Mundlos, 2010) (Figure 5-19 
and Appendix C). Multiple ontological categories associated with AD 
progression and pathology were identified as being enriched amongst 
hyperacetylated peaks, including “lipoprotein particle binding” (Jaeger and 
Pietrzik, 2008, Liu et al., 2013) (P = 1.10E-06), “beta-amyloid metabolic process” 
(Ittner and Gotz, 2011) (P = 4.94E-08), “neurofibrillary tangles” (Spillantini and 
Goedert, 2013) (P = 3.93E-05), “response to hypoxia” (Sun et al., 2006, Zlokovic, 
2011) (P = 3.17E-14), “neuronal loss in central nervous system” (Wenk, 2003) (P 
= 4.93E-04),  and “Pick’s disease” (P = 2.93E-07), a form of fronto-temporal 
dementia also characterized by tau pathology (Warren et al., 2013, Spillantini and 









































categories related to neurotransmitter-functions, including “GABA receptor 
activity” (Limon et al., 2012) (P = 2.70E-07) as well as categories related to 
neuronal transmission and synapses, such as “protein location to synapse” (P = 





Figure 5-19. Neurobiological and disease-related pathways are enriched in hyper- and 
hypoacetylated regions. Using all significantly hyper- and hypoacetylated peaks (FDR <0.05), 
we conducted functional enrichment analyses using GREAT (McLean et al., 2010). Shown are 
the top five independent enrichments in the categories molecular function, biological process and 
disease ontology (see Methods). (a) AD-related pathways enriched in the hyperacetylated peaks 
include “lipoprotein particle binding” (P = 1.10E-06) and “response to hypoxia” (P = 3.17E-14) as 
well as “Pick’s disease” (P = 2.93E-07), a form of fronto-temporal dementia. (b) Amongst 
hypoacetylated pathways we identified neuronal transmission pathways, including “protein 
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5.3.6 Integrative analysis of DNA and histone modifications reveals unique 
distributions of DNA modifications across regions of differential 
acetylation  
Our previous work identified cortex-specific variation in DNA methylation (5mC) 
associated with AD pathology (Lunnon et al., 2014, De Jager et al., 2014). We 
were therefore interested in exploring the relationship between H3K27ac and 
both 5mC and another DNA modification – DNA hydroxymethylation (5hmC), 
which is enriched in the brain and believed to play an important role in neuronal 
function, learning and memory (Lunnon et al., 2016, Kaas et al., 2013, Kinde et 
al., 2015) - in AD. Both modifications were profiled using DNA isolated from the 
same entorhinal cortex samples using oxidative bisulfite conversion in 
conjunction with the Illumina 450K HumanMethylation array (“450K array”) (see 
Methods). 6,838 probes mapped to within 1kb of differentially acetylated peaks 
(FDR < 0.5; mapping to 1,649 unique peaks). We tested differential 5mC and 
5hmC associated with AD at these probes, controlling for age at death and cell-
type proportion estimates. None of the differences in 5mC (minimum P = 2.47E-
03) or 5hmC (minimum P = 1.53E-03) were significant when correcting for 
multiple testing (n = 6,838 tests; P < 7.31E-05), indicating that there is little direct 
overlap in AD-associated variation in H3K27ac and DNA modifications. 
Furthermore, comparing effect sizes at these 6,838 peak–probe pairs identified 
no evidence for a correlation between AD-associated H3K27ac and 5mC 
differences (r = 0.009, P = 0.443; Figure 5-20) with a small, but significant, 
negative correlation for 5hmC (r = -0.045, P = 1.63E-04; Figure 5-20). As 
expected, both DNA modifications are significantly lower in the vicinity of 
H3K27ac peaks compared to the genome-wide 450K array background (5mC: P 
< 1.00E-50, beta difference = 12%, Figure 5-20; 5hmC: P = 3.61E-30, beta 
difference = 0.16%; Figure 5-20), consistent with H3K27ac being localized at 
active enhancers and promoters. Interestingly, peaks characterized by 
significantly hyperacetylated H3K27ac in AD are enriched for intermediate levels 
of 5mC (beta in [0.4,0.6]) compared to the array-wide background (P = 2.95E-07, 
hypergeometric test). Furthermore, peaks characterized by AD-associated 
hyperacetylation have increased 5hmC compared to hypoacetylated peaks (P < 
1.00E-50, beta difference = 2.17%), the non-significant peaks (P = 3.12E-25, beta 
difference = 1.33%) and the whole array background (P = 5.04E-20, beta 
difference = 1.17%; Figure 5-20). 
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Figure 5-20. Diverging DNA methylation patterns are observed around AD hyperacetylated 
peaks. (a) Effect sizes for association between AD and DNA methylation at CpG probes within 
1kb of FDR significant differentially acetylated peaks are not correlated with log fold change in 
H3K27ac at these peaks (P = 0.443). (b) Probes in vicinity of entorhinal cortex H3K27ac peaks 
show a skew towards lower DNA methylation compared to the array-background (P < 1.00E-50, 
beta difference = 12%), whereas hyperacetylated peaks show an enrichment in intermediate DNA 
methylation values, compared to the whole array background (P = 2.95E-07). (c) Effect sizes for 
association between AD and DNA hydroxymethylation at CpG probes within 1kb of FDR 
significant peaks are minimally but significantly negatively correlated with log fold change in 
H3K27ac at these peaks (r = -0.045, P = 1.63E-04). (d) DNA hydroxymethylation was derived by 
subtracting the true methylation percentage measured using oxidised bisulfite treatment from the 
combined methylation value assessed using regular bisulfite treatment. DNA hydroxymethlation 
is slightly lower near H3K27ac peaks, compared to the array background (P = 3.61E-30, beta 
difference = 0.16%), while probes in vicinity of AD hyperacetylated H3K27ac peaks show higher 
levels of DNA hydroxymethylation compared to those near hypoacetylated (P < 1.00E-50, beta 
difference = 2.17%), or not significantly differentially acetylated peaks (P = 3.12E-25, beta 
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In this study, we quantified genome-wide levels of H3K27ac in post-mortem 
entorhinal cortex tissue samples, identifying widespread AD-associated 
acetylomic variation. Strikingly, differentially acetylated peaks were identified in 
the vicinity of genes implicated in both tau and amyloid neuropathology (MAPT, 
APP, PSEN1, PSEN2), as well as genomic regions containing variants 
associated with sporadic late-onset AD (CR1, TOMM40). Both MAPT and PSEN2 
are characterized by an extended hyperacetylated region upstream of the 
transcription start site mapping to brain-related enhancers. We show that genes 
annotated to AD-associated hyper- and hypoacetylated peaks are enriched for 
brain- and neuropathology-related functions. This is first study of variable 
H3K27ac yet undertaken for AD, and in addition to identifying molecular 
pathways associated with AD neuropathology, introduces a framework for 
genome-wide studies of this modification in complex disease.  
Given its close relationship with transcriptional activation, for example via the 
mediation of transcription factor binding, the identification of AD-associated 
variation in H3K27ac highlights potential novel regulatory genomic pathways 
involved in disease etiology. We find widespread alterations in H3K27ac 
associated with AD, including in the vicinity of several genes directly involved in 
the progression of neuropathology. Two main mechanisms are speculated to 
trigger pathogenesis in AD: Ab and tau pathology (Selkoe and Hardy, 2016, Ittner 
and Gotz, 2011). Our results show disrupted regulatory variation at genes 
involved in both of these pathways (APP, PSEN1, PSEN2, MAPT), supporting 
the notion that both processes are involved in the onset of neuropathology. 
Interestingly, although we profile brains affected by sporadic late-onset AD, we 
identify widespread altered H3K27ac in the vicinity of genes implicated in familial 
early-onset AD. This indicates that these two forms of the disease may share 
common pathogenic pathways and mechanisms. Given that histone-acetylation 
modifiers are amongst the most promising target pharmacological treatments of 
AD (Graff and Tsai, 2013a, Fischer, 2014), the identification of altered H3K27ac 
in AD is important, giving clues as to which genes and pathways may be involved. 
Non-coding genetic variation, in form of acetylation-QTLs, may play a role in this 
context, in light of reports showing that variable H3K27ac regions are associated 
with genetic variation (Kasowski et al., 2013).  
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Our study has a number of limitations, which need to be considered when 
interpreting these results. First, we undertook ChIP-seq using “bulk” entorhinal 
cortex samples comprising a mix of neuronal and non-neuronal cell-types. This 
is an important limitation in studies of a disease characterized by cortical neuronal 
loss. However, we were able to control for variation in neuronal proportions in our 
samples by deriving neuronal proportion estimates for each sample using DNA 
methylation data generated on the same tissue samples using an established 
method (Guintivano et al., 2013). Second, our cross-sectional analysis of post-
mortem brain tissue makes direct causal inference difficult, and it is plausible that 
the differences in H3K27ac we observe result from the AD pathology itself. In this 
regard, however, it is interesting that we see disease-associated H3K27ac in the 
vicinity of genes causally implicated in familial forms of AD. Third, we have 
assessed a relatively small number of samples. In this light, it is notable that we 
identify robust differences between AD cases and controls, with disease-
associated regulatory variation in genes and functional pathways known to play 
a role in the onset and progression of neuropathology. The clear clustering 
between patients and controls at our differentially acetylated peaks suggests that 
despite a complex and heterogeneous etiology, AD is characterized by a 
common molecular pathology in the entorhinal cortex. Fourth, chromatin 
architecture and transcriptional regulation is influenced by a multitude of 
epigenetic mechanisms. Although H3K27ac profiles provide relatively robust 
information about transcriptional activity, they represent only one of perhaps 
~100 post-translational modifications occurring at > 60 histone amino-acid 
residues regulating genomic function.  
In summary, we provide compelling evidence for widespread acetylomic 
dysregulation in the entorhinal cortex in AD. Our data suggest that H3K27ac at 
multiple loci, including in the vicinity of several known AD risk genes – APP, CR1, 
MAPT, PSEN1, PSEN2 and TOMM40 – is robustly associated with disease, 
supporting the notion of common molecular pathways in both familial and 
sporadic AD. In addition to identifying molecular pathways associated with AD 
neuropathology, we present a framework for genome-wide studies of histone 
modifications in complex disease, integrating our data with results obtained from 
genome-wide association studies as well as other epigenetic marks profiled on 











6.1 Key findings  
6.1.1 Severe psychosocial deprivation in early childhood is associated with 
increased DNA methylation across a region spanning the transcription start 
site of CYP2E1 
The primary aim of my first empirical data chapter was to study methylomic 
correlates of severe early-life institutional deprivation. Using the English and 
Romanian Adoption Study (ERA), a unique longitudinal cohort established 
following a “natural experiment”, I investigated the association between genome-
wide patterns of DNA methylation quantified in buccal swab DNA of 49 individuals 
and the duration of deprivation exposure. A differentially methylated region 
(DMR) spanning 9 sequential CpG sites and overlapping the transcription start 
site of the cytochrome P450 gene CYP2E1 was significantly hypermethylated in 
individuals exposed to extended periods of severe institutional deprivation (> 6 
months). In addition to the deprivation related methylomic variation, I found a 
significant association between the same CYP2E1 DMR and measures of social 
cognitive performance. These findings provide support for the hypothesis that 
severe early-life adverse exposures induce enduring epigenetic variation and 
potentially mediate the socio-cognitive sequelae of these stressful events. 
 
6.1.2 There is no systematic association between early-life victimisation 
and epigenetic variation in whole blood 
For my second empirical chapter, I set out to follow-up the association between 
severe early-life adversity and epigenetic variation by profiling DNA methylation 
in a large population-based cohort. To my knowledge this represents the most 
comprehensive analysis undertaken characterising epigenetic correlates of 
victimisation across the first two decades of life. Using whole blood DNA 
methylation profiles from 1,658 participants of the Environmental Risk (E-Risk) 
Longitudinal Twin Study, I interrogated methylomic variation associated with a 
variety of victimisation exposures in childhood (age 5-12) and adolescence (age 
12-18). Overall, this study found little evidence for epigenetic variation in blood 
associated with victimisation exposure in childhood, adolescence or cumulatively. 
This study highlights both the importance of undertaking epidemiological studies 
in the disease-affected tissue and the importance of adequately controlling for 
potential confounders such as smoking. 
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6.1.3 Tissue-specific allelically-skewed DNA methylation is widespread and 
often associated with DNA sequence variation 
The third empirical chapter of my PhD thesis focussed on profiling intra- and inter-
individual patterns of allele-specific DNA methylation (ASM). Using matched 
post-mortem samples dissected from seven different brain regions and whole 
blood collected prior to death from multiple individuals, I characterised covariation 
of ASM between blood, cerebellum and cortex. This study uncovered the 
widespread and frequently tissue-specific occurrence of ASM across the human 
genome. In addition to confirming ASM at known imprinted regions, I identified 
examples of putative genotype-driven ASM, some of which are tissue-specific. 
This chapter highlighted how inter-individually variable ASM tends to be flanked 
by larger regions of intermediate DNA methylation and is enriched in DNase I 
hypersensitivity sites. 
 
6.1.4 Widespread cortical dysregulation of H3K27ac is identified in 
Alzheimer’s Disease, including at MAPT and PSEN2 
In my final empirical chapter I characterised H3K27ac profiles in 47 entorhinal 
cortex samples from neuropathologically well-characterised individuals. The 
main aim of this study was to identify variation in histone-acetylation associated 
with Alzheimer’s disease (AD). Using ChIP-seq, I profiled H3K27ac in post-
mortem brain samples from patients affected by AD as well as neuropathology-
free control samples. This chapter provides evidence for widespread disease-
associated variation in H3K27ac, including at several genes previously implicated 
in tau and amyloid pathology (APP, MAPT, PSEN1, PSEN2). Using an integrated 
genetic and epigenetic approach I identified regions exhibiting converging 
evidence for disease-associated variation from genetic and epigenetic profiling. 
This is one of the first genome-wide studies of histone acetylation of any complex 
disease and the largest to date of AD and therefore also outlines a framework for 
genome-wide studies of histone modifications in disease. 
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Figure 6-1. Summary of the key findings and implications of my PhD thesis, in relation to 
the research themes described in the introduction. Findings are coloured in blue, implications 
in green. For image credits see Figure 1-10. 
	
6.2 Implications of my findings 
During my PhD I employed a variety study designs, experimental approaches 
and technologies as well as analysis strategies to explore aspects of epigenetic 
variation in brain-related phenotypes. This thesis contributes to the field of 
epigenetic epidemiology of mental health in a number of important ways: First, 
two unique and complementary approaches were used to characterise epigenetic 
correlates of early-life adversity in surrogate tissue. Used together, these two 
approaches were able to overcome several challenges faced by previously 
published work in this field, including sample size concerns, confounding and 
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selection biases. Second, the thesis contributes to a growing body of work 
identifying brain-specific epigenetic dysregulation associated with Alzheimer’s 
disease. Third, it presents one of the first genome-wide studies of H3K27ac, 
providing a framework for future epidemiological analyses involving histone 
modifications. Fourth, the work presented in this thesis enhances our 
understanding of tissue-specific epigenetic variation and the utility of surrogate 
tissues in epigenetic studies of psychiatric phenotypes. Fifth, this thesis presents 
novel insights into the interplay of genetic and epigenetic variation, both in the 
pathology-free brain and in the context of AD-associated dysregulation. Key 
findings and implications of my PhD thesis are summarised in Figure 6-1. 
 
6.2.1 Epigenetic correlates of adverse environments 
Several previously published studies have reported variation in DNA methylation 
regulating the function of genes of the hypothalamic-pituitary-adrenal (HPA) axis 
in consequence to early-life stress and adversity. Using both animal and human 
samples, these studies have focused primarily on candidate genes, including 
NR3C1, FKBP5 and SLC6A4. Chapters 2 and 3 of my thesis used two 
complementary designs, a unique natural experiment and a large-population 
based cohort including twins to further investigate the association between early-
life adversity and DNA methylation in peripheral tissue. Using Illumina 450K 
Human Methylation microarrays and bioinformatics approaches, DNA 
methylation was quantified at ~ 450,000 CpG sites in the human genome in 
buccal cells (Chapter 2) or whole blood (Chapter 3). Together, these chapters 
allowed me to address the question of epigenetic signatures of early-life adversity 
in two important ways: Using a natural experiment focussing on severe early-life 
stress, Chapter 2 interrogates methylation associated with the extreme adversity 
experienced in the orphanages of Ceausescu’s Romania. Chapter 3 provides 
comprehensive insights from the largest study to date of early-life victimisation, 
using a UK-representative population-based sample and detailed longitudinal 
phenotypic data recorded across the first two decades of life. In addition, Chapter 
3 exploits the twin design of the E-Risk Longitudinal Study, allowing me to control 
for confounding effects caused by DNA sequence variation and/or shared family 
environments. While the two studies have diverging results, neither of them 
identified DNA methylation variation in any of previously reported candidate 
	 236	
genes. However, a striking association was identified in a DMR overlapping the 
promoter and TSS of CYP2E1 in Chapter 2. Methylation at this DMR was 
additionally associated with measures of social cognition. In Chapter 3 I did not 
observe significant associations between DNA methylation and early-life 
adversity beyond those confounded by smoking. The non-replication of the 
CYP2E1 finding could be related to a number of differences between the studies: 
First, the tissues used were different, and there is a possibility that DNA 
methylation in whole blood is not an ideal surrogate for neuroepigenetic variation. 
Second, the exposure experienced in ERA is more extreme and less 
heterogeneous – i.e. severe global institutional deprivation - and might not be 
directly comparable with the victimisation exposures characterised in E-Risk. 
Third the exposure timing in ERA is focused on the first four years of life, while 
victimisation profiling in E-Risk begins at age 5. There is a possibility that the first 
few years of life represent a developmentally more sensitive period and that 
adverse experiences in this period has a more dramatic impact on long-term 
biological outcomes.  
 
6.2.2 AD associated epigenetic variation 
Previous work in epigenetic epidemiology of brain disorders has focussed almost 
exclusively on DNA methylation, often profiled in peripheral tissues. However, the 
human epigenome is highly complex and tissue-specific (Kundaje et al., 2015, 
Marzi et al., 2016) and surrogate tissues may not be adequate proxies for 
molecular biological processes occurring in and possibly causally contributing to 
neuropsychiatric disease. There is a growing body of research implicating brain-
specific dysregulation of DNA methylation in Alzheimer’s disease neuropathology 
(Lunnon et al., 2014, De Jager et al., 2014). The work presented in Chapter 5 of 
this PhD thesis contributes to this existing body of research by characterising AD-
associated variation in the histone modification H3K27ac in post-mortem 
entorhinal cortex in a highly novel approach: a genome-wide association study of 
histone acetylation. I found widespread patterns of acetylomic dysregulation 
associated with AD in this study, enriched in several disease- and 
neurotransmitter-specific biological pathways. Unlike results from previously 
published work based on DNA methylation data, two of the most striking findings 
from this study implicate hyperacetylation clusters associated with MAPT and 
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PSEN2, two well-established AD-related genes in the disease. Intriguingly, both 
clusters are characterised by brain-related active chromatin states. Furthermore, 
acetylomic dysregulation is observed around other well-known AD-associated 
genes including APP and PSEN1 (familial, early-onset AD), as well as TOMM40 
and CR1 (sporadic AD; (Lambert et al., 2013)). My work also shows that regions 
of AD-associated differential acetylation and DNA modifications (5mC and 5hmC) 
are largely non-overlapping, and therefore this H3K27ac-EWAS provides unique 
novel insights into epigenetic dysregulation in Alzheimer’ disease. Given, the 
clear enrichment of brain-specific regulatory pathways and functions of my 
results, these findings have the potential to advance our understanding of the 
pathways by which epigenetic drugs function:  HDAC inhibitors are known to be 
potent candidate drugs in neurodegenerative disease and show pervasive effects 
on synaptic plasticity and memory formation (Guan et al., 2009, Fischer et al., 
2007, Kilgore et al., 2010), possibly affecting specific AD-dysregulated histone-
acetylation clusters.  
	
6.2.3 Genome-wide epidemiological studies of histone modifications 
In addition to strengthening the evidence for a role of epigenetic dysregulation in 
AD, Chapter 5 also represents one of the first large-scale genome-wide studies 
of histone acetylation in a complex disease. While histone-modifications have 
been profiled across numerous human cell- and tissue-types in recent years 
(Kundaje et al., 2015), most of the work has focused on characterising histone 
modification patterns from individual pathology-free samples. A first genome-
wide study of H3K27ac was published for autism spectrum disorder last year (Sun 
et al., 2016). Reassuringly, the cortical H3K27ac peaks identified by Sun and 
colleagues - as well as brain-specific H3K27ac peaks from the NIH Roadmap 
Epigenomic Consortium - overlap those identified in entorhinal cortex samples 
profiled in Chapter 5. Building on the work from Sun and colleagues, my analyses 
demonstrate the suitability of post-mortem brain tissue for histone modification 
profiling using ChIP-seq. A research framework for this type of study is described, 
including stringent laboratory protocols, automated immunoprecipitation, data 
pre-processing and quality control (Figure 6-2). I also addressed the appropriate 
statistical modelling of ChIP-seq data, including controls for potential biological 
(age, cell-type composition) and technical covariates (library size, dispersion). 
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Future epidemiological studies of histone modifications will hopefully benefit from 




Figure 6-2. Overview of the research framework developed for genome-wide studies of 
histone modifications.  
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6.2.4 Tissue-specificity of epigenetic modifications  
Chapter 4 characterised tissue-specific profiles of allelically-skewed DNA 
methylation across human brain and blood, adding to published tissue-specific 
maps of epigenetic modifications (Kundaje et al., 2015, Hannon et al., 2015), but 
importantly also considering intra-individual epigenetic covariation across tissues 
(Davies et al., 2012, Hannon et al., 2015). In addition to confirming allelically-
skewed DNA methylation in the vicinity of known imprinted regions, my results 
highlight putative genetically-driven instances of allelic-skewing, some of which 
are highly tissue-specific. The comprehensive profiling of tissue-specific genetic 
effects on epigenetic states is of particular importance in uncovering the 
molecular pathways that connect genetic variation with phenotypic outcomes in 
disease-affected tissues (Meaburn et al., 2010) and the work presented in 
Chapter 4 contribute an important piece to this puzzle. 
Chapters 2, 3 and 5 profile exposure- and disease-associated epigenetic 
variation collected from three different sources: buccal swabs, whole blood and 
post-mortem brain. Previous work in AD has highlighted tissue-specific 
dysregulation of DNA methylation, with disease-associated differentially 
methylated probes (DMPs) identified only in the cortex but not in the pathology-
free cerebellum or whole blood of AD patients (Lunnon et al., 2014). In line with 
these findings, we observe widespread AD-associated variation in H3K27ac in 
the disease-affected entorhinal cortex. Furthermore, some of our key findings are 
characterised by cortex-specific active chromatin states and histone-acetylation 
profiles, suggesting that these regulatory marks may also be cortex-specific. 
Results for epigenetic correlates of adverse psychosocial environments in 
surrogate tissues are more mixed: In Chapter 2, I was able to identify regional 
differences in DNA methylation associated with severe institutional deprivation in 
buccal cells. On the other hand, I found no robust associations between early-life 
victimisation and DNA methylation in whole blood in Chapter 3. This may indicate 
that buccal cells could be a better proxy of brain epigenomic variation than blood. 
Nonetheless, epigenetic profiling of blood in epidemiological contexts can be a 
valuable biomarker of other factors, as illustrated by the pervasive associations 
identified with cigarette smoking. 
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6.2.5 Genetic and epigenetic variation 
For my PhD thesis, I applied a variety of techniques (both experimental and 
analytical) to study multiple epigenetic phenomena across a range of health 
questions related to the brain. Importantly, epigenetic mechanisms do not act 
independently of the genetic sequence or other epigenetic modifications, even 
though they are generally interrogated individually. Throughout my thesis, I have 
employed a variety of strategies that aimed to address (epi-)genetic variation in 
an integrated manner. First, Chapter 4 addresses the question of allelic 
imbalances in DNA methylation across the human genome, most of which are 
genetically driven. To characterise this phenomenon, epigenetic and genetic 
laboratory methods were combined: a cocktail of methylation-sensitive restriction 
enzymes was used to digest DNA prior to hybridisation to a genotyping 
microarray. Relative genotype signal intensity changes were used as a measure 
to quantify allelic-skew in DNA methylation, exploiting heterozygosity to discern 
between methylation on the two alleles. The resulting tissue-specific ASM maps 
have important implications for genetic studies of psychiatric disease as 
mediating or interacting factors (Meaburn et al., 2010). Second, I exploit the fact 
that monozygotic twins are genetically identical, to explore methylomic correlates 
of victimisation exposure while controlling for genetic effects in Chapter 3. Twin 
studies offer one of the most powerful designs in epigenetic epidemiology 
controlling for several confounding factors including familial environment and 
genetic effects (Castillo-Fernandez et al., 2014, Mill and Heijmans, 2013). In the 
E-Risk cohort, methylomic effects at smoking-confounded victimisation 
associated probes are attenuated in a twin-difference model, even when not 
controlling directly for smoking-differences between twins, despite reported 
differences in smoking behaviour. Finally, Chapter 5 uses a multitude of public 
and additionally collected data sources to explore genetic and epigenetic 
variation implicated in AD in an integrated approach. To supplement the primary 
analysis focussing on disease-associated H3K27ac variation, I examined linkage 
disequilibrium blocks, to explore epigenetic variation in genomic regions 
associated with disease, characterising acetylomic variation in these regions. 
Using DNA methylation and hydroxymethylation profiles from the same samples, 
I find that regions exhibiting AD-associated differential acetylation and DNA 
modifications are largely non-overlapping, but that disease-associated hyper- 
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and hypoacetylated regions are characterised by different profiles of 5mC and 
5hmC.  
 
6.3 Limitations and future research directions 
As outlined in the introduction, a perfect study design does not exist in epigenetic 
epidemiology of brain disorders, and the studies presented in this thesis are 
subject to a number of methodological limitations. These limitations are 
discussed in detail at the end of each chapter, but several recurring limitations 
affect the data presented in many of my chapters and will be discussed in the 
broader context of this thesis discussion. 
 
6.3.1 Sample size and replication 
Some of the studies presented in this PhD thesis are somewhat limited in sample 
size, usually for specific reasons: The work conducted for Chapter 2 focuses on 
a unique small sample, a subset of the English and Romanian Adoption Study. 
Replication of the results is warranted, but similar samples exposed to severe 
adversity are scarce and clearly cannot be repeated experimentally for ethical 
reasons. Follow-up including the full cohort of ERA is planned and could be 
complemented by replication in larger population-based studies. Although we 
profiled a wide range of brain regions and blood from the same donors, the 
number of samples used in Chapter 4 is very limited, making definitive 
statements about genetically-driven methylomic variation or general profiles of 
inter-individual variation difficult. Larger studies of ASM, in particular in 
combination with profiling of methylation and expression QTLs, would provide 
invaluable new maps and insights about genetic, methylomic and transcriptional 
covariation. The work presented in Chapter 5 constitutes the largest study of 
histone acetylomic variation in AD and in the entorhinal cortex to date. Post-
mortem brain samples are not as readily available as peripheral tissue, but brain 
banking is increasingly enabling research into the molecular biology of the human 
brain (Kretzschmar, 2009); meanwhile the costs associated with ChIP-seq, if 
employed in a larger epidemiological study design, are still substantial. However, 
the widespread acetylomic differences observed in my study and, and particularly 
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those in several known AD genes, are extremely promising and encourage future 
research on larger cohorts. 
 
6.3.2 Tissue and cell-types 
The two studies interrogating early-life adversity (Chapters 2 and 3) were 
conducted on peripheral tissue samples. With very few exceptions (e.g., suicide 
completer brain samples), studies of these types of exposures will always have 
to be based on surrogate tissue, in particular if part of larger longitudinal cohorts. 
Given my results and previous reports, it is possible that buccal cells may be a 
more appropriate surrogate for brain methylomic variation (Lowe et al., 2013), but 
the profiled ERA sample was limited in size and the presented results require 
replication. Additional and more accurate maps of intra-individual epigenetic 
variation across tissues are required, but buccal cells are not yet generally 
collected in the context of brain banking. Work detailing blood-brain methylomic 
covariation across a larger sample has been published previously (Hannon et al., 
2015) and my work outlined in Chapter 4 contributes to the collection of blood-
brain epigenomic maps (Marzi et al., 2016). Despite the lack of significant 
associations between victimisation and blood methylomic variation in Chapter 3, 
whole blood has immense potential as an epidemiological biomarker for other 
exposures, including smoking behaviour (Joehanes et al., 2016). 
The second big issue with regards to cell- and tissue-types is cellular 
heterogeneity, and its potential to confound epigenetic association studies. 
Reference-based estimators for blood (used in Chapter 3) and brain (used in 
Chapter 5) cell-type compositions have been published and shown to perform 
well (Houseman et al., 2012, Guintivano et al., 2013). However, the CETS 
algorithm for brain cell-type estimates only distinguishes between neurons and 
non-neuronal cells, while more detailed subtyping of neurons, or identification of 
specific non-neuronal cell-types like microglia may be of interest in the context of 
some psychiatric diseases. Furthermore, the reference dataset, on which the 
CETS algorithm was fitted, was based on NeuN immunolabelling, which fails to 
capture some types of neurons, including cerebellar Purkinje cells and Golgi cells 
(Jeffries and Mill, 2017). In addition to estimation error for both reference-based 
estimators, these post-hoc statistical approaches also may not be able to pick up 
epigenetic differences in single cell-subtypes, due to a convolution of signal, 
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meaning that a significant epigenetic difference in a single cell-type may be 
drowned out by the epigenetic noise produced by all other cell-types occurring in 
the heterogeneous tissue sample. Single cell-type extraction methods, including 
fluorescent activated cell sorting (FACS) or laser capture microdissection (LCM), 
would be able to target questions of single cell-type epigenomic variation, but are 
highly work-intense and not feasible on previously isolated DNA samples. 
 
6.3.3 Causality and mechanism 
All the analyses presented in this thesis (Chapters 2, 3 and 5) are cross-
sectional, studying epigenetic variation across multiple individuals collected at a 
single time. This makes attribution of causal and even temporal relationships 
between exposures, phenotypic and epigenetic variation elusive. In Chapter 2 
we use a natural experiment, allowing us to rule out effects of genetics or external 
factors on the institutional exposure duration. Assuming, that institutional 
deprivation lead to the observed epigenetic differences, we still cannot conclude 
that the psychosocial components of the exposure caused the variation in DNA 
methylation. While we ascertained that smoking and medication use were 
unrelated to the exposure duration, other factors pertaining to the institutional 
environment, such as environmental toxins, could have contributed to the 
association with DNA methylation. In contrast, in Chapter 3 we find that the 
association between victimisation exposure and DNA methylation is confounded 
by smoking. One possible explanation is that socioeconomic status increases 
both the likelihood of victimisation exposure and smoking. Planned subsequent 
repeated profiling of DNA methylation in these two longitudinal cohorts will give 
us better insights into the temporal profiles of epigenetic variation and effects of 
new environmental exposures. 
The widespread acetylomic associations with AD reported in Chapter 5 are very 
encouraging, implicating known AD genes and highly disease- and brain-specific 
pathways, further establishing them as candidates for a mechanistic role in AD 
aetiology and progression. However, given the cross-sectional setup of this 
study, it is completely unknown whether the epigenetic dysregulation predates 
the disease or arises as a consequence. Epigenetic variation could causally 
contribute to AD, but could also reflect a downstream effect of the disease or 
medication, or a by-product relating to other factors. Future functional work will 
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be required to shed more light onto these associations. For example, given the 
dysregulated acetylation cluster upstream of MAPT is covered by enhancers, 
methods profiling 3D chromatin structure, such as chromatin conformation 
capture (3C) or enhancer luciferase assays could be used to profile the genes it 
interacts with. Furthermore, CRISPR-mediated knockouts in mouse models or 
cell-culture could be employed to see how disrupting the enhancer affects 
transcription of MAPT. In addition to functional experimental approaches, 
genotypic profiling would open up the possibility of Mendelian randomisation for 
statistical causal inference. However, to optimise power for the detection of 
mQTLs, larger samples than those presented in Chapter 2 and 5 would be 
required.  
 
6.3.4 Genetics and data integration 
While indirect approaches involving genetic variation have been described in 
Chapters 3, 4 and 5, direct profiling of genotypic variation in the context of 
epigenetic association studies would be useful, enabling a more detailed analysis 
of genetic and epigenetic contributions to the epidemiological measures, and 
efforts to follow-up the work presented in Chapters 2, 3 and 5 with genotypic 
information are indeed ongoing. One potential benefit resulting from genotyping 
is the interrogation of acetylomic variation not only in regions of risk variants but 
in their actual context. For example, do carriers of the APOE-e4 risk variant for 
Alzheimer’s disease exhibit different profiles of histone acetylation in the 
surrounding genomic region? A second line of investigation could look into allelic 
variation in H3K27ac. Using genotypic information of the samples characterised 
in Chapter 5, a haplotyped genome could be assembled, to which ChIP-seq 
reads would be aligned allele-specifically. This would enable us to assess 
naturally occurring allelic biases in histone acetylation across the entorhinal 
cortex (using only the pathology-free samples), as well as the identification of 
disease-specific allelic-biases in H3K27ac (using all samples). Genotyping in the 
longitudinal cohorts examined in Chapters 2 and 3 will hopefully allow us to tease 
apart genetic and environmentally induced epigenetic changes in greater detail. 
Using both risk variants but importantly also polygenic risk scores (PRS) for 
mental health outcomes observed following adversity, genetic contributions to 
these outcomes could be better accounted for (Hannon et al., 2016a). Another 
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important methodological advantage of collecting genotypic information on the 
participants of these studies would be to rule out effects of population-
stratification, where population-specific genotypic variation correlates both with 




Most technologies used in epigenetic epidemiology have certain limitations, 
including technical noise, genomic coverage/resolution or sample requirements. 
The Illumina 450K Human Methylation array used to profile DNA methylation 
following adversity in Chapters 2 and 3 is limited to profiling methylation at 
~450,000 CpG sites, a fraction of the total 28 million sites found across the human 
genome. While it is purposefully designed to cover CpG sites annotated to most 
protein-coding genes it lacks broader coverage of identified regulatory elements. 
Additionally, traditional sodium-bisulfite conversion, as employed in Chapters 2 
and 3, is unable to distinguish between the two cytosine modifications 5-
methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). While this should 
not present a serious problem for these two studies, given the extremely low 
prevalence of 5hmC in most non-neuronal tissues, it needs to be considered 
when profiling DNA modifications across the brain: the additional DNA 
methylation and hydroxymethylation data presented in Chapter 5, used oxidative 
bisulfite-conversion, making the distinction between true 5mC and 5hmC 
possible. 
 
6.4 Final words 
Psychiatric epigenetics is a rapidly advancing field with many encouraging 
developments and findings in recent years. Researchers are beginning to link 
regulatory variation with genetic and environmental risk factors associated with 
neuropsychiatric phenotypes. My PhD explored epigenetic variation in the 
context of psychosocial environments and neuropsychiatric health and disease 
employing novel technologies and unique study designs to shed light onto how 
genetic and environmental factors influence risk of psychiatric disease. My 
findings encourage further work, inferring causal, functional and mechanistic 
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relationships of epigenetic signatures of mental health and neuropathology, 
which will hopefully eventually lead to novel therapeutic and pharmacological 
interventions, ameliorating adverse mental health sequelae following early-life 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendices (on CD-ROM) 
 
Appendix A 
Supplementary file 1: Association statistics for all probes annotated to the 
seven candidate genes – AVP, BDNF, CRHR1, CYP2E1, FKBP5, NR3C1, 
SLC6A4 – examined in Chapter 3. 
 
Appendix B 
Supplementary file 1: Association statistics for the 1,475 hyperacetylated peaks 
(FDR < 0.05) identified in Chapter 5. 
Supplementary file 2: Association statistics for the 2,687 hypoacetylated peaks 
(FDR < 0.05) identified in Chapter 5. 
 
Appendix C 
Supplementary file 1: Gene ontology enrichments of hyperacetylated peaks 
(FDR < 0.05) in the category “Biological Process” (Chapter 5) 
Supplementary file 2: Gene ontology enrichments of hyperacetylated peaks 
(FDR < 0.05) in the category “Molecular Function” (Chapter 5) 
Supplementary file 3: Gene ontology enrichments of hyperacetylated peaks 
(FDR < 0.05) in the category “Disease Ontology” (Chapter 5) 
Supplementary file 4: Gene ontology enrichments of hyperacetylated peaks 
(FDR < 0.05) in the category “Human Phenotype” (Chapter 5) 
Supplementary file 5: Gene ontology enrichments of hypoacetylated peaks 
(FDR < 0.05) in the category “Biological Process” (Chapter 5) 
Supplementary file 6: Gene ontology enrichments of hypoacetylated peaks 
(FDR < 0.05) in the category “Molecular Function” (Chapter 5) 
Supplementary file 7: Gene ontology enrichments of hypoacetylated peaks 
(FDR < 0.05) in the category “Disease Ontology” (Chapter 5) 
Supplementary file 8: Gene ontology enrichments of hypoacetylated peaks 
(FDR < 0.05) in the category “Human Phenotype” (Chapter 5) 
 
 
 
